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 General Introduction 2 
1.1 Mammalian Adenylyl Cyclases 
 
1.1.1 Cyclic Nucleoside 3´:5´-Monophosphates as Second Messengers 
The role of a cyclic nucleotide in signal transduction was first demonstrated in 
1957 by Sutherland and Rall, who found cyclic adenosine 3´:5´-monophosphate 
(cAMP) to be a “second messenger” inducing hepatic glycogenolysis upon glucagon 
and epinephrine stimulation (Berthet et al., 1957a, b). Since then, the role of cAMP 
(Fig. 1) as a second messenger was found to comprise mediation of the biological 
effects of many hormones (Sutherland, 1972), non-endocrine regulation, e.g. control 
of immune (Parker et al., 1974) and visual (Bitensky et al., 1971) responses, blood 
coagulation (Steer and Salzman, 1980), neural functions (Kebabian, 1977a-c) and 
malignant transformation (DeRubertis and Craven, 1980). Therefore, cAMP is a key 
messenger in essential processes like function of the brain and the central nervous 
system, regulation of smooth muscle and vascular tone, skeletal muscle control and 
contraction of the heart, as well as regulation of gene transcription, cellular 
differentiation and ontogenic development. 
In the 1970s, a second cyclic nucleotide, cyclic guanosine 3´:5´-
monophosphate (cGMP), was discovered as an intracellular regulator in both 
endocrine and non-endocrine mechanisms (Goldberg et al., 1973, 1975; Murad et al., 
1979). Since 1974, the potential occurrence and possible physiological relevance of 
a third cyclic nucleotide, cyclic cytidine 3´:5´-monophosphate (cCMP) is discussed 
controversially (Bloch et al., 1974; Gaion and Krishna, 1979). 
 
 
Fig. 1: Structures of cyclic nucleoside 3´:5´-monophosphates. A: Cyclic 
adenosine 3´:5´-monophosphate (cAMP); B: Cyclic guanosine 3´:5´-monophosphate 
(cGMP); C: Cyclic cytidine 3´:5´-monophosphate (cCMP). 
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1.1.2 The cAMP Signaling Pathway 
The formation of cAMP by adenylyl cyclase (AC) is part of a signal 
transduction cascade including stimulation of integral membrane receptors by 
hormones, activation of heterotrimeric G proteins and subsequent activation of AC 
(Fig. 2). G protein-coupled receptors (GPCRs) are cell membrane proteins consisting 
of seven hydrophobic transmembrane segments, with an extracellular amino 
terminus and an intracellular carboxyl terminus (Kolakowski, 1994; Palczewski et al., 
2000). 
 
 
β γ Gα
Hormone
Biological
effect
GPCR Adenylyl cyclase
cAMP
M1 M2
C1 C2
 
Fig. 2: The cAMP signaling pathway. Extracellular binding of hormones to G 
protein-coupled receptors (GPCRs) activates heterotrimeric G protein complexes 
consisting of Gα and Gβγ. Subsequently, adenylyl cyclase (AC) is activated to form 
the second messenger cAMP. 
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GPCRs represent the largest family of membrane proteins in the human 
genome and the most important source of targets for pharmacologic therapy (Venter 
et al., 2001; Nambi and Aiyar, 2003; Kobilka, 2007). Binding of intracellular signaling 
molecules like epinephrine, dopamine, histamine or serotonin to GPCRs induces 
changes in receptor conformation, leading to an increased affinity for intracellular G 
protein complexes. Heterotrimeric G proteins consist of a guanine nucleotide binding 
Gα subunit and a Gβγ heterodimer. In the inactive state, GDP is bound to the Gα 
subunit. Upon interaction with the activated receptor, GDP is released and replaced 
by GTP. This exchange reduces the affinity of the Gα subunit to the Gβγ heterodimer 
and leads to a disruption of the ternary complex. GTP-bound Gα dissociates from 
Gβγ and interacts with AC either in a stimulatory (Gαs family), or inhibitory (Gαi 
family) manner (Gilman, 1987; Kristiansen, 2004). Gα returns to the inactive state by 
its GTPase activity, hydrolyzing GTP to GDP and inorganic phosphate followed by 
reassociation with Gβγ. The βγ-subunits also regulate AC, but in an AC subtype-
specific manner (Sunahara et al., 1996; Smit and Iyengar, 1998; Patel et al., 2001). 
Depending on G protein stimulus, AC converts the substrate ATP to cAMP and 
pyrophosphate. cAMP exerts biological effects by activation of further signaling 
proteins, e.g. cyclic nucleotide-gated ion channels or protein kinase A (with 
subsequent protein phosphorylation steps). As one example demonstrating the 
importance of the cAMP signaling pathway, binding of hormones to β-adrenoceptors 
in the heart results in Gαs-mediated AC stimulation and hence, elevated cAMP levels 
increasing cardiac contractility. 
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1.1.3 Structure and Catalytic Mechanism of Mammalian Adenylyl Cyclases  
Mammalian AC consists of two hydrophobic regions with six transmembrane-
spanning domains each (M1 and M2) and of two cytoplasmic domains (C1 and C2), 
yielding a pseudo-symmetrical protein (Fig. 3). The C1 and C2 regions are further 
subclassified into C1a and C1b, C2a and C2b, respectively. C1a and C2a are highly 
conserved among all AC isoforms and contact each other forming the cytosolic, 
catalytically active core of AC where binding of the substrate ATP and cyclization to 
cAMP and PPi occur (Tesmer et al., 1997, 1999; Zhang et al., 1997a, b; Tang and 
Hurley, 1998). 
 
 
Fig. 3: Schematic model of the proposed structure of membrane-bound 
mammalian AC (Tang and Gilman, 1992; Hanoune et al., 1997; Hurley, 1998). AC 
consists of the N-terminus (N), two hydrophobic domains (M1 and M2) with six 
transmembrane spans each, two cytosolic domains (C1 and C2) and the C-terminus 
(C). The intracellular domains are further divided into C1a/C1b and C2a/C2b. The 
catalytical core is formed by C1a and C2a. 
 
 
The AC reaction proceeds by inversion of the configuration at the α-
phosphorous atom, resulting from in-line displacement of pyrophosphate by 
nucleophilic attack of the 3´-OH group on the α-phosphate group (Eckstein et al., 
1981; Liu et al., 1997; Tang and Hurley, 1998). This mechanism is also observed in 
the action of bacterial AC toxins and is described in detail in chapter 1.2.1. In 
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mammalian AC, a hydrophobic pocket accommodates the adenine base. Hydrogen 
bonds between the adenine N1 and K938 as well as between N6 and D1018 (AC2) 
confer specificity for adenine in advantage over guanine (Tang and Hurley, 1998). 
Therefore, in contrast to guanylyl cyclases, ACs bind ATP and lack the conversion of 
GTP to cGMP. The negatively charged phosphate tail formed by the α-, β- and γ-
phosphates of the nucleotide interacts with the positive residues R484, R1029 and 
K1065 (AC2) as well as R398 and R1011 (AC1). Most importantly, N1025 and the 
guanidino group of R1029 bind the α-phosphate and are essential for catalysis. D396 
and D440 (AC5) coordinate two Mg2+ cations. The first Mg2+ ion activates the 3´-OH 
group for nucleophilic attack while the second ion interacts with the β- and γ-
phosphates.  
 
 
1.1.4 Tissue-Specific Distribution and Pathophysiological Importance of 
Mammalian Adenylyl Cyclase Isoforms 
Adenylyl cyclase type 1 (AC1) was the first AC to be cloned in 1989 (Krupinski 
et al., 1989). Today, nine closely related AC isoforms, AC1-AC9, as well as two 
splice variants of AC8 (Cali et al., 1996) have been cloned and characterized in 
mammals (Iyengar, 1993; Hanoune et al., 1997; Simonds, 1999), all of them sharing 
large sequence homology in the primary structure of their catalytic site and the same 
predicted three-dimensional structure. Additionally, a tenth gene encoding a soluble 
AC isoform was found (Buck et al., 1999). For the assessment of the role of AC for 
physiological processes and pathological disease states, two approaches were 
considered: Firstly, overexpression studies using cell transfection or transgenic 
animals expressing certain AC isoforms in increased amounts, and secondly, gene 
disruption studies utilizing genetic knockouts resulting in a loss of the corresponding 
AC isoform (Patel et al., 2001; Sadana and Dessauer, 2009). 
The tissue-specific distribution of distinct AC isoforms was investigated using 
mRNA studies (Tab. 1). AC2, AC4 and AC6 are widely expressed, whereas other 
isoforms are more specifically expressed. In particular, AC1 is abundant in certain 
domains of the brain (hippocampus, cerebral cortex and the pineal gland) pointing to 
a very important role in learning and memory (Xia et al., 1991). Studies with AC1-
deficient mice showed decreased long-term potentiation in the hippocampus and 
synaptic plasticity, including deficiencies in learning and memory storage (Storm et 
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al., 1998; Villacres et al., 1998). Additionally, AC1(-/-) mice showed significantly 
reduced behavorial nociceptive responses and altered pain transmission (Vadakkan 
et al., 2006), altered behavior (Wu et al., 1995) as well as enhanced sensitivity to the 
sedative effect of ethanol (Defer et al., 2000; Maas et al., 2005). Excessive activation 
of neuronal receptors results in damage and dying of nerve cells. As AC1(-/-) 
attenuated neuronal cell death induced by excessive injections of the agonist N-
methyl-D-aspartate, AC1 may serve as a novel target in stroke and 
neurodegenerative diseases (Wang et al., 2007; Sadana and Dessauer, 2009).  
 
 
Tab. 1: Tissue-specific expression of AC isoforms and potential associated 
functions (Reiach et al., 1999; Hanoune and Defer, 2001; Abdel-Majid et al., 2002; 
Sunahara and Taussig, 2002; Tantisira et al., 2005; Hines et al., 2006; Dwivedi and 
Pandey, 2008). 
AC isoform Tissue distribution  Potential associated functions and 
pathophysiological relevance 
AC1 Brain, adrenal gland Circadian rhythm, synaptic plasticity, 
learning, memory, long-term 
potentiation, drug dependency 
AC2 Brain, lung, skeletal muscle Arrest of cell proliferation, synaptic 
plasticity 
AC3 Brain, olfactory epithelium, 
male germ cells, pancreas 
Olfaction, sperm function 
AC4 Brain, kidney, liver, lung Mood disorders, depression, 
photoreception 
AC5 Heart, brain Cardiac contraction, drug dependence, 
pain responses, motor coordination 
AC6 Widespread, heart Cardiac contraction, cell proliferation 
AC7 Brain, platelets, widespread Ethanol dependency, depression 
AC8 Brain, lung Synaptic plasticity, learning, memory, 
long-term potentiation, drug 
dependency 
AC9 Brain, skeletal muscle, 
widespread 
Polymorphism relevant in asthma 
treatment, learning, memory 
sAC Testis Sperm capacitation, fertilization 
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Both AC1 and AC8 form the neuronal group of AC mainly expressed in the 
brain. Genetic disruption of both isoforms resulted in loss of long-term memory and 
long-term potentiation (Wong et al., 1999; Wang et al., 2003). Additionally, as a result 
from AC1 and AC8 deletion, a reduction in withdrawal behavior and altered morphine 
responses were observed, pointing to a potential role of the neuronal AC isoforms in 
the therapy of drug addiction (Li et al., 2006). As AC activity in hippocampus and 
cerebellum from patients with Alzheimer´s disease is significantly reduced, the neural 
AC isoforms may be promising targets for future therapies of Alzheimer´s disease 
(Schnecko et al., 1994; Yamamoto et al., 1997). AC2 was found in brain and lung 
tissue pointing to importance in synaptic plasticity and in regulation of growth 
pathways in pulmonary artery myocytes (Furuyama et al., 1993; Jourdan et al., 
2001). 
The highest expression of AC3 is found in olfactory neuroepithelium (Xia et al., 
1992). AC3 deficient mice fail several olfaction-based behavorial tests implicating 
anosmia and a critical role for AC3 in olfaction (Wong et al., 2000). Additionally, AC3 
accounts for spermatozoa function and male fertility (Livera et al., 2005). 
Immunolabeling of AC4 and investigation of AC activity in post-mortem brain of 
depressed suicide victims revealed decreased cAMP signaling indicating a 
correlation between AC activity and mood disorders (Reiach et al., 1999; Dwivedi 
and Pandey, 2008). 
AC5 and AC6 are highly expressed in the heart and striatal neurons. However, 
AC6 is also highly expressed in many other tissues. In cardiac myocytes, AC5 and 
AC6 are the major AC isoforms. Studies on transgenic mice overexpressing AC5 or 
AC6 demonstrate important differences between these two isoforms in cardiac 
tissue. In murine models of heart failure (HF) induced by Gαq overexpression, 
cardioprotective effects, improved cardiac function and increased responsiveness to 
β-adrenoceptor stimulation are attributed to AC6, but not to AC5 (Roth et al., 1999, 
2000; Tepe et al., 1999). Overexpression of AC6 resulted in increased left ventricular 
function, reduced apoptosis and attenuated deleterious left ventricular remodeling 
suggesting a cardioprotective role in heart failure (Lai et al., 2004, 2008; Timofeyev 
et al., 2006). Additionally, gene transfer of AC6 reduced mortality in HF (Hammond, 
2006; Phan et al., 2007). In acute myocardial infarction, increased cardiac AC6 
content preserved left ventricular contractile function and increased survival rates 
(Takahashi et al., 2006). Deletion of AC6 decreased left ventricular function via 
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impaired calcium handling (Tang et al., 2008). Taken together, these data suggest 
that increased AC6 activity might be beneficial in HF which may be accomplished by 
stimulating agents selective for AC6, e.g. forskolin analogs. 
In contrast, disruption of AC5 preserved cardiac function against pressure 
overload (Okumura et al., 2003) and prevented myocardial apoptosis (Iwatsubo et 
al., 2004). Most interestingly, mice lacking cardiac AC5 had considerably increased 
lifespans and were protected against age-induced cardiac myopathy (Chester and 
Watts, 2007; Yan et al., 2007; Vatner et al., 2009). AC5(-/-) also effectively prevented 
apoptosis induced by isoproterenol stimulation (Ishikawa et al., 2005). As chronic 
activation of cAMP signaling results in cardiomyopathy and heart failure, limiting AC 
activity by β-adrenergic blockade therapy is the standard treatment in HF (Iwase et 
al., 1997; Engelhardt et al., 1999; Antos et al., 2001). However, the use of β-
adrenoceptor antagonists is limited in the case of decreased receptor number 
(desensitization), in non-responders due to receptor polymorphisms and in case of 
impaired respiratory function due to pulmonary diseases as β-adrenoceptors of the 
respiratory system might also be blocked as a side-effect. Therefore, inhibiting AC5 
instead of β-adrenergic receptors is an attractive alternative in future 
pharmacotherapy of HF. 
Besides its importance in the heart, AC5 may also play a role in dopaminergic 
signaling in the striatum (Lee et al., 2002) as AC5(-/-) mice showed Parkinson-like 
motor dysfunction and abnormal coordination (Iwamoto et al., 2003). Additionally, 
attenuation of all major behavorial effects of morphine including analgesia and 
physiological dependence as well as loss of opioid-induced AC inhibition in the 
striatum was observed in AC5(-/-) mice, pointing to a major role of AC5 in the 
mediation of morphine action (Kim et al., 2006; Sadana and Dessauer, 2009). 
Therefore, AC5 inhibitors might be used in the treatment of drug dependency (Kreek, 
1997). Furthermore, AC5(-/-) mice had attenuated pain responses in several 
mechanical pain tests pointing to a role of AC5 in acute and chronic pain 
transmission (Kim et al., 2007). AC5 inhibitors may also be used in the treatment of 
depression and anxiety (Kim et al., 2008; Krishnan et al., 2008). 
In AC7 transgenic mice, acute responsiveness and tolerance to morphine was 
enhanced (Yoshimura et al., 2000). Additionally, AC7 was found to be sensitive to 
ethanol (Yoshimura et al., 2006) and seems to play a sex-specific role in depression 
(Hines et al., 2006). AC8 is the only Ca2+/calmodulin-stimulated isoform expressed in 
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the hypothalamus (Matsuoka et al., 1992; Cali et al., 1994; Mons and Cooper, 1994) 
suggesting importance in neuroendocrine function and drug dependence (Matsuoka 
et al., 1994; Lane-Ladd et al., 1997). AC8 deficient mice showed altered anxiety 
behavior, allowing to deduce an involvement of AC8 in the generation of stress-
induced anxiety (Schaefer et al., 2000). A polymorphism in AC9 was found to impact 
responsiveness to asthma treatment with β-adrenoceptor agonists and 
corticosteroids, showing relevance of AC9 in the respiratory system (Tantisira et al., 
2005). Moreover, AC9 contributes to learning and memory (Antoni et al., 1998). 
Soluble AC (sAC) is predominantly expressed in the testis and associated with 
sperm development suggesting the possibility of the development of sAC inhibitors 
as male contraceptives (Sunahara and Taussig, 2002; Geng et al., 2005; Marquez 
and Suarez, 2008). sAC splice variants have been identified displaying a broader 
distribution pattern. sAC activity diverges significantly from the membrane-bound 
isoforms as it is unresponsive to hormones, G proteins and forskolin (Yanagimachi, 
1994; Buck et al., 1999; Jaiswal and Conti, 2001).  
Cells or tissues chronically treated with ethanol exhibit reduced 
responsiveness of AC to agents that usually enhance AC activity, e.g. cerebral 
cortical membranes of chronically ethanol-treated mice show a decrease in AC 
activity stimulated by β-adrenoceptors (Tabakoff et al., 1995; Yoshimura et al., 2000). 
These data suggest that ethanol dependence greatly relies on the cAMP signaling 
pathway possibly offering new therapeutic points of action (Moore et al., 1998; Yang 
et al., 1998). Finally, polycystic kidney disease is also linked to the cAMP system as 
increased cytosolic cAMP levels correlate with increased cellular proliferation being a 
key factor in the enlargement of renal cysts (Yamaguchi et al., 2000). 
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1.1.5 Isoform-Specific Regulation of Adenylyl Cyclase 
Only the cytoplasmic domains C1 and C2 of AC, which form the catalytic 
domain, are subject to intracellular regulations specific for each AC isoform. Gαs 
contacts both domains, with most of the binding surface contributed to the C2 domain 
(Sunahara et al., 1997; Tesmer et al., 1997). Gαs increases the affinity between C1 
and C2 and facilitates closure of the active site around ATP. Thereby, key residues in 
the active site reach closer to the 3´-hydroxyl group of ATP, creating a conformation 
more favorable for catalysis. As shown in Tab. 2, stimulation by Gαs is the major 
mechanism by which all membranous AC isoforms are activated and the intracellular 
cAMP level is elevated (Tang et al., 1992). Different ACs display different affinities for 
Gαs, possibly providing an explanation for the various responses of different cell 
types to hormones and neurotransmitters that elevate cAMP levels (Harry et al., 
1997). 
 
 
Tab. 2: Regulations of mammalian AC (Defer et al., 2000; Hanoune and Defer, 
2001; Sunahara and Taussig, 2002; Iwatsubo et al., 2003; Sadana and Dessauer, 
2009). 
 AC1 AC2 AC3 AC4 AC5 AC6 AC7 AC8 AC9 sAC 
Gαs ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ - 
Gαi ↓ - ↓  ↓ ↓  ↓ ↓ - 
Gβγ ↓ ↑ - ↑ ↓ ↓ ↑ ↑ - - 
Forskolin ↑ ↑ ↑ ↑ ↑ ↑ ↑ ↑ - - 
Protein kinase A     ↓ ↓     
Protein kinase C ↑ ↑ ↑ ↓ ↑ ↓ ↑  ↓  
Ca2+/Calmodulin ↑  ↑     ↑   
Calmodulin kinase ↓  ↓        
 
 
By binding to the C1 domain, Gαi decreases the affinity of the C1 and C2 
domains for one another and stabilizes a more open inactive conformation. Thereby, 
Gαs-stimulated AC5 and AC6 activities are inhibited, whereas Gαi has no effect on 
AC2 and AC8, showing isoenzyme specific actions of Gαi-coupled receptors (Chen 
and Iyengar, 1993; Taussig et al., 1993, 1994; Kozasa and Gilman, 1995; Rodbell, 
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1995; Scholich et al., 1997; Dessauer et al., 1998). This inhibitory action of GPCRs 
on AC activity can be blocked by pertussis toxin, causing ADP-ribosylation of the Gi 
protein. 
Besides Gα, Gβγ subunits are effective modulators of AC activity inhibiting 
AC1, AC5, AC6 and AC8, and activating AC2, AC4 and AC7, which explains many 
aspects of cross-talk between different receptors (Gao and Gilman, 1991; Tang and 
Gilman, 1991; Federman et al., 1992; Bygrave and Roberts, 1995; Taussig and 
Gilman, 1995; Yung et al., 1995; Bayewitch et al., 1998). For example, stimulation of 
Gq-coupled receptors can lead to an increase of intracellular calcium concentrations 
mediated by Gαq and additionally, to an increase in cAMP due to the stimulation of 
AC by Gβγ. Gβγ is specifically relevant in brain physiology, because the Gαi family 
and their accompanying βγ subunits are, together with AC1 and AC8, highly 
expressed in brain tissue (Sternweis and Robishaw, 1984).  
With the exceptions of AC9 and sAC, all AC isoforms are strongly activated by 
the diterpene forskolin, a natural plant extract from Coleus forskolii used in traditional 
medicine in India (Seamon and Daly, 1981a, b; Seamon et al., 1981). Elucidating the 
structure of AC and particularly the interface of C1a/C2a, a hydrophobic pocket was 
discovered, implicating binding of forskolin (Fig. 4). By interacting with residues in 
C1a and C2a, forskolin stabilizes the interactions between the two cytoplasmic 
domains and increases the affinity of the two domains for each other, resulting in 
assembly of the catalytically active core of AC and stimulated enzymatic activity 
(Sunahara et al., 1997; Tesmer et al., 1997; Zhang et al., 1997b). In AC9, one single 
mutation (Y1082L) confers binding of forskolin and therefore, AC activation (Yan et 
al., 1998). Forskolin analogs selectively activating distinct AC isoforms could be used 
in pharmacotherapy of diseases related to decreased AC activity, e.g. Alzheimer´s 
disease (Pinto et al., 2008). 
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Fig. 4: Crystal structure of the catalytic domain of AC formed by C1a and C2a in 
complex with Gαs (Mou et al., 2005). The C1a and C2a domains are colored tan and 
mauve, respectively; Gαs is shown as a red cylinder. Forskolin and the substrate 
analog MANT-GTP are drawn as stick models at the forskolin binding site and the 
catalytic site, respectively. Two Mn2+ ions are shown as orange spheres. 
 
 
Elevated concentrations of pyrophosphate inhibit AC, which has also been 
shown for the antiviral agent foscarnet, a pyrophosphate anolog (Kudlacek et al., 
2001). The so-called P-site inhibitors are purine-based substrate analogs, binding to 
the catalytic site of AC resulting in non-competitive AC inhibition (Desaubry et al., 
1996a, b; Desaubry and Johnson, 1998; Dessauer et al., 1999). For example, 2´,5´-
dideoxyadenosine 3´-tetraphosphate inhibited AC purified from bovine brain with a Ki 
value of 23 nM. 
Modulation of AC activity by phosphorylation is a common feature of 
downstream and feedback regulations within signal transduction cascades mediated 
by protein kinase A (PKA) or protein kinase C (PKC). Thus, phosphorylation of AC5 
and AC6 by PKA provides a means of desensitization at the effector level (Iwami et 
al., 1995; Chen et al., 1997). Interestingly, phosphorylation by PKC enhances Gαs-
stimulated AC2 activity, inhibits Gαs-stimulated AC4 activity, but causes both AC2 
and AC4 to lose responsiveness to the stimulatory effect of Gβγ (Zimmermann and 
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Taussig, 1996). While AC1, AC2, AC3, AC5 and AC7 activities are increased by PKC 
(Jacobowitz and Iyengar, 1994; Kawabe et al., 1994; Watson et al., 1994), Gαs-
stimulated AC4 and AC6 activity is decreased in presence of PKC (Zimmermann and 
Taussig, 1996; Lai et al., 1999). 
Submillimolar concentrations of Ca2+ inhibit all AC isoforms, possibly by 
competition with magnesium, which is essential for catalysis of the cyclization 
reaction. While AC5 and AC6 are inhibited by lower Ca2+ concentrations, the 
endogenous Ca2+ sensor protein calmodulin (CaM) stimulates AC1, AC3 and AC8 in 
a Ca2+-dependent manner (Choi et al., 1992; Vorherr et al., 1993; Cali et al., 1994; 
Gu and Cooper, 1999). AC3 is stimulated by Ca2+/calmodulin in vitro (Choi et al., 
1992), but inhibited in vivo, presumably through phosphorylation by calmodulin 
kinase (Wei et al., 1996), which has also been shown for AC1 (Wayman et al., 1996). 
AC9 is not affected by Ca2+/calmodulin but is inhibited by the protein phosphatase 
calcineurin (Antoni et al., 1998). 
Binding of AC5 to the PKA-scaffolding protein AKAP79 was observed, 
facilitating PKA-mediated inhibition of AC5 (Bauman et al., 2006; Sadana and 
Dessauer, 2009). Finally, the hydrophobic transmembrane-spanning domains of AC, 
M1 and M2, are subject to isoform-specific glycosylation, which is an additional 
mechanism for modulation of the functional properties of AC (Wu et al., 2001). 
In conclusion, different AC isoforms have different regulatory properties and 
the same effector can exert positive or negative regulating effects. In different cell 
types displaying different protein expression patterns, the same AC isoform may be 
regulated differently, and different signaling pathways can talk together in regulating 
cell functions. The cAMP signaling pathway is very complex, offering many 
therapeutic implications.  
However, many unanswered questions still remain, e.g. heterodimerization of 
different AC isoforms has been discovered (Gu et al., 2002; Cooper and 
Crossthwaite, 2006; Baragli et al., 2008), but the detailed functional importance of 
this phenomenon is unknown. What is the exact role of the large transmembrane 
domains of AC? What is the relevance of localization of AC in lipid rafts and caveolae 
in combination with other signaling components? What are the effects of isoform-
specific glycosylation? What is the detailed role of AC in mental disorders, addiction, 
pain transmission and cardiac function? And how can the different AC isoforms be 
targeted selectively for the multiplicity of different therapeutic indications? Detailed 
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characterization of AC from different tissues will contribute to the clarification of 
mechanisms of pathogenesis and to the development of new therapeutic 
approaches. In particular, pharmacological characterization of AC in the heart is 
required for the exploration of isoform-selective AC inhibitors and activators as a 
novel therapeutic strategy in heart failure. 
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1.1.6 MANT-Nucleotides as Fluorescent Inhibitors of AC 
2´(3´)-O-(N-methylanthraniloyl)- (MANT)-substituted nucleotides form a class 
of fluorescent substrate analogs that are used in the investigation of a broad variety 
of nucleotide binding enzymes (Hiratsuka, 1983; Jameson and Eccleston, 1997). Fig. 
5 shows the general structure of MANT-nucleotides, substrate analogs bearing a 
MANT-group which isomerizes between the 2´- and 3´-ribosyl position by acyl 
migration (Hiratsuka, 1982).  
 
 
      
 
    
 
Fig. 5: Structure of 2´(3´)-O-(N-methylanthraniloyl)- (MANT)-substituted 
nucleotides. Besides adenine, different bases may be attached to ribose. Oxygen in 
the phosphate tail may be substituted by sulfur. The MANT-group isomerizes 
between the 2´- and 3´-ribosyl position by acyl migration. 
 
 
Previously, MANT-substituted nucleoside 5´-triphosphates were found to 
constitute a novel class of potent and competitive AC inhibitors (Gille and Seifert, 
2003a, b). The aromatic MANT-group forms hydrophobic interactions with lipophilic 
residues of AC, e.g. F400, W1020, V1006 in C1:C2, accounting for the increased 
affinity of MANT-substituted nucleotides in comparison to non-substituted nucleotides 
(Mou et al., 2005). As shown in Fig. 4, elucidation of the crystal structure of the 
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catalytic site of AC in complex with accommodated MANT-nucleotides showed the 
MANT-group to act as a wedge preventing closure of the catalytic site resulting in AC 
inhibition (Mou et al., 2005). Investigating the interactions of MANT-nucleotides 
bearing different bases and different substitution patterns at the phosphate tail, e.g. 
MANT-ATP, MANT-GTP, MANT-ITPγS and MANT-ADP, the catalytic site of AC was 
found to be spacious and flexible, binding both purine and pyrimidine nucleotides 
(Gille et al., 2004; Mou et al., 2005, 2006). A tripartite pharmacophore model was 
established to describe the contributions of the ribose substituent (MANT-group), the 
phosphate residue and the base to nucleotide affinity to AC. Major significance was 
attributed to the ribose substituent and, to a smaller degree, to the triphosphate tail, 
while the contribution of the base to nucleotide-affinity was found to be inferior (Mou 
et al., 2006). As different MANT-nucleotides showed differential inhibitory potency on 
different AC isoforms, the development of isoform-selective AC inhibitors and their 
application as a novel therapeutic strategy in various diseases is feasible. 
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1.2 Bacterial Adenylyl Cyclase Toxins 
 
Disruption of crucial cellular processes is often a very critical event in the 
pathogenesis of infectious diseases of animals and humans. Several pathogenic 
bacteria secrete toxins to alter the intracellular cAMP concentration in mammalian 
host cells, resulting in a profound effect on various cellular processes. These toxins 
either disrupt the normal regulation of the cAMP signaling system or they themselves 
catalyze the synthesis of cAMP in the host cell. The latter are known as the AC toxins 
having a catalytic rate of 100-fold to 1000-fold higher than mammalian ACs. AC 
toxins are able to enter the cytosol of eukaryotic host cells and become activated by 
eukaryotic cofactors, like calmodulin (CaM), triggering uncontrolled synthesis of 
cAMP. As mammalian immune effector cells are the primary target of AC toxins, the 
resulting toxic cAMP accumulation poisons the immune system and thus facilitates 
the survival of the bacteria in the host (Ahuja et al., 2004). For instance, toxin-
induced elevation of cAMP levels causes loss of bactericidal functions of phagocytes 
and promotes apoptosis of macrophages (Boyd et al., 2005; Basler et al., 2006). 
Hence, AC toxins are a bacterial strategy to manipulate and subvert host defenses, 
impairing cellular antimicrobial responses. 
 
1.2.1 Adenylyl Cyclase Toxin Edema Factor (EF) from Bacillus anthracis 
Anthrax is primarily an infection of herbivores caused by pathogenic strains of 
Bacillus anthracis, a spore-forming, aerobic, gram-positive bacterium (Mock and 
Fouet, 2001; Mourez et al., 2002; Oncu et al., 2003). Humans are accidental hosts 
through the contact with infected animals, contaminated food or animal products; 
historical accounts on anthrax disease reach back to antiquity. Since the late 1800s, 
there has been impressive progress in the development of anthrax vaccines (Brey, 
2005; Scorpio et al., 2006, 2007). Anthrax disease is divided in three types 
depending on the mode of entry of the agent: Cutaneous anthrax, gastrointestinal 
anthrax and inhalational anthrax. Cutaneous anthrax results from entry of the agent 
through skin injuries and results in necrosis, edema and black eschar, see Fig. 6. 
Gastrointestinal anthrax as a result from ingestion of anthrax spores causes edema 
and necrosis accounting for a considerably high mortality rate. Inhalation of anthrax 
spores results in the most lethal form of anthrax disease which is characterized by 
fever, cough, dyspnea, respiratory failure and finally, death within days.  
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Fig. 6: Cutaneous anthrax with the typical black eschar. The name anthrax is 
derived from Ανθρακιτις, the Greek word for anthracite (coal). The pictures are taken 
from the Center for Biologic Counterterrorism and Emerging Diseases (CBC-ED), 
MedStar Health Group, Washington, DC (http://bepast.org). 
 
 
The high virulence and fatality rates of anthrax are a product of the secretion 
of multiple exotoxins by the agent. Bacillus anthracis produces a tripartite toxin 
comprising a receptor binding moiety termed protective antigen (PA) and two effector 
moieties termed edema factor (EF) and lethal factor (LF) (Brossier and Mock, 2001; 
Ascenzi et al., 2002; Cunningham et al., 2002). Secreted from the bacteria as non-
toxic monomers, these proteins assemble on the cell surface of receptor-bearing 
eukaryotic cells to form toxic non-covalent complexes (Cunningham et al., 2002; 
Mourez et al., 2002). As shown in Fig. 7, PA binds to certain cell membrane 
receptors: Firstly, tumor endothelial marker-8 (TEM8), which is expressed in a wide 
variety of tissues but at increased levels in colon tumor vasculature and secondly, 
capillary morphogenesis protein-2 (CMG2), which was initially identified in human 
umbilical vein endothelial cells induced to undergo capillary formation (Bradley et al., 
2001; Liu and Leppla, 2003; Scobie et al., 2003; Santelli et al., 2004; Hong et al., 
2005). Upon receptor binding, PA is cleaved into two fragments by cell-associated 
proteases (Klimpel et al., 1992). The smaller 20 kDa fragment PA20 dissociates 
allowing the larger 63 kDa C-terminal receptor-bound fragment PA63 to self-associate 
into ring-shaped heptamers (Milne et al., 1994; Petosa et al., 1997; Cunningham et 
al., 2002). The heptamer binds three molecules of EF and/or LF and is endocytosed 
and trafficked to an acidic intracellular compartment (Gordon et al., 1988; 
Cunningham et al., 2002; Mogridge et al., 2002; Abrami et al., 2003; Christensen et 
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al., 2006). There, the low pH induces conformational changes in the heptameric PA63 
moiety allowing it to form a membrane-spanning pore and translocate bound EF 
and/or LF across the membrane into the cytosol (Friedlander, 1986; Benson et al., 
1998; Cunningham et al., 2002).  
 
 
 
 
Fig. 7: Mechanism of PA-mediated delivery of EF and LF to the cytosol of host 
cells. 1: Binding of PA to the host cell receptors TEM8 or CMG2; 2: Cleavage of PA 
into PA20 and PA63; 3: Formation of heptameric complexes of PA63; 4: Binding of 3 
molecules of EF and/or LF; 5: Endocytosis to the complex; 6: Release of EF and LF 
to the cytosol by PA induced by low pH. EF is activated by calmodulin and effects 
cAMP accumulation, LF disrupts MAPKK signaling. The figure is adapted from 
literature (Krantz et al., 2004, 2006; Wigelsworth et al., 2004) and 
http://mcb.berkeley.edu/labs/krantz/research/anthrax.html. 
 
 
LF is a Zn2+-dependent protease cleaving members of the mitogen-activated 
protein kinase kinase family (Duesbery et al., 1998; Vitale et al., 1998; Hong et al., 
2005). LF can induce apoptosis of macrophages and endothelial cells and impair the 
function of dendritic cells (Park et al., 2002; Agrawal et al., 2003; Kirby, 2004). 
Edema factor (EF) is an AC toxin that is inactive outside the host cell. However, 
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within the cell, EF binds calmodulin resulting in assembly of the active catalytic site 
and toxin activation (Fig. 8). 
 
  
Fig. 8: Crystal structure of EF with bound calmodulin (Drum et al., 2002; Guo et 
al., 2005). The catalytic region of EF coordinating 3´d-ATP is shown in green, 
calmodulin is shown in red. The subunits of EF binding and embracing calmodulin 
are colored blue, yellow and cyan. 
 
 
By effecting excessive cAMP accumulation, EF activity protects the bacteria 
from phagocytic destruction (Confer and Eaton, 1982; Leppla, 1982) and causes a 
broad range of tissue damage (Hong et al., 2005). EF can block the phagocytic 
abilities of monocytes (O´Brien et al., 1985), compromise the function of dendritic 
cells (Tournier et al., 2005), impair activation and proliferation of T-cells (Paccani et 
al., 2005) and manipulate cytokine secretion (Tournier et al., 2005). Additionally, 
inhibition of human neutrophil NADPH oxidase activity was observed (Crawford et al., 
2006). EF is lethal to mice, causing multiple tissue damage and cardiovascular 
malfunction (Stanley and Smith, 1961; Pezard et al., 1991). EF and LF synergize in 
their action against host immunity (Paccani et al., 2005; Tournier et al., 2005; Firoved 
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et al., 2007) and deletion of the EF or LF gene leads to reduced virulence of anthrax 
bacteria (Pezard et al., 1991; Brossier et al., 2000). A strain of anthrax with a 
defective EF gene caused 100-fold reduced lethality in mice (Brossier et al., 2000) 
pointing to major importance of EF in the pathogenesis of anthrax. Peptide inhibitors 
can prevent binding of LF and EF to PA neutralizing anthrax toxin in vivo (Pini et al., 
2006). 
As shown in Fig. 9, the catalytic mechanism of EF is assumed to proceed in 
two-metal-ion catalysis, involving two divalent metal ions in nucleotide cyclization and 
a nucleophilic attack of the 3´-oxygen atom of ribose on the α-phosphate group (Guo 
et al., 2004; Shen et al., 2005; Gupta et al., 2006). The adenine moiety of ATP is 
recognised by a main chain carbonyl group. Two divalent metal ions are coordinated 
by D491, D493 and H577. The negatively charged triphosphate tail is coordinated by 
the positive residues K346, K353, K372 and R329. N583 interacts with the ribose 
oxygen atom, decreasing the rotational freedom of ribose and holding the 3´-OH 
group of ribose in position for its nucleophilic attack. H351 serves as a catalytic base 
to activate a surrounding water molecule by deprotonation. The protonated H351 
stabilizes an OH- ion near the 3´-OH of ATP, which facilitates the deprotonation of 3´-
OH. Mutation of H351 results in dramatically reduced catalytic activity, confirming the 
important role of H351 (Shen et al., 2005; Gupta et al., 2006). The first divalent metal 
ion also facilitates the deprotonation of 3´-OH by stabilizing the negative charge of 
the resulting 3´-oxyanion. Thus, the action of the first divalent metal ion and H351 is 
additive with respect to deprotonation of 3´-OH. The second metal ion facilitates the 
bond breakage between α- and β-phosphates by stabilizing the developing negative 
charges. The positive residues K346, K353, K372 and R329 coordinating the 
triphosphate tail also stabilize the negative charges developing during catalysis. 
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Fig. 9: Catalytic mechanism of EF (Shen et al., 2005). The cyclization of ATP to 
cAMP and PPi occurs by nucleophilic attack of the 3´-oxygen atom of ribose on the 
α-phosphate group. Two divalent metal ions are coordinated by D491, D493 and 
H577. H351 serves as a catalytic base. The first divalent metal ion stabilizes the 
negative charge of the resulting 3´-oxyanion. The second metal ion facilitates the 
bond breakage between α- and β-phosphates by stabilizing the developing negative 
charges. The negatively charged triphosphate tail is coordinated by positive amino 
acid residues (K346, K353, K372 and R329). 
 
 
In 2001, Bacillus anthracis was unleashed upon the US public by bioterrorists. 
Of the eleven infected people who had inhaled the agent, five died within a few days 
after infection. Thus, antibiotic treatment used for the victims resulted in a survival 
rate of only about 50% (Stubbs, 2002; Shen et al., 2004). Anthrax kills because the 
agent overwhelms the patient before innate host defense systems have the chance 
to eradicate the invaders. Generally, when the bacteria are inhaled, sepsis and 
toxaemia occur, resulting in death 2 to 5 days after infection (Little and Ivins, 1999). 
This restricted time frame, limited efficacy of antibiotic treatment, and additionally, the 
possibility that the anthrax strain had been made resistant to known antibiotics make 
anthrax an ideal offensive weapon for bioterrorists (Trull et al., 2007; Wallin et al., 
2007). Additionally, anthrax still is a civilian medical problem in several developing 
countries (Vijaikumar et al., 2001; Rao et al., 2007). Further investigations are 
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Fig. 10: Colonization of 
ciliated epithelium of the 
respiratory tract by the 
agent of whooping cough, 
Bordetella pertussis. 
needed for the elucidation of agent-host interactions, and particularly, the function of 
EF has to be clarified in detail. This is the prerequisite for the development of EF 
inhibitors that could be administered in combination with antibiotics to improve 
cellular antimicrobial responses and survival rates. 
 
 
1.2.2 Adenylyl Cyclase Toxin CyaA from Bordetella pertussis 
With about 50 million yearly cases of whooping cough and with up to 400,000 
deaths worldwide, mostly young infants in developing countries, the circulation of the 
disease throughout the world continues (Mattoo and Cherry, 2005; Tan et al., 2005; 
Yeh and Mink, 2006). Bordetella pertussis (Fig. 10), the etiologic agent of whooping 
cough, is a Gram-negative bacterial pathogen secreting numerous toxins, including 
pertussis toxin (PTX) and AC toxin CyaA (Hewlett et al., 1989; Gentile et al., 1990; 
Antoine et al., 2000). PTX ADP-ribosylates the α-
subunit of heterotrimeric Gi proteins in 
mammalian cells manipulating a wide range of 
effects of signaling pathways (Munoz et al., 1981; 
Moss et al., 1983; Reisine, 1990; Carbonetti et al., 
2003, 2005). 
The AC toxin CyaA is one of the major 
virulence factors of Bordetella pertussis facilitating 
respiratory tract colonization by the agent 
(Carbonetti et al., 2005; Mattoo and Cherry, 2005; 
Bauche et al., 2006). Deletion of the structural 
gene encoding for this toxin dramatically 
decreases the pathological effects of the 
infection as shown by reduced bacteria numbers 
found in the lung, almost abolished lung lesions, 
as well as loss of haemolysis and inflammatory cell recruitment (Guermonprez et al., 
2001; Hewlett et al., 2006). CyaA is able to invade eukaryotic cells by a unique 
mechanism comprising direct translocation of the CyaA catalytic domain across the 
plasma membrane of the target cells without the need for endocytosis (Ladant and 
Ullmann, 1999; Basler et al., 2006; Bauche et al., 2006). As shown in Fig. 11, CyaA 
consists of an N-terminal AC enzyme domain, a pore-forming region with four 
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hydrophobic segments, a region where CyaA possesses a palmitoyl chain as well as 
a glycine- and aspartate-rich nonapeptide repeat. The latter mediates binding to the 
cell and is able to undergo conformational changes translocating the AC domain to 
the cytosol, where it is activated by CaM and consequently, effects uncontrolled 
conversion of cellular ATP to cAMP (Ladant and Ullmann, 1999; Basler et al., 2006). 
 
 
Fig. 11: Hypothetical mechanism for the translocation of Bordetella pertussis 
AC toxin across the target cell membrane. The four hydrophobic domains and the 
palmitoyl chain insert into the cell membrane. The repeated motifs bind divalent 
cations and mediate translocation of the AC domain across the membrane (Ladant 
and Ullmann, 1999).  
 
 
By its hydrophobic residues, CyaA is able to form small cation-selective pores 
in target cell membranes, accounting for its haemolytic activity on erythrocytes 
(Basler et al., 2006). CyaA specifically targets immune effector cells like neutrophils, 
macrophages or dendritic cells expressing the αMβ2 membrane receptor 
(Guermonprez et al., 2001). CyaA inhibits neutrophil functions, including chemotaxis, 
phagocytic abilities, superoxide generation (Confer and Eaton, 1982; Friedman et al., 
1987; Weingart and Weiss, 2000) and induces apoptosis in macrophages (Khelef et 
al., 1993; Gueirard et al., 1998; Carbonetti et al., 2005). 
Several crystal structures of CyaA have been resolved, revealing the 
interactions of the substrate ATP with amino acid residues of the catalytic site and 
the domain interacting with the activator protein CaM (Guo et al., 2005). Cyclization 
of ATP to cAMP and pyrophosphate by CyaA is assumed to occur by two-metal-ion 
catalysis which is described in more detail for the catalysis by Bacillus anthracis AC 
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toxin edema factor (EF). Amino acid residues crucial for catalysis by CyaA are well 
aligned with the corresponding residues of EF. At the catalytic site of CyaA, divalent 
metal ions are coordinated by D188, D190 and H298 (Glaser et al., 1991; Guo et al., 
2005). The metal ions interact with the negatively charged triphosphate residue of 
ATP, which is also accommodated by the positive residues R37, K58, K65 and K84. 
N304 interacts with the ribose oxygen atom and holds the ribose in position. H63 
serves as a catalytic base to deprotonate the 3´-OH group allowing the nucleophilic 
attack of the 3´-oxyanion on the α-phosphate group. 
It has been reported that under certain circumstances, standard antibiotic 
treatment of whooping cough may not be sufficient to ensure complete eradication of 
the bacteria, e.g. a low-weight neonate relapsed after antibiotic treatments 
(Bonacorsi et al., 2006). Therefore, further research is necessary to identify 
host/organism factors associated with severe disease and death. A combination of 
vaccines, antibiotics and - in particular - potent and selective CyaA inhibitors may be 
used to reduce morbidity and mortality and to control the ongoing circulation of 
Bordetella pertussis. As the CyaA enzyme contains the tryptophan residues W69 and 
W242, enzyme-tryptophan fluorescence approaches may be developed for the 
search for inhibitor molecules possessing affinity to CyaA. 
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1.2.3 Fluorescence Methods in the Investigation of Bacterial AC Toxins 
Aromatic tryptophan residues in proteins can be excited by ultraviolet light to 
yield fluorescence emission. Additionally, tryptophan fluorescence is subject to 
environmental properties like polarity of the solvent or of interacting amino acid 
residues. Therefore, enzyme-tryptophan fluorescence approaches can be applied to 
study essential processes like conformational changes within the protein structure 
upon ligand binding or protein-protein interactions.  
Fluorescence resonance energy transfer (FRET) has become widely used in 
many applications of fluorescence. FRET is an electrodynamic phenomenon 
between a donor molecule in the excited state and an acceptor molecule in the 
ground state (Lakowicz, 1999). Based on the concept of a fluorophore as an 
oscillating dipole, which can exchange energy with another dipole with a similar 
resonance frequency, excitation energy of the donor is transferred to the acceptor via 
a long-range dipole-dipole coupling mechanism resulting in an increase of 
fluorescence intensity of the acceptor molecule. The extent of FRET is predictable 
from the spectral properties of the fluorophores and is not significantly affected by the 
biomolecules in the sample. As a function of the extent of spectral overlap of the 
emission spectrum of the donor with the absorption spectrum of the acceptor, FRET 
depends on the quantum yield of the donor and the relative orientation of donor and 
acceptor. Moreover, the rate of energy transfer E  strongly depends on the distance r 
between the donor and the acceptor molecule and is proportional to r -6: 
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0R  is called the Förster radius and is the distance at which FRET is 50% 
efficient, typically being in the range of 20 to 60 Å. Therefore, FRET is convenient for 
studies of biological macromolecules. With κ  being a factor describing the relative 
spacial orientation of donor and acceptor, the refractive index of the medium n , the 
quantum yield of the donor DQ  and the overlap integral expressing the degree of 
spectral overlap between the donor emission and the acceptor absorption )(λJ , the 
Förster radius is given by Eq. 1.2. The greater the overlap of the emission spectrum 
of the donor with the absorption spectrum of the acceptor, the higher the value of 0R . 
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Tryptophan residues can be excited at a wavelength of 280 nm, fluorescence 
emission occurs at 350 nm. The MANT-group in MANT-substituted nucleoside 
triphosphates is fluorescent; light is absorbed at a wavelength of 350 nm yielding 
fluorescence emission at 430 nm. Thus, the tryptophan emission spectrum and the 
MANT excitation spectrum overlap. Consequently, when tryptophan residues in AC 
are excited with MANT-nucleotides being in spacial proximity, e.g. due to binding at 
the catalytic site, FRET occurs, increasing fluorescence emission of the MANT-group 
at 430 nm (Fig. 12). 
 
 
 
Fig. 12: Principle of FRET experiments with AC and MANT-nucleotides. 
Tryptophan residues in AC are excited at a wavelength of 280 nm, effecting 
fluorescence at 350 nm. Binding of MANT-nucleotides to the catalytic site of AC 
causes FRET, yielding emission at a wavelength of 430 nm. 
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As shown in Fig. 13, two tryptophan residues are contained within the 
Bordetella pertussis CyaA protein, one close to the catalytic site (W69) and one 
being part of the domain interacting with CaM (W242). Therefore, binding of MANT-
substituted nucleotides to the catalytic site of CyaA can be monitored by the 
occurrence of FRET due to excitation of tryptophan residues. Additionally, when the 
MANT-nucleotide binds to the protein, the MANT-group resides in an environment 
different from the solvent as it interacts with certain, mainly hydrophobic amino acid 
residues, e.g. phenylalanine. Therefore, fluorescence intensity and emission 
wavelength of MANT fluorescence change upon binding of the substituted nucleotide 
to the protein. Thus, MANT-nucleotide binding to CyaA can also be monitored by 
directly exciting the MANT-group at 350 nm and recording the resulting changes in 
direct fluorescence. 
 
 
 
 
Fig. 13: Crystal structure of CyaA in complex with the substrate analog 
PMEApp bound at the catalytic site. Two metal ions coordinating the triphosphate 
chain of PMEApp are indicated as green spheres. W69 and W242 are located in 
close proximity of the catalytic site and the CaM binding site, respectively. Carbon 
atoms are colored green, nitrogen blue, phosphorous orange and oxygen red. 
PMEApp is the active metabolite of adefovir, a drug for the treatment of chronic 
hepatitis B virus infection, and a potent inhibitor of EF and CyaA. The figure was 
generated according to the structure reported previously (Guo et al., 2005) using the 
PDB Protein Workshop 3.3 (Moreland et al., 2005). 
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1.2.4 cCMP as a Third Cyclic Nucleotide Serving as Second Messenger 
Besides the well-known key second messengers cAMP and cGMP, cyclic 
cytidine 3´:5´-monophosphate (cCMP) could be a third important cyclic nucleotide 
serving as a second messenger. Since the initial reports in 1974 by Bloch et al., the 
natural occurrence of cCMP in various mammalian organs was confirmed 
unambiguously by mass spectrometry methods (Bloch et al., 1974; Newton et al., 
1984). The kinetic parameters of the cytidylyl cyclase (CC) reaction were revealed 
and CC activities were characterized in nine organs of rat (Newton et al., 1990, 
1997). The discovery of phosphodiesterase activity accounting for the selective 
degradation of cCMP accentuates the potential importance of cCMP as a regulator of 
cell function (Newton et al., 1986, 1999). Additionally, cCMP has been shown to 
stimulate protein kinase activity (Newton et al., 1992) and ten proteins underwent 
cCMP-stimulated phosphorylation in brain tissue (Bond et al., 2007; Ding et al., 
2008). 
Most importantly, cCMP was shown to impair immune system functions. The 
cell-permeant cCMP-analog dibutyryl-cCMP inhibited the formation of thromboxanes 
and leukotrienes in macrophages, two important mediators of inflammation. Hence, 
dibutyryl-cCMP modulates macrophage eicosanoid synthesis (Elliott et al., 1991). 
Dibutyryl-cCMP also inhibited the superoxide (O2
-) formation in human neutrophils 
and effected neutrophil inactivation (Ervens and Seifert, 1991). Therefore, these 
findings point to cCMP being a potential novel second messenger with a negative 
regulatory function on immune responses. The question arises if bacterial adenylyl 
cyclase toxins might also possess cytidylyl cyclase activity forming cCMP to cause 
collateral impairment of host immune responses. 
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1.3 Scope and Objectives of the Work 
 
The cAMP signaling pathway is crucial for many physiological processes and 
many disease states like neurodegenerative diseases, mood disorders, pain, drug 
dependency or heart failure. The use of drugs targeting GPCRs to exert influence on 
the cAMP signaling pathway is limited, e.g. due to receptor desensitization, receptor 
polymorphisms or additional receptors not targeted by the specific drug. As 
mammalian AC isoforms are expressed in a tissue-specific manner, isoform-selective 
AC activation or inhibition may be a promising novel therapeutic strategy. Therefore, 
the aim of this doctoral thesis is to develop analytical methods for the investigation 
and characterization of AC enzyme activity in specific mammalian tissues, e.g. in the 
heart. It is intended to develop a procedure for preparing cell membrane-bound AC 
from mammalian tissues exhibiting enzymatic activity. It is planned to clarify the 
expression patterns of the different AC isoforms in the considered tissues by using 
molecular biological approaches and immunoblotting methods. The biochemical 
parameters required for AC activity will be determined. With these prerequisites 
fulfilled, biochemical assays will be developed to pharmacologically characterize AC 
activity and to screen for molecules stimulating or inhibiting AC. The structure-activity 
relationships for AC inhibitors and activators shall be explored; highly potent and 
isoform-selective inhibitors and activators will be developed. As the cAMP signaling 
pathway is essential for cardiac contractility, and as heart failure is one of the most 
important causes for morbidity and mortality in elderly patients, the heart - hence AC 
from cardiac tissue - will be considered primarily. Thus, this work will provide the 
basis for exploring AC as target for the treatment of heart failure. 
Anthrax disease and whooping cough, caused by Bacillus anthracis and 
Bordetella pertussis, respectively, are characterized by high morbidity rates and by 
severe courses of disease, causing death in many cases. Bacterial AC toxins are key 
virulence factors contributing to impairment of host immune responses and 
worsening of the infections. Therefore, the aim of this doctoral thesis is to provide the 
basis for the development of inhibitors of the AC toxins EF and CyaA from B. 
anthracis and B. pertussis, respectively. Biochemical methods will be developed 
allowing fluorescence-based screening for AC toxin inhibitors. Moreover, the detailed 
modes of action of EF and CyaA will be clarified. The question will be answered, if 
 General Introduction 32 
cAMP formation is the only enzymatic activity of the AC toxins, or if the agents 
possess other hitherto unknown activities. 
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2.1 Abstract 
 
Chronic heart failure is one of the most frequent causes of death in humans. 
Knock-out of type 5 adenylyl cyclase (AC) in mice causes longevity and protection 
from cardiomyopathy, and an AC5 inhibitor reduces β-adrenoceptor-stimulated Ca2+ 
inward currents in isolated mouse cardiomyocytes. These data indicate that selective 
AC5 inhibitors may be beneficial in chronic heart failure patients. Therefore, we 
characterized AC in mouse heart membranes. Real-time polymerase chain reaction 
and immunoblot analysis suggested that AC5 is an important heart AC isoform. 
Enzyme kinetics of heart AC and recombinant AC5 in the presence of Mg2+ were 
similar. Moreover, the stimulatory profile of forskolin and six forskolin analogs on 
mouse heart AC was similar to recombinant AC5. Furthermore, the inhibitory profile 
of eight 2´(3´)-O-(N-methylanthraniloyl) (MANT)-nucleoside 5´-([γ-thio])triphosphates 
on mouse heart in the presence of Mg2+ was similar to AC5. MANT-ITP was the most 
potent inhibitor of heart AC and recombinant AC5 with Ki values in the 1-5 nM range 
in the presence of Mn2+ and in the 15-25 nM range in the presence of Mg2+. 
However, in the presence of Mn2+, we also noted differences between mouse heart 
AC and AC5 with respect to enzyme kinetics and forskolin analog effects. In 
conclusion, with respect to expression, kinetics, activation by forskolin analogs and 
inhibition by MANT-nucleotides in the presence of Mg2+, AC5 is an important AC 
isoform in the heart, with MANT-ITP being an excellent starting point for the design of 
AC5-selective inhibitors. Unfortunately, a limitation of our study is the fact that 
immunologically and biochemically, AC5 and AC6 are quite similar although they play 
different roles in heart function. Moreover, lack of antibody specificity was a problem. 
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2.2 Introduction 
 
In the human heart, the β1-adrenoceptor-Gs-protein-AC system is the major 
physiological mechanism for acute modulation of contractility (Lohse et al., 2003). 
Gene knock-out studies confirmed the major significance of the β1-adrenoceptor for 
the regulation of heart function in mouse (Devic et al., 2001). Nine membrane-bound 
AC isoforms (AC1-AC9), producing the second messenger cAMP, have been cloned 
in mammals. Gene expression studies showed that AC5 is the major cardiac AC 
isoform (Defer et al., 2000; Sunahara and Taussig, 2002; Beazely and Watts, 2006). 
The diterpene forskolin (FS) from Coleus forskohlii effectively activates ACs 1-8 but 
not AC9 (Sunahara and Taussig, 2002). Moreover, FS and FS analogs differentially 
activate recombinant ACs 1, 2 and 5 expressed in Sf9 insect cells (Pinto et al., 2008). 
This was not expected in view of the fact that the FS binding site is highly conserved 
among the various AC isoforms (Sunahara and Taussig, 2002). 
Chronic heart failure is one of the most important causes of death in humans 
(Fonarow, 2008; Yu et al., 2008). In chronic heart failure, desensitization of the 
myocardial β1-adrenoceptor occurs, reducing the positive inotropic effects of 
catecholamines. An inverse correlation between survival and activation of the 
sympathetic system has been observed in chronic heart failure patients. Thus, β1-
adrenoceptor desensitization can be interpreted as energy-saving adaptation, 
protecting against the detrimental consequences of excessive adrenergic drive (El-
Armouche et al., 2003; Lohse et al., 2003). Accordingly, the standard long-term 
treatment of chronic heart failure includes β1-adrenoceptor antagonists, considerably 
reducing morbidity and mortality (Bristow, 2000; Lohse et al., 2003). 
In a pressure overload model based on thoracic aortic banding, AC5 knock-out 
mice show a stable left ventricular ejection fraction, whereas the cardiac performance 
of wild-type mice is impaired (Okumura et al., 2003a, b). Most strikingly, compared to 
wild-type mice, AC5 knock-out mice show a considerably increased lifespan and 
protection from aging-induced cardiomyopathy and oxidative stress (Yan et al., 
2007). Additionally, the AC5 knock-out protects mice against β1-adrenoceptor-
induced cardiomyocyte apoptosis (Iwatsubo et al., 2004). However, AC regulation in 
the heart is more complex. Specifically, the overexpression of AC6 in the heart 
reduces left ventricular remodeling, preserves left ventricular function and reduces 
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mortality in a myocardial infarction model (Takahashi et al., 2006). Thus, it appears 
that AC5 and AC6 play opposing roles in heart function. 
MANT-nucleotides inhibit AC isoforms 1, 2, 5 and 6, with ACs 1, 5 and 6 being 
more sensitive to inhibition than AC2 (Gille et al., 2004). In mouse ventricular 
cardiomyocytes, the AC5 inhibitor MANT-GTPγS effectively reduces isoproterenol-
stimulated L-type Ca2+ inward currents, while in myocytes from AC5 knock-out mice, 
the residual Ca2+ current is not further attenuated by MANT-GTPγS (Rottländer et al., 
2007). These data support the notion that AC5 is the major AC isoform mediating 
acute β-adrenergic stimulation in mouse heart. 
Based on all of the above findings, AC5 inhibitors should be explored as new 
candidates for chronic heart failure therapy. Therefore, as a first step towards this 
ambitious goal, the aim of our present study was to provide a detailed 
characterization of mouse heart AC in comparison to recombinant AC isoforms, 
specifically AC5, using MANT-nucleotides and FS analogs as pharmacological tools. 
For the preparation of crude mouse heart membranes, we used a membrane 
preparation protocol that had previously shown to yield robust AC activities (Rohrer 
et al., 1996). To the best of our knowledge, this is the first study on the 
pharmacological characterization of AC activity in a native membrane system. 
Fig. 1 shows the structures of the MANT-nucleotides and FS analogs 
examined in this study. All nucleotides possess a MANT-group at the 2´(3´)-O-ribosyl 
function. The MANT-group spontaneously isomerizes between the 2´- and 3´-O-
ribosyl function (Gille et al., 2004; Taha et al., 2009). We studied MANT-nucleotides 
with purine bases (guanine, adenine or hypoxanthine) as well as nucleotides with 
pyrimidine bases (uracil or cytosine). Moreover, we studied nucleotides with a 
triphosphate chain and nucleotides with a thiophosphate at the γ-position, with the 
thiophosphate introducing bulkiness into the molecule and resistance against 
degradation by nucleotidases (Eckstein, 1985). Concerning FS derivatives, we 
studied FS and FS derivatives missing an OH-function at the 1´- or 9´-position of the 
diterpene ring or the acetyl group at the 7´-position. We also examined the diterpene 
with the acetyl group at the 6´- instead at the 7´-position, also referred to as iso-FS. 
Finally, we examined FS analogs with bulky substituents at the 6´-position, i.e. the 
fluorescent FS analog BODIPY-FS, and the water-soluble FS analog DMB-FS, which 
is commonly used in experiments with intact cells (Pinto et al., 2008).  
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Fig. 1: Structures of compounds analyzed in this study. A: Structures of MANT-
nucleotides. Note that the MANT-group spontaneously isomerizes between the 2´- 
and 3´-O-ribosyl group. B: Structures of FS and FS derivatives. In some structures, 
numbers highlight important carbon atoms bearing substitutions. 
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2.3 Materials and Methods 
 
Materials. MANT-ITP, MANT-CTP and MANT-UTP were synthesized as 
described (Taha et al., 2009). MANT-ATP, MANT-GTP, MANT-ATPγS, MANT-
GTPγS and MANT-ITPγS were from Jena Bioscience (Jena, Germany). [α-32P]ATP 
(800 Ci/mmol) was purchased from PerkinElmer (Wellesley, MA, USA). Neutral 
alumina (N Super 1) was purchased from MP Biomedicals (Eschwege, Germany). 
Histamine, serotonin, dopamine, (-)-isoproterenol, (-)-epinephrine, (-)-norepinephrine, 
6A7DA-FS, 7DA-FS, 1d-FS, 9d-FS, cAMP, IBMX and triethanolamine were from 
Sigma-Aldrich (St. Louis, MO, USA). BODIPY-FS was purchased from Molecular 
Probes (Eugene, OR, USA). Glucagon was from American Peptide Company 
(Sunnyvale, CA, USA). FS was from LC Laboratories (Woburn, MA, USA). MnCl2 and 
MgCl2 (highest quality) were from Merck (Darmstadt, Germany). GTP, GTPγS, ATP 
and creatine kinase were purchased from Roche (Mannheim, Germany). Porcine 
neuropeptide Y was synthesized by solid phase synthesis at the Institute of Organic 
Chemistry, University of Regensburg. Antibodies for ACs 2, 3, 4 and 6 were from 
Abcam (Cambridge, UK). The AC1 antibody (V-20) and the AC5/6 antibody (C-17) 
were from Santa Cruz Biotechnology, Inc. (Santa Cruz CA, USA). DMB-FS was from 
Calbiochem (San Diego, CA, USA). 
 
Real-Time PCR. Total RNA from mouse hearts was extracted and reverse-
transcribed and real-time PCR was carried out as described (Matzdorf et al., 2007). 
In brief, total RNA was extracted using TRIzol reagent (Invitrogen, Karlsruhe, 
Germany). cDNA was synthesized in a 20-µL reaction with 2 µg total RNA, 0.5 µg 
oligo(dT)12-18, 20 U RNasin (Promega, Mannheim, Germany), 4 µL of 5x RT buffer, 
0.5 mM dNTPs, and 20 U Moloney murine leukemia virus RT enzyme (Invitrogen). 
Real-time PCR was performed with the LightCycler System (Roche). All PCR 
experiments were performed using a LightCycler-FastStart DNA Master SYBR Green 
kit (Roche). Each reaction (20 µL) contained 2 µL of cDNA, 3.0 mM MgCl2, 1 pmol of 
each primer, and 2 µL of Fast Starter Mix (containing buffer, dNTPs, SYBR Green, 
and Taq polymerase). 
The specific primer sequences used are shown in Tab. 1. The amplification 
program consisted of one cycle of 95°C with 10-min hold (“hot start”) followed by 30 
cycles of 15 s at 95°C, 5 s at 60°C, and 20 s at 72°C. Amplification was followed by 
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melting curve analysis (increasing the temperature of the reaction mixtures up to 
95°C, by 0.1°C/s, starting at 50°C for 15 s) to verify the correctness of the amplicon. 
To verify the accuracy of amplification, PCR products were further analyzed on 
ethidium bromide-stained 2% (m/v) agarose gels (Fig. 2). AC primers produced 
specific PCR products of the following sizes: 121 bp (AC1), 141 bp (AC2), 443 bp 
(AC3), 121 bp (AC4), 456 bp (AC5), 131 bp (AC6), 569 bp (AC7), 133 bp (AC8), 134 
bp (AC9). Data were analyzed using the LightCycler software, version 3.5.3.  
 
Tab. 1: Primer sequences for real-time PCR of AC isoforms in mouse heart. 
AC isoform 
 
Primer sequence 
AC1 Forward: 5´-CCAGCCAAGAGGATGAAGTT-3´ 
 Reverse: 5´-AATGCCCTCCGCTTGTC-3´ 
AC2 Forward: 5´-AGCATTCAAGTACTACGTGACC-3´ 
 Reverse: 5´-ACAAAGAGGATGAAGATGAGGG-3´ 
AC3 Forward: 5´-CATCGAGTGTCTACGCTTC-3´ 
 Reverse: 5´-GGATGACCTGTGTCTCTTCT-3´ 
AC4 Forward: 5´-TGCTGTCTTCTCTGGAGGG-3´ 
 Reverse: 5´-GTGGACACGGGACTGTCAA-3´ 
AC5 Forward: 5´-ACGATTGGTAGTACAGCTCGTCATTGCGCC-3´ 
 Reverse: 5´-TGCTCAGCCTGCTGGCCTGCTCCGTGTTCC-3´ 
AC6 Forward: 5´-GAGGCAAACAACGAGGGC-3´ 
 Reverse: 5´-GCCATGTAGGTGCTACCG-3´ 
AC7 Forward: 5´-GCTTGCTCATCAGGGCCATGCTAA-3´ 
 Reverse: 5´-CCAGTTATTTAGAGAGAGACCT-3´ 
AC8 Forward: 5´-CGCATCTACATCCATCGCTAT-3´ 
 Reverse: 5´-GGTCGAATCTGGCAAAGAGTT-3´ 
AC9 Forward: 5´-ATGGGCGGCTTGAAGAAATA-3´ 
 Reverse: 5´-GCAGGCGTGAGCTTGGA-3´ 
 
 
Sf9 Cell Culture and Expression of Recombinant ACs. Sf9 cell culture, 
expression of recombinant AC isoforms 1, 2, 4, 5 and 6 and the preparation of Sf9 
membranes were performed as described (Gille et al., 2004). For the AC assay, Sf9 
membranes were thawed and sedimented by a 15-min centrifugation at 4°C and 
15,000 x g to remove residual endogenous nucleotides and resuspended in assay 
buffer as described below. 
 
SDS-Polyacrylamide Gel Electrophoresis and Immunoblot Analysis. The 
detection of AC proteins using isoform-specific antibodies was performed as 
described with minor modifications (Houston et al., 2002). Mouse heart membrane- 
 Characterization of Mouse Heart Adenylyl Cyclase 62 
  
or Sf9 membrane proteins were separated on SDS-polyacrylamide gels containing 
5% (m/v) acrylamide. Proteins were transferred onto Trans-Blot nitrocellulose 
membranes (Bio-Rad Laboratories, Hercules, CA) and reacted with the 
corresponding AC antibody (1:200-1:500). Protein bands were visualized by 
enhanced chemiluminescence (Pierce Chemical, Rockford, IL) using peroxidase-
coupled goat anti-rabbit IgG (1:1,000; Santa Cruz Biotechnology, Inc.). 
 
Preparation of Mouse Heart Membranes. Female CD1 mice were housed in 
cages in a temperature- and light-controlled environment according to the German 
animal protection law. At the age of eight weeks, mice were sacrificed by cervical 
dislocation and hearts were removed, shock-frozen in liquid nitrogen and stored at -
80°C. Mouse heart membranes were prepared according to a previously described 
protocol with minor modifications (Rohrer et al., 1996). Briefly, hearts were thawed 
and rinsed in ice-cold homogenization buffer containing 5 mM Tris/HCl, pH 7.4, and 5 
mM EDTA. All membrane preparation steps were conducted at 4°C. Homogenization 
was performed in a buffer volume amounting to 20-fold the heart tissue weight. 
Hearts were cut into small pieces and then homogenized in a glass-glass 
homogenizer (Braun, Melsungen, Germany) at 1,500 rpm, applying 5 series of 5 
strokes each with a 1-min cooling period between each series. Organ debris was 
removed by an 8-min centrifugation at 500 x g. The supernatant suspension was 
sedimented by a 30-min centrifugation at 40,000 x g. The resultant membrane pellet 
was washed in a buffer volume amounting to 60-fold the heart tissue weight and 
sedimented by a 30-min centrifugation at 40,000 x g. In order to remove residual 
endogenous ligands and nucleotides, this washing procedure was performed three 
times before the membranes were resuspended in assay buffer consisting of 50 mM 
triethanolamine and 1 mM EGTA, pH 7.4. Membranes were resuspended with 
syringes in the sequence 21 G, 25 G, 27 G and then shock-frozen in liquid nitrogen 
and stored at -80°C. In order to detect robust AC activity in heart membranes, it was 
essential to follow the protocol described above. Specifically, the use of the above-
described buffers was critical. When hearts were homogenized in the standard buffer 
used for Sf9 cell homogenization (Houston et al., 2002; Gille et al., 2005), no AC 
activity was recovered.  
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AC Activity Assay. Assay tubes contained 10 µL of FS analogs, MANT-
nucleotides or receptor ligands and 20 µL of reaction mixture consisting of (final) 7 
mM Mn2+ or Mg2+, 10 µM GTP, 10 µM GTPγS, 100 µM cAMP, 0.4 mg/mL creatine 
kinase, 9 mM phosphocreatine, 100 µM IBMX, 10 µM isoproterenol and, unless 
stated otherwise, 100 µM FS. In experiments aiming at the assessment of GPCR 
ligand effects on AC activity, GTPγS and FS were omitted from reaction mixtures. 
Tubes also contained 40 µM ATP and 0.2-1.0 µCi [α-32P]ATP. Tubes were 
preincubated for 2 min at 30°C, and reactions were initiated by the addition of 20 µL 
of membranes (20 µg of protein per tube), yielding 20 mM triethanolamine and 0.4 
mM EGTA, pH 7.4, as assay buffer. For determination of Km and Vmax values, 
ATP/Mn2+ or ATP/Mg2+ (10 µM - 2 mM) plus 7 mM of free Mn2+ or Mg2+ were added. 
In experiments with FS analogs, the MnCl2 concentrations were increased to 10 mM 
to match previous conditions (Pinto et al., 2008). Moreover, in those studies, GTPγS 
(10 µM) was included in reaction mixtures. To ensure linear reaction progress, tubes 
were incubated for 10 min at 30°C. In experiments for the determination of inhibitor 
potencies on cardiac AC, incubation time was reduced to 1-2 min to avoid nucleotide 
degradation. Reactions were terminated by the addition of 20 µL of 2.2 N HCl, and 
denatured protein was sedimented by a 1-min centrifugation at 12,000 x g. 
[
32P]cAMP was separated from [α-32P]ATP by transferring the samples to columns 
containing 1.4 g of neutral alumina. [32P]cAMP was eluted into 20-ml scintillation vials 
by adding 4 mL of 0.1 M ammonium acetate, pH 7.0. Blank values were ~0.02% of 
the total amount of [α-32P]ATP added; substrate turnover was < 3% of the total added 
[α-32P]ATP. Scintillation vials were filled up with 10 mL double-distilled water, and 
Čerenkov radiation was determined. 
 
Miscellaneous. Protein was determined using the DC protein assay kit (Bio-
Rad, Hercules, CA). Data shown in Tab. 2 to 5 and Figs. 4, 5 and 7 were obtained by 
non-linear regression analysis performed with the Prism 4.02 software (Graphpad, 
San Diego, CA). Statistical comparisons shown in Figs. 5 and 6 were performed 
using the t-test. 
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2.4 Results 
 
2.4.1 Detection of AC Isoforms in Mouse Heart by Real-Time PCR and 
Immunoblot Analysis 
To investigate the mRNA expression levels of AC isoforms in mouse heart, we 
reverse-transcribed mRNA and performed real-time PCR using isoform-specific 
primers (Tab. 1). PCR products were detected for ACs 1, 3 to 7, and 9 (Fig. 2). No 
PCR products were obtained for ACs 2 and 8. The threshold values were 22 cycles 
for ACs 5 and 6, 25 cycles for ACs 1, 3, and 4, 26 cycles for AC7, and 27 cycles for 
AC 9.  
 
 
 
Fig. 2: Detection of AC isoforms in mouse heart by real-time PCR. Total RNA 
extraction from mouse hearts, reverse transcription and real-time PCR were carried 
out as described under “Materials and Methods”. PCR products were analyzed on 
ethidium bromide-stained 2% (m/v) agarose gels after completion of the PCR. Mouse 
heart cDNA fragments produced specific PCR products of the following sizes: 121 bp 
(AC1), 141 bp (AC2), 443 bp (AC3), 121 bp (AC4), 456 bp (AC5), 131 bp (AC6), 569 
bp (AC7), 133 bp (AC8), 134 bp (AC9). Data analysis was performed using the 
LightCycler software, version 3.5.3, and LightCycler Relative Quantification 
(RelQuant) Software. Data shown are representative of experiments with 5 different 
mice. 
 
 
Next, we examined AC expression at the protein level. The AC5/6 antibody 
yielded bands at ~120 to 140 kDa in mouse heart membranes using recombinant 
AC5 as positive control (Fig. 3A). Immunologically detected bands were diffuse, 
compatible with ACs being glycosylated (Beazely and Watts, 2006). Sf9 membranes 
expressing AC3 were used as negative control and did not show an immunoreactive 
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band. The difference in migration between recombinant AC5 and native cardiac 
AC5/6 may be due to differences in AC5 glycosylation between Sf9 insect cells and 
mouse heart. It is also possible that the antibody primarily detected AC6 in heart 
membranes.  
 
 
Fig. 3: Detection of AC isoforms in mouse heart and Sf9 insect cell membranes 
by immunoblot analysis. A: Immunoblot with the AC5/6 antibody C-17 from Santa 
Cruz Biotechnology, Inc. (1:500) with membranes from Sf9 cells expressing AC3 
(negative control, 25 µg of protein per lane), AC5 (positive control, 25 µg of protein 
per lane), and mouse heart membranes (100 µg of protein per lane). B: Immunoblot 
with the AC1 antibody V-20 from Santa Cruz Biotechnology, Inc. (1:200), with three 
different membrane preparations expressing AC1 (“positive” control, 75 µg of protein 
per lane) and membranes from uninfected (uninf.) Sf9 cells (“negative” control, 75 µg 
of protein per lane). Immunoblot analysis was performed as described under 
“Materials and Methods”. Data shown are representative of three independent 
experiments. 
 
 
Unfortunately, our substantial efforts to conduct a comprehensive analysis of 
AC isoform expression in heart membranes were not successful. First, except for the 
AC5/6 antibody, in our hands, the other antibodies examined did not display sufficient 
sensitivity and/or selectivity to obtain reliable information about AC isoform 
expression in heart membranes, using Sf9 membranes expressing the corresponding 
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AC isoform as standard. In pars pro toto, Fig. 3B illustrates this problem for AC1. In 
Sf9 cell membranes, AC1 is expressed very well as assessed by enzyme activity 
(Gille et al., 2004; Pinto et al., 2008). Thus, we expected to obtain clear 
immunoreactive bands with the AC1 antibody. However, both in membranes from 
uninfected Sf9 cells and AC1-expressing Sf9 cells, bands in the 120-kDa region and 
in the 50-kDa region were detected, but we failed to reveal a unique band in the AC1-
expressing membranes. The immunologically recognized bands in membranes from 
uninfected Sf9 cells were actually more intense than in AC1 virus-infected cells, 
probably reflecting that the expression of certain proteins in Sf9 cells is decreased as 
a result of virus infection (Pinto et al., 2008). Real-time PCR experiments and 
stimulation experiments with Ca2+/calmodulin confirmed that the AC expressed in Sf9 
cells infected with AC1 virus was actually AC1 (data not shown). In heart 
membranes, the AC1 antibody failed to detect a specific band as well (data not 
shown). Similar problems concerning the specificity of AC antibodies are already 
described to some extent in the literature (Defer et al., 2000; Liu et al., 2007). 
Moreover, we do not yet have in hand all recombinant AC isoforms in functionally 
active form, resulting in a lack of positive and negative controls. Collectively, these 
data indicate that the presently available AC isoform antibodies must be used with 
great caution and very critically, both in native systems and in membranes 
expressing recombinant ACs. This unsatisfying situation also emphasizes the 
importance of real-time PCR studies to assess AC isoform expression in native 
tissues. 
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2.4.2 Stimulation of Mouse Heart AC by FS and FS Analogs: Comparison with 
Recombinant AC Isoforms 
FS and FS analogs differentially activate AC isoforms (Pinto et al., 2008). FS 
robustly increased AC activity in mouse heart membranes (Fig. 4A). In the presence 
of Mn2+ or Mg2+, the EC50 values for FS and the relative maximum stimulatory effects 
of FS were similar (Tab. 2). FS activated ACs in the order of potency AC1 > AC5 ~ 
mouse heart AC > AC2 (Fig. 4B; Tab. 2).  
 
Fig. 4: Stimulation of mouse heart membrane AC and recombinant AC isoforms 
by FS. Reaction mixtures contained 7 mM Mn2+, 40 µM ATP, [α-32P]ATP (0.2-1.0 
µCi/tube), 100 µM cAMP, 0.4 mg/mL creatine kinase, 9 mM phosphocreatine and 
100 µM IBMX. Reactions were carried out for 10 min at 30°C as described in 
“Materials and Methods”. A: Stimulation of heart membrane AC by FS. B: 
Comparison of FS concentration-response curves obtained for heart membrane AC 
and recombinant ACs 1, 2 and 5 expressed in Sf9 cells. Data shown are the means ± 
SD of representative experiments performed in duplicates. Summaries of the results 
of 3-4 independent experiments are shown in Tab. 2 and 3. 
 
 
FS increased basal AC activity in Sf9 cell membranes expressing ACs 1 and 2 
by ~2 to 5-fold, whereas in Sf9 cell membranes expressing AC5 and mouse heart 
membranes, FS increased AC activity by ~15 to 20-fold. Thus, using FS as probe, 
there is a similarity of heart membrane with AC5. As outlined below, the situation with 
FS analogs is different. 
In mouse heart membranes FS analogs activated AC in the order of potency 
BODIPY-FS > FS ~ 6A7DA-FS > DMB-FS > 7DA-FS ~ 9d-FS (Tab. 3). The order of 
efficacy was DMB-FS > FS ~ 9d-FS ~ 7DA-FS > 6A7DA-FS > BODIPY-FS >> 1d-FS 
(ineffective). Tab. 3 also includes the pharmacological profile of FS analogs on 
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recombinant AC5. Note that the pharmacological profile of FS analogs on mouse 
heart AC and AC5 was assessed in the presence of Mn2+. With respect to the EC50 
values of FS analogs, we observed a significant correlation between mouse heart 
and AC5. However, the slope of the correlation was considerably steeper than 1.00, 
which value would have reflected pharmacological identity of the ACs studied (Fig. 
5A). With respect to the efficacies of FS analogs, the correlation between mouse 
heart and AC5 was not significant (Fig. 5B). These data indicate that under Mn2+-
conditions, AC isoforms other than AC5 contribute to total AC activity in mouse heart 
membranes. 
 
 
Tab. 2: EC50 values of FS for stimulation of mouse heart AC and AC isoforms 
and relative maximum stimulatory effect of FS on basal AC activity. 
Parameter, cation 
 
AC1 AC2 AC5 Cardiac AC 
EC50 [µM], Mn
2+ 0.42 ± 0.07 6.0 ± 2.1 4.0 ± 0.6 3.0 ± 0.2 
EC50 [µM], Mg
2+ 1.1 ± 0.4 11.4 ± 3.1 4.9 ± 1.0 2.3 ± 0.2 
Relative maximum 
stimulatory effect 
[x-fold], Mn2+ 
3.5 ± 0.1 5.2 ± 0.2 15.2 ± 0.05 22.8 ± 0.2 
Relative maximum 
stimulatory effect 
[x-fold], Mg2+ 
2.4 ± 0.02 3.0 ± 0.3 13.9 ± 0.9 18.0 ± 2.0 
AC activities were determined as described under “Materials and Methods”. Reaction 
mixtures contained 5 mM Mg2+ or Mn2+, 40 µM ATP, [α-32P]ATP (0.2-1.0 µCi/tube), 
0.4 mg/mL creatine kinase, 9 mM phosphocreatine, 100 µM cAMP, 100 µM IBMX 
and FS at concentrations from 0.1-300 µM. Data were analyzed by non-linear 
regression and are the means ± SD of 3-4 independent experiments performed in 
duplicates. 
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Tab. 3: Potencies and efficacies of FS and FS analogs on mouse heart AC and 
AC5. 
Diterpene Cardiac AC Cardiac AC AC5 AC5 
 EC50 [µM] Efficacy [%] EC50 [µM] Efficacy [%] 
FS 3.0 ± 0.2 100 4.0 ± 0.6 100 
6A7DA-FS 3.6 ± 0.5 76 ± 10 7.4 ± 2.8* 103 ± 11* 
BODIPY-FS 1.4 ± 0.5 54 ± 6 2.3 ± 1.1* 48 ± 2* 
7DA-FS 30.2 ± 10.2α 83 ± 5α 63.3 ± 10.6* 63 ± 4* 
9d-FS 38.6 ± 19.2α 90 ± 12α 65.3 ± 9.0* 79 ± 10* 
DMB-FS 17.4 ± 2.0α 118 ± 4α 48.0 ± 9.6* 95 ± 1* 
1d-FS ineffective ineffective* 
AC activities were determined as described under “Materials and Methods”. Reaction 
mixtures contained 10 mM Mn2+, 40 µM ATP, [α-32P]ATP (0.2-1.0 µCi/tube), 10 µM 
GTPγS, 0.4 mg/mL creatine kinase, 9 mM phosphocreatine, 100 µM cAMP and 100 
µM IBMX. EC50 values and efficacies were obtained by non-linear regression 
analysis and are the means ± SD of 3-4 independent experiments performed in 
duplicates. Values labelled with (*) were taken from (Pinto et al., 2008). 
α For those FS analogs not reaching saturation of the concentration/response curves, 
the actual stimulatory effect at a concentration of 300 µM was used for calculation of 
efficacy. Extrapolated EC50 values marked with an “
α” were derived from 
concentration/response curves that did not reach saturation. 
 
 
 
Fig. 5: Correlation of the potencies and efficacies of FS analogs on mouse 
heart AC and AC5. Data shown in Tab. 3 provide the basis for the correlations. Data 
were analyzed by linear regression. Dashed lines represent 95% confidence intervals 
of the linear regression lines. A: Correlation of potencies of FS analogs on mouse 
heart AC vs. AC5. Slope, 1.858 ± 0.2460; r2, 0.9344; p, 0.0016. B: Correlation of 
efficacies of FS analogs on mouse heart AC vs. AC5. Slope, 0.6371 ± 0.4330; r2, 
0.4191; p, 0.2376 (not significant). 
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2.4.3 Regulation of Mouse Heart AC by GTPγS, GTP and Receptor Ligands 
The non-hydrolysable GTP analog GTPγS activates AC through stimulation of 
Gsα (Eckstein, 1985; Gilman, 1987; Gille et al., 2005). In the presence of Mg
2+, 
GTPγS increased AC activity 4-fold with an EC50 value of 80 nM (data not shown). In 
the presence of GTP (10 µM), the β-adrenoceptor agonist isoproterenol increased 
AC activity about 2-fold with an EC50 value of 12 nM (Fig. 6A). Using a very similar 
heart membrane preparation as in the present study, Rohrer et al. (1996) reported 
that isoproterenol increased AC activity by 150% with 53 µM GTP. Thus, our results 
correspond well with the previous data, but Rohrer et al. (1996) did not report the 
absolute AC activities. Previous studies had already shown that in mouse heart, 72% 
of the β-adrenoceptors belong to the β1-subtype, whereas 28% belong to the β2-
subtype (Rohrer et al., 1996). In addition, studies with β1-adrenoceptor knock-out 
mice showed that ~90% of the isoproterenol-stimulated AC activity is attributable to 
the β1-adrenoceptor (Rohrer et al., 1996). 
Fig. 6B shows the concentration/response curves for the effect of GTP on 
basal and isoproterenol-stimulated AC activity. GTP effectively supported 
isoproterenol-stimulated AC activity; the EC50 for GTP was 100 nM. GTP also 
exhibited a modest stimulatory effect on basal AC activity; the EC50 was 140 nM. 
GTP did not only increase isoproterenol-stimulated AC activity but also basal AC 
activity (Fig. 6B).  
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Fig. 6: Regulation of mouse heart membrane AC by isoproterenol, metoprolol 
and GTP. Reaction mixtures contained 7 mM Mg2+, 40 µM ATP, [α-32P]ATP (0.2-1.0 
µCi/tube), 100 µM cAMP, 0.4 mg/mL creatine kinase, 9 mM phosphocreatine and 
100 µM IBMX. Reactions were carried out for 10 min at 30°C as described in 
“Materials and Methods”. A: Reaction mixtures contained isoproterenol at the 
concentrations indicated on the abscissa and GTP (10 µM). B: Reaction mixtures 
contained GTP at the concentrations indicated on the abscissa and water (control), 
isoproterenol or metoprolol (10 µM each). Data shown are means ± SD of 3 
independent experiments performed in duplicates. The statistical significance of the 
effect of metoprolol on AC activity vs. control was assessed with the t-test. However, 
the effect of metoprolol was not significant. 
 
 
In accordance with the literature (Engelhardt et al., 2001), this basal GTP-
dependent AC activity was reduced by the inverse agonist metoprolol. However, it 
should be emphasized that the inhibitory effect of metoprolol on GTP-stimulated AC 
activity did not reach statistical significance, indicating that the constitutive activity of 
the β1-adrenoceptor at least in this system is small. The inhibitory effect of GTP >10 
µM on AC activity is due to competition of GTP with ATP at the catalytic site of AC 
(Gille et al., 2005). The stimulatory effect of isoproterenol on AC in the absence of 
added GTP is explained by nucleoside diphosphokinase-mediated conversion of 
endogenous GDP to GTP by ATP (Kimura and Shimada, 1988).  
To identify GPCRs mediating stimulation (via Gs) or inhibition (via Gi) of AC in 
mouse heart, we examined several GPCR agonists in heart membranes (Fig. 7). 
Histamine, serotonin, glucagon and neuropeptide Y did not exhibit significant effects 
on AC activity. In contrast, the full β-adrenoceptor agonists epinephrine, 
norepinephrine and isoproterenol increased AC activity about 2-fold, while dopamine 
showed partial β1-adrenoceptor agonism. Partial agonism of dopamine has recently 
been reported for the recombinantly expressed β1-adrenoceptor (Weitl and Seifert, 
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2008). As the histamine H2-receptor is known to stimulate AC in human heart (Fryer 
et al., 2006; Salazar et al., 2007), we also examined the effects of the selective H2-
receptor agonists dimaprit and impromidine (Dove et al., 2004) on AC activity in 
mouse heart membranes. However, impromidine and dimaprit did not exhibit a 
stimulatory effect on AC activity (data not shown). 
 
 
Fig. 7: Effects of various GPCR agonists on AC activity in mouse heart 
membranes. Reaction mixtures contained 7 mM Mg2+, 40 µM ATP, [α-32P]ATP (0.2-
1.0 µCi/tube), 10 µM GTP, 100 µM cAMP, 0.4 mg/mL creatine kinase, 9 mM 
phosphocreatine and 100 µM IBMX. Reactions were carried out for 10 min at 30°C 
as described in “Materials and Methods”. Reaction mixtures contained histamine, 
dopamine, (-)-epinephrine, (-)-norepinephrine, (-)-isoproterenol, GTPγS or FS (100 
µM each) or serotonin (5-HT) and glucagon (10 µM each) or porcine neuropeptide Y 
(pNPY) (100 nM). Data shown are means ± SD of 3 independent experiments 
performed in duplicates. The statistical significance of the effects of receptor agonists 
on AC activity vs. control was assessed with the t-test. *, p < 0.05. 
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2.4.4 Enzyme Kinetics of Mouse Heart AC and Recombinant AC5 
Substrate saturation experiments under maximum stimulatory conditions were 
performed for mouse heart membranes and recombinant AC5. Note the different 
scales of the y-axes in Fig. 8, A and B, and the different scales of both the x- and y-
axes in Fig. 8, C and D. In the presence of Mg2+, AC5 and mouse heart AC exhibited 
similar Km and Vmax values (Figs. 8A and 8B; Tab. 4). Under Mn
2+-conditions, mouse 
heart AC showed 3- to 4-fold lower Km and Vmax values than recombinant AC5 (Figs. 
8C and 8D; Tab. 5). 
 
 
Fig. 8: Substrate saturation kinetics of recombinant AC5 and mouse heart 
membrane AC. Reaction mixtures contained 7 mM Mn2+ or Mg2+, [α-32P]ATP (0.2-
1.0 µCi/tube), 10 µM GTP, 10 µM GTPγS, 100 µM cAMP, 0.4 mg/mL creatine kinase, 
9 mM phosphocreatine, 100 µM IBMX, 10 µM isoproterenol and 100 µM FS. 
ATP/Mn2+ or ATP/Mg2+ (10 µM to 2 mM) plus 7 mM of free Mn2+ or Mg2+ were added 
to reaction mixtures. In order to ensure linear reaction progress, tubes were 
incubated for 10 min at 30°C. A: Substrate saturation curve for AC5 in the presence 
of Mg2+. B: Substrate saturation curve for heart membrane AC in the presence of 
Mg2+. C: Substrate saturation curve for AC5 in the presence of Mn2+. D: Substrate 
saturation curve for heart membrane AC in the presence of Mn2+. Experiments were 
performed as described in “Materials and Methods”. Data shown are means ± SD of 
3 independent experiments performed in duplicates. 
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2.4.5 Inhibitor Potencies at Mouse Heart AC and Recombinant AC Isoforms 
MANT-nucleotides differentially inhibit AC isoforms (Gille et al., 2004). We 
examined the inhibitory effects of 8 MANT-nucleotides on mouse heart AC and 
recombinant ACs. In the presence of Mg2+, the rank order of inhibitory potency of 
MANT-nucleotides at mouse heart AC was MANT-ITP ~ MANT-ITPγS > MANT-
GTPγS > MANT-ATPγS ~ MANT-GTP > MANT-UTP > MANT-ATP > MANT-CTP 
(Tab. 4).  
 
 
Tab. 4: Kinetic properties of mouse heart AC and ACs 1, 2 and 5 and potencies 
of MANT-nucleotides at ACs in the presence of Mg2+. 
Parameter AC1 AC2 AC5 Cardiac AC 
Km [µM] 160 ± 20* 110 ± 30* 87 ± 31 68 ± 5 
Vmax [pmol · mg
-1 · min-1] 660 ± 90* 300 ± 70* 2,400 ± 760 1,600 ± 160 
 
Nucleotide 
 
Ki [nM] 
   
MANT-ITP 24 65 13 24 
MANT-ITPγS 300* 450* 150* 26 
MANT-GTP 1,500* 3,700* 760* 780 
MANT-GTPγS 990* 1,800* 550* 340 
MANT-ATP 3,200* 5,700* 2,000* 2,000 
MANT-ATPγS 1,400 2,300 1,100 770 
MANT-CTP 3,600 15,000 3,600 3,300 
MANT-UTP 1,800 10,000 1,000 1,200 
AC activities were determined as described under “Materials and Methods”. Km and 
Vmax values were obtained by non-linear regression analysis of substrate-saturation 
experiments and are the means ± SD of 3-4 independent experiments performed in 
duplicates. Values labelled with (*) were taken from (Gille et al., 2004). The Ki values 
for MANT-ITP, MANT-ATPγS, MANT-CTP and MANT-UTP on AC1, AC2 and AC5 
were determined in this work as described (Gille et al., 2004) and represent the 
means of at least three independent experiments. Ki values on cardiac AC were 
determined in this work as described in “Materials and Methods” and are the means 
of at least 3 independent experiments performed in duplicates. Standard deviations 
were generally smaller than 20% of the means. Inhibition curves were analyzed by 
non-linear regression. 
 
 
 
 Chapter 2 75 
 
The inhibitor profile of mouse heart AC was very similar to the inhibitor profile 
of AC5, with AC1 showing moderate and AC2 showing large differences relative to 
mouse heart AC (Tab. 4 and Fig. 9A). A correlation of the Ki values of MANT-
nucleotides on mouse heart AC and AC5 revealed a highly significant correlation with 
a slope close to 1.00, indicative for pharmacological identity between the two 
enzymes compared (Fig. 9B). Note that this correlation concerns Mg2+-conditions 
only. 
 
 
Fig. 9: Comparison of the inhibitory potencies of MANT-nucleotides on heart 
membrane AC and recombinant AC isoforms expressed in Sf9 cells in the 
presence of Mg2+. A: Ki values of MANT-nucleotides on heart membrane AC and 
ACs 1, 2 and 5 shown in Tab. 4 were plotted. B: Correlation of the Ki values of 
MANT-nucleotides on mouse heart AC vs. AC5. Data were analyzed by linear 
regression. Dashed lines represent 95% confidence intervals of the linear regression 
lines. Slope, 1.033 ± 0.065; r2, 0.9768; p < 0.0001. 
 
 
In the presence of Mn2+, the rank order of inhibitory potency of MANT-
nucleotides at mouse heart AC was MANT-ITP > MANT-ITPγS > MANT-UTP > 
MANT-GTP ~ MANT-GTPγS ~ MANT-CTP > MANT-ATP ~ MANT-ATPγS (Tab. 5). 
Overall, inhibitory potencies of MANT-nucleotides were higher in the presence of 
Mn2+ than in the presence of Mg2+, but the potency-enhancing effect of Mn2+ ranged 
from just 3-fold for MANT-ITPγS to ~100-fold for MANT-CTP and MANT-UTP. 
Differential effects of Mg2+ and Mn2+ on inhibitor potency of MANT-nucleotides were 
also observed for recombinant ACs (Gille et al., 2004). The inhibitor profile of mouse 
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heart AC in the presence of Mn2+ was clearly different from the profile of AC2, but we 
also noted several differences between mouse heart AC, on the one hand, and ACs 
1, 5 and 6, on the other hand. Specifically, in the presence of Mn2+, MANT-ITPγS, 
MANT-GTP, MANT-GTPγS, MANT-ATP, MANT-CTP and MANT-UTP were all more 
potent inhibitors of mouse heart AC than of the ACs 1, 5, and 6. Thus, heart 
membranes may contain an AC isoform that under Mn2+-conditions is more potently 
inhibited by several MANT-nucleotides than AC5.  
 
 
Tab. 5: Kinetic properties of mouse heart AC and ACs 1, 2, 5 and 6 and 
potencies of MANT-nucleotides at ACs in the presence of Mn2+. 
Parameter AC1 AC2 AC5 AC6 Cardiac 
AC 
Km [µM] 110 ± 29* 99 ± 22* 40 ± 5 120 ± 42* 11 ± 2 
Vmax [pmol · mg
-1 · min-1] 1,500 ± 
230* 
1,200 ± 
140* 
3,200 ± 
400 
1,300 ± 
260* 
1,010 ± 
370 
 
Nucleotide 
 
Ki [nM] 
    
MANT-ITP 3 14 1 3 4 
MANT-ITPγS 41* 120* 31* 43* 8 
MANT-GTP 90* 620* 55* 91* 21 
MANT-GTPγS 62* 360* 35* 48* 23 
MANT-ATP 210* 850* 200* 280* 64 
MANT-ATPγS 160 380 77 72 67 
MANT-CTP 150 690 150 280 29 
MANT-UTP 46 460 32 71 12 
AC activities were determined as described under “Materials and Methods”. Km and 
Vmax values were obtained by non-linear regression analysis of substrate-saturation 
experiments and are the means ± SD of 3-4 independent experiments performed in 
duplicates. Values labelled with (*) were taken from (Gille et al., 2004). The Ki values 
for MANT-ITP, MANT-ATPγS, MANT-CTP and MANT-UTP on AC1, AC2, AC5 and 
AC6 were determined in this work as described (Gille et al., 2004) and represent the 
means of at least three independent experiments. Ki values on cardiac AC were 
determined in this work as described in “Materials and Methods” and are the means 
of at least 3 independent experiments performed in duplicates. Standard deviations 
were generally smaller than 20% of the means. Inhibition curves were analyzed by 
non-linear regression using the Prism 4.02 software (Graphpad, San Diego, CA). 
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All inhibition curves with MANT-nucleotides in heart membranes were 
monophasic (data not shown) so that we could not discriminate between various AC 
isoforms. In accordance with our previous study (Gille et al., 2004), AC2 was less 
sensitive to inhibition by MANT-nucleotides than ACs 1, 5 and 6 (Tab. 5). 
Unfortunately, the inhibitor profiles of ACs 1, 5 and 6 were very similar, allowing no 
differentiation between those three AC isoforms. 
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2.5 Discussion 
 
The specific aim of this work was to characterize mouse heart AC, the long-
term aim being the development of novel drugs for the treatment of chronic heart 
failure, particularly AC5 inhibitors. To achieve the specific aim of our work, we 
performed real-time PCR for the detection of AC mRNA, immunoblots and 
enzymological analysis of cardiac AC enzyme activity. 
 
2.5.1 Real-Time PCR and Immunoblot Studies 
In real-time PCR experiments, we obtained evidence for the expression of 
ACs 1, 3 to 7, and 9 (Fig. 2). The threshold values for detection of AC5 and AC6 
were lower than for the other AC isoforms indicating that AC5 and AC6 are the most 
prominent AC isoforms on mRNA level in the heart. These findings are in agreement 
with the literature pointing to high expression of ACs 5 and 6 in mammalian heart 
(Defer et al., 2000; Hanoune and Defer, 2001; Beazely and Watts, 2006). There are 
reports on the expression of ACs1, 3, 4 and 7 in mammalian heart tissue 
(Manolopoulos et al., 1995; Ferrand et al., 1999; Defer et al., 2000; Sunahara and 
Taussig, 2002; Risoe et al., 2007). Our findings are consistent with the literature. 
Unfortunately, the functional roles of ACs 1, 3, 4, and 7 in the heart are much less 
understood than the roles of ACs 5 and 6. Furthermore, our data suggest that ACs 2 
and 8 are not expressed in the heart. Despite numerous limitations of AC immunoblot 
analysis concerning antibody specificity and availability of recombinant ACs, positive 
immunoblot signals were obtained with the AC5/6 antibody in mouse heart 
membranes (Fig. 3A). Therefore, our results from immunoblot analysis complement 
the results from RT-PCR experiments and indicate high expression of ACs 5 and 6 in 
the heart. 
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2.5.2 GPCR-Regulation of AC in Mouse Heart Membranes 
Isoproterenol, GTPγS and FS effectively stimulated AC in mouse heart 
membranes, showing that the specific membrane preparation used in this work 
contained all components of the signaling cascade, i.e. β1-adrenoceptors, Gs proteins 
and AC in a functionally intact form. In our hands, it was anything but trivial to obtain 
functionally active mouse heart membranes. 
Gs-coupled histamine H2-receptors and glucagon receptors are expressed in 
mammalian heart as well (Mery et al., 1990; Matsuda et al., 2004; Fryer et al., 2006; 
Salazar et al., 2007), but no modulation of murine cardiac AC activity was observed 
in this work using ligands for those GPCRs (Fig. 7). The Gi protein-coupled NPY 
receptor subtypes Y1, Y2 and Y5 are known to mediate functional responses in the 
heart as well (McDermott and Bell, 2007), but no response was detected with 
neuropeptide Y. In addition, functional Gs-coupled serotonin 5-HT4-receptors are 
present in human ventricular myocardium (Levy et al., 2008), but serotonin did not 
modulate cardiac AC activity. These findings suggest that in mouse heart, the β1-
adrenoceptor is the most important Gs-coupled GPCR, and we have no positive 
evidence for a Gi-coupled GPCR. In this study, we did not examine Gq/11- or G12/13-
mediated signal transduction pathways. The constitutive activity of the β1-
adrenoceptor was not significant in the native heart membranes (Fig. 6) (Lefkowitz et 
al., 1993; Zhou et al., 2000; Engelhardt et al., 2001; Wenzel-Seifert et al., 2002). It 
cannot be excluded that Gs-coupled GPCRs other than the β1-adrenoceptor play a 
functional role in the heart. Specifically, our crude heart membrane preparation 
predominantly consists of cardiomyocytes, but other cell types such as fibroblasts, 
vascular smooth muscle cells and endothelial cells contribute to the total cell mass, 
too. Thus, AC regulation by GPCRs in the latter three cell types may be below the 
detection limit of our global AC assay. We can also not exclude the possibility that 
the membrane preparation destroyed the integrity of some signaling pathways. 
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2.5.3 Regulation of Heart AC by FS and FS Analogs 
FS analogs differentially regulate ACs 1, 2 and 5 (Pinto et al., 2008). The EC50 
values and relative maximum stimulatory effects of FS on heart AC and AC5 were 
similar, compatible with AC5 being the major cardiac AC isoform. Moreover, 
BODIPY-FS was a partial agonist on heart AC and AC5, whereas on AC2, BODIPY-
FS was an inverse agonist. These data indicate that compared with AC5, AC2 is not 
of functional relevance in the heart, a conclusion in agreement with the real-time 
PCR experiments. Considering the low basal AC activity in mouse heart membranes 
and the very robust stimulation by FS as well as AC9 being FS-insensitive (Yan et 
al., 1998), the contribution of AC9 to the AC activity in heart membranes seems to be 
of minor importance, too. Intriguingly, the correlations of potencies and particularly 
efficacies of FS analogs on heart AC and AC5 obtained in the presence of Mn2+ 
indicate that AC5 is not the only active AC isoform in heart membranes. 
 
2.5.4 Regulation of Heart AC by Divalent Cations 
Mg2+ is the physiological cation for AC activation in vivo. However, since with 
the non-physiological cation Mn2+ inhibitor potencies are higher than in the presence 
of Mg2+, the former cation is often used for in vitro studies (Gille et al., 2004, 2005; 
Taha et al., 2009). For comparison with previous studies, we conducted some AC 
studies with heart membranes both in the presence of Mg2+ and Mn2+. Regarding the 
effects of FS on AC, the exchange of Mg2+ against Mn2+ had little effect on potencies 
and relative maximum stimulatory effects on heart AC and recombinant ACs 1, 2 and 
5 (Pinto et al., 2008). However, as expected, MANT-nucleotides inhibited heart 
membrane more potently in the presence of Mn2+ than in the presence of Mg2+. 
With Mg2+ as physiological divalent cation, recombinant AC5 and mouse heart 
AC showed similar Km and Vmax values, supporting the notion that AC5 is an 
important AC isoform in mouse heart in vivo. However, under Mn2+-conditions, AC5 
showed a 4-fold higher Km value than cardiac AC and Vmax of AC5 was 3-fold higher 
than that of heart membranes. It is possible that under physiologically relevant Mg2+-
conditions, predominantly AC5 is activated in heart membranes, whereas under non-
physiological Mn2+-conditions, other AC isoforms than AC5 are activated as well, 
masking, at least partially, AC5. This interpretation is supported by the finding that 
under Mg2+-conditions, the inhibitory profiles of MANT-nucleotides on mouse heart 
AC and AC5 were quite similar, whereas in the presence of Mn2+, differences 
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between these ACs were noted. Under Mn2+-conditions, the kinetics of mouse heart 
AC and the inhibitory profile of MANT-nucleotides on mouse heart AC do also not 
match the profiles of ACs 1, 2 and 6. Moreover, the correlations of the potencies and 
efficacies of FS analogs between mouse heart AC and AC5 in the presence of Mn2+ 
point to nonidentity of the enzymes studied. These data indicate that under Mn2+-
conditions, the relative contribution of AC5 to the total AC activity in mouse heart 
membranes is smaller than in the presence of Mg2+. The elusive Mn2+-activated 
mouse heart AC isoform is more sensitive to inhibition by most MANT-nucleotides 
than recombinant AC5. 
A further limitation of our study concerns the lack of pharmacological and 
immunological discrimination between ACs 5 and 6, both of which are functionally 
important in the heart (Okumura et al., 2003a, b; Takahashi et al., 2006). To learn 
more on the properties of AC5 in a native membrane environment, it will be important 
to examine tissues that are highly enriched in AC5 relative to other tissues. The 
striatum may represent such a tissue (Glatt and Snyder, 1993). 
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2.5.5 Conclusions 
The real-time PCR experiments, immunoblot studies, FS analog stimulation 
experiments, enzyme kinetics and MANT-nucleotide inhibition experiments under 
Mg2+-conditions as well as our previous electrophysiological studies (Rottländer et 
al., 2007) indicate that AC5 is an important cardiac AC isoform, provided Mg2+-
conditions are considered. To the best of our knowledge, MANT-ITP is the most 
potent competitive AC5 and cardiac AC inhibitor reported so far. Thus, hypoxanthine 
nucleotides provide an excellent starting point for the future development of AC5 
inhibitors. However, a major as yet unresolved issue is the fact that immunologically 
and pharmacologically, ACs 5 and 6 are difficult to discriminate although at the organ 
level, they have different functions (Okumura et al., 2003a, b; Takahashi et al., 2006). 
Moreover, Mn2+ reduces the contribution of AC5 to overall AC activity in heart 
membranes and unmasks an elusive AC isoform. Thus, future AC studies in native 
membranes should be preferably conducted in the presence of Mg2+ although Mn2+ is 
very popular in AC studies. 
With respect to in vivo application, AC5 inhibitors with high stability against 
enzymatic degradation are required. By analogy to antiviral drugs, lipophilic 
nucleotide prodrugs with high bioavailability have to be designed. Conversion of the 
nucleotide prodrug to the active nucleoside 5´-triphosphate by phosphorylation is 
then accomplished by specific kinases (Laux et al., 2004). It is noteworthy that 
MANT-NTPs and the corresponding MANT-NTPγSs possess comparable potencies 
on heart AC. The advantage of MANT-NTPγSs relative to MANT-NTPs is that the 
phosphorothioates are resistant to cleavage by phosphatases (Eckstein, 1985), 
rendering them valuable experimental tools for electrophysiological studies in which 
nucleotides diffuse into the cytosol via the patch pipette (Rottländer et al., 2007). 
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3.1 Abstract 
 
The calmodulin (CaM)-dependent adenylyl cyclase (AC) toxin from Bordetella 
pertussis (CyaA) substantially contributes to the pathogenesis of whooping cough. 
Thus, potent and selective CyaA inhibitors may be valuable drugs for prophylaxis of 
this disease. We examined the interactions of fluorescent 2´,3´-N-methylanthraniloyl 
(MANT)-, anthraniloyl (ANT)- and trinitrophenyl (TNP)-substituted nucleotides with 
CyaA. Compared to mammalian AC isoforms and Bacillus anthracis AC toxin edema 
factor, nucleotides inhibited catalysis by CyaA less potently. Introduction of the 
MANT-substituent resulted in 5- to 170-fold increased potency of nucleotides. Ki 
values of 3´MANT-2´d-ATP and 2´MANT-3´d-ATP in the AC activity assay using Mn2+ 
were 220 nM and 340 nM, respectively. Natural nucleoside 5´-triphosphates, 
guanine-, hypoxanthine- and pyrimidine-MANT- and TNP-nucleotides and di-MANT-
nucleotides inhibited CyaA, too. MANT-nucleotide binding to CyaA generated 
fluorescence resonance energy transfer (FRET) from tryptophans W69 and W242 
and multiple tyrosine residues, yielding Kd values of 300 nM for 3´MANT-2´d-ATP 
and 400 nM for 2´MANT-3´d-ATP. Fluorescence experiments and docking 
approaches indicate that the MANT- and TNP-groups interact with F306. Increases 
of FRET and direct fluorescence with MANT-nucleotides were strictly CaM-
dependent, whereas TNP-nucleotide fluorescence upon binding to CyaA increased in 
the absence of CaM and was actually reduced by CaM. In contrast to low-affinity 
MANT-nucleotides, even low-affinity TNP-nucleotides generated strong fluorescence 
increases upon binding to CyaA. We conclude that the catalytic site of CyaA 
possesses substantial conformational freedom to accommodate structurally diverse 
ligands and that certain ligands bind to CyaA even in the absence of CaM, facilitating 
future inhibitor design. 
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3.2 Introduction 
 
Bordetella pertussis toxin CyaA is a 1706-amino acid virulence factor 
interacting with surface receptors of eukaryotic host cells and translocating its AC 
domain into the cytosol (Confer and Eaton, 1982; Hewlett et al., 1989; Ladant and 
Ullmann, 1999). After activation by calmodulin (CaM), an endogenous calcium 
sensor, CyaA catalyzes massive synthesis of cAMP (Mock and Ullmann, 1993; Shen 
et al., 2002; Ahuja et al., 2004). cAMP inhibits phagocyte function and facilitates 
respiratory tract infection by Bordetella pertussis (Boyd et al., 2005; Carbonetti et al., 
2005; Hewlett et al., 2006). Substrate analogs may be used to inhibit the catalytic 
activity of CyaA (Johnson and Shoshani, 1990; Soelaiman et al., 2003; Gille et al., 
2004) and for prophylaxis of Bordetella pertussis infection. We have discovered N-
methylanthraniloyl (MANT)-substituted NTPs as competitive inhibitors of mammalian 
and bacterial ACs including CyaA (Gille et al., 2003, 2004). Additionally, 2´,3´-(2,4,6-
trinitrophenyl) (TNP)-substituted NTPs are potent inhibitors of mammalian AC (Mou 
et al., 2006). Furthermore, adefovir, a drug for the treatment of chronic hepatitis B 
virus infection, is a potent CyaA inhibitor (Shen et al., 2004). 
Mammals express nine membranous AC isoforms (ACs 1-9) and a soluble 
AC. We have employed the cytosolic catalytic domains C1 of type 5 AC and C2 of 
type 2 AC for molecular AC analysis (Gille et al., 2004; Mou et al., 2005, 2006). 
Comparing the crystal structures of C1:C2 bound to MANT-GTP, MANT-ATP and 
TNP-ATP, we found the catalytic site of AC to consist of three binding pockets, 
accommodating the base, the 2´,3´-ribosyl substituent and the phosphate chain. We 
have also reported the crystal structure of CyaA in complex with CaM and PMEApp, 
the active metabolite of adefovir (Guo et al., 2005). Forty-nine amino acid residues of 
CyaA and 41 residues of CaM form salt bridges, hydrogen bonds and hydrophobic 
contacts, resulting in high affinity of CyaA for CaM (Kd = 0.2 nM). However, the 
precise conformational changes in the catalytic site of CyaA underlying its activation 
by CaM are still unknown. An understanding of these processes will greatly facilitate 
future inhibitor design. 
To monitor nucleotide binding to and conformational changes in CyaA, 
different approaches can be employed. First, MANT- and ANT-nucleotides are 
environmentally sensitive probes displaying increased fluorescence and blue-shift of 
the emission maximum upon exposure to a hydrophobic environment (Hiratsuka, 
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1983; Jameson and Eccleston, 1997). As is obvious from the CyaA crystal structure 
in complex with PMEApp (Shen et al., 2004; Guo et al., 2005), the catalytic site 
contains the hydrophobic residue F306. Nucleotide binding to CyaA allows 
hydrophobic interactions between the MANT-/ANT-group and F306, resulting in an 
increased fluorescence signal (Sarfati et al., 1990; Guo et al., 2005). This notion is 
supported by the fact that CyaA-F306A does not increase the fluorescence signal of 
3´ANT-2´d-ATP. Second, the catalytic domain of CyaA bears two tryptophan 
residues, W69 located 21 Å and W242 38 Å away from the catalytic site (Guo et al., 
2005). These distances allow fluorescence resonance energy transfer (FRET) 
(Lakowicz, 1999) from tryptophan (excitation wavelength, 280 nm; emission 
wavelength, 350 nm) to MANT (excitation wavelength, 350 nm; emission wavelength, 
450 nm) (Gilles et al., 1990; Sarfati et al., 1990; Mou et al., 2005, 2006). Third, TNP-
nucleotides are environmentally sensitive fluorescence probes, too (Hiratsuka, 2003). 
Like MANT-nucleotides, TNP-nucleotides show a blue-shift in emission in a 
hydrophobic environment (Hiratsuka, 2003). Compared to MANT-/ANT-nucleotides, 
TNP-nucleotides are more rigid since the fluorophore is attached through both the 2´- 
and 3´-ribosyl position (Jameson and Eccleston, 1997; Hiratsuka, 2003). A potential 
advantage of TNP-nucleotides compared to MANT-nucleotides is the fact that the 
relative fluorescence increases can be substantially larger, depending on the specific 
protein studied (Jameson and Eccleston, 1997; Hiratsuka, 2003; Mou et al., 2005, 
2006). 
In the present study, we used MANT-/ANT- and TNP-nucleotides as probes to 
determine their potencies at inhibiting CyaA and to investigate conformational 
changes in the catalytic site. Nucleotides 12, 14, 15, 18, 19, 20, 25, 30 and 31 (Tab. 
1) represent newly synthesized fluorescent probes. Moreover, the binding mode of 
nucleotides was explored by docking of representative derivatives to a CyaA model 
derived from the crystal structure in complex with PMEApp (Shen et al., 2004; Guo et 
al., 2005). 
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3.3 Materials and Methods 
 
Materials. MANT- and ANT-substituted NTPs of adenosine, cytidine, inosine 
and uridine were synthesized according to a documented procedure (Hiratsuka, 
1983). The modification of the synthesis by lowering the pH value from 9.6 to 8.6 
induced higher yields. In case of the starting material methyl-isatoic anhydride, the 
major portion of the excessive compound was removed by CHCl3-extraction. In 
general, the separation of starting materials could be achieved by using size 
exclusion chromatography with Sephadex® LH-20 in water. However, HPLC-analysis 
and liquid chromatography/mass spectrometry coupling still showed by-product of the 
corresponding (M)ANT-diphosphate residue. Pure MANT-nucleotides were obtained 
by preparative reversed-phase HPLC with a Phenomenex Luna C18(2) column 
(particle size, 10 µm; length, 250 mm; inner diameter, 21.2 mm). The nucleoside 5´-
diphosphates were also collected because of their putative inhibitory effects. 
(M)ANT-nucleoside 5´-diphosphates and triphosphates were obtained in high purity 
of 99%. Di-MANT-IMP (31) bearing two MANT-groups at the 2´,3´-ribosyl position 
was also found as a by-product of our synthesis and was purified to 99% content, 
too. MANT-ATP (8), MANT-GTP (10), ANT-GTP (24), 3´MANT-2´d-ATP (21), 
2´MANT-3´d-ATP (22), TNP-CTP (28), TNP-UTP (29) and γS-substituted MANT-
nucleotides (9, 11, 13) were obtained from Jena Bioscience, Jena, Germany. In case 
of MANT-ATP, the MANT-group isomerizes between the 2´- and 3´-position of the 
ribose ring, whereas in 2´MANT-3´d-ATP and 3´MANT-2´d-ATP the MANT-group is 
fixed to the corresponding position due to the absence of the neighboring hydroxyl 
group. PMEApp (1) was supplied by Gilead Sciences, Foster City, CA, USA. TNP-
ATP (26) and TNP-GTP (27) were from Molecular Probes, Eugene, OR, USA. ITP 
was from Sigma-Aldrich, Seelze, Germany; GTP was from Roche, Mannheim, 
Germany. UTP and CTP were from Boehringer, Ingelheim, Germany. The catalytic 
domain of Bordetella pertussis AC protein (CyaA, amino acids 1 to 373) was purified 
as described (Shen et al., 2002). Lyophilized calmodulin from bovine brain was 
purchased from EMD Biosciences, Calbiochem, Darmstadt, Germany. [α-32P]ATP 
(800 Ci/mmol) was purchased from PerkinElmer, Wellesley, MA, USA. Aluminum 
oxide 90 active, neutral (activity 1, particle size 0.06 - 0.2 mm) was purchased from 
Merck, Darmstadt, Germany. Albumin from bovine serum, fraction V, highest quality, 
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was from Sigma-Aldrich. MnCl2 tetrahydrate and MgCl2 hexahydrate (highest quality) 
were from Merck. 
 
FRET and Direct Fluorescence Experiments with MANT-Nucleotides. 
Experiments were performed using a quartz UV ultra-microcuvette from Hellma, 
Müllheim, Germany (type 105.251-QS; light path length, 3 mm; center, 15 mm; total 
volume, 70 µL). Measurements were performed in a Varian Cary Eclipse 
fluorescence spectrometer at a constant temperature of 25°C (slit width, 5 nm; scan 
rate, 120 nm/min; averaging time, 0.5 s; data interval, 1 nm; PMT voltage, 700 V). 
The cuvette contained at first 64 µL of 75 mM Hepes/NaOH buffer, 100 µM CaCl2, 
100 mM KCl and 5 mM MnCl2, pH 7.4. Next, nucleotide, CyaA and CaM were added 
in sequence. The cuvette content (final volume, 70 µL) was mixed after each 
addition. In FRET experiments, nucleotides were used at final concentrations from 10 
nM to 2 µM, and CyaA and CaM were 300 nM each. The excitation wavelength was 
280 nm, and emission was scanned from 300 nm to 550 nm. To investigate the 
kinetics of CyaA interaction with MANT-nucleotides, the excitation wavelength was 
280 nm and changes in fluorescence intensity were measured over time at 430 nm. 
Nucleotides, CyaA and CaM were applied at a final concentration of 300 nM. MANT-
nucleotides were finally displaced from CyaA using PMEApp (10 nM to 3 µM). In 
saturation studies, independent FRET experiments were performed using MANT-
nucleotides from 10 nM to 2 µM final concentration; CyaA and CaM were 300 nM 
each. Saturation curves were obtained by subtracting the fluorescence intensity at 
430 nm after the addition of CyaA from the maximal fluorescence (FRET) after the 
addition of CyaA/CaM. 
In direct fluorescence experiments, MANT-nucleotides were excited at 350 nm 
and emission spectra were recorded from 380 nm to 550 nm. In order to obtain large 
increases in direct fluorescence, CyaA and CaM (final concentrations, 2.4 µM) were 
used in excess relative to MANT-nucleotides (final concentration, 100 nM). For an 
estimation of the hydrophobic properties of the binding site interacting with the 
MANT-group, direct fluorescence of the nucleotides was determined in water and in 
30% (v/v) dimethyl sulfoxide. 
 
 
 
 Chapter 3 94 
 
Fluorescence Studies with TNP-Nucleotides. Fluorescence studies with 
TNP-nucleotides were essentially performed as for MANT-nucleotides with some 
modifications. Specifically, the concentrations of TNP-nucleotides, CyaA and CaM 
were 5 µM each. The higher protein concentrations were necessary to compensate 
for the lower quantum yield with TNP-nucleotides compared to MANT-nucleotides 
(Jameson and Eccleston, 1997; Hiratsuka, 2003).The excitation wavelength was 405 
nm, and emission was scanned from 480 to 620 nm. 
 
AC Activity Assay. For the determination of the potency of CyaA inhibitors, 
assay tubes contained 10 µL of inhibitor at final concentrations from 10 nM to 100 µM 
and 20 µL of CyaA protein (10 pM final concentration) in 75 mM Hepes/NaOH, pH 
7.4, containing 0.1% (m/v) bovine serum albumin. Tubes were preincubated for 2 min 
at 25°C, and reactions were initiated by the addition of 20 µL of reaction mixture 
consisting of the following components to yield the given final concentrations: 100 
mM KCl, 10 µM free Ca2+, 5 mM free Mn2+ or Mg2+, 100 µM EGTA, 100 µM cAMP, 
100 nM CaM. ATP was added as non-labeled substrate at a final concentration of 40 
µM and as radioactive tracer [α-32P]ATP (0.2 µCi/tube). For the determination of Km 
and Vmax values, 10 µM to 2 mM ATP/Mn
2+ or ATP/Mg2+ were added, plus 5 mM of 
free Mn2+ or Mg2+. In order to ensure linear reaction progress, tubes were incubated 
for 10 min at 25°C, and reactions were stopped by the addition of 20 µL of 2.2 N HCl. 
Denaturated protein was sedimented by a 1-min centrifugation at 12,000 x g. 
[
32P]cAMP was separated from [α-32P]ATP by transferring the samples to columns 
containing 1.4 g of neutral alumina. [32P]cAMP was eluted by the addition of 4 mL 0.1 
M ammonium acetate solution, pH 7.0. Blank values were about 0.02% of the total 
added amount of [α-32P]ATP; substrate turnover was < 3% of the total added [α-
32P]ATP. Samples collected in scintillation vials were filled up with 10 mL of double-
distilled water and Čerenkov radiation was measured in a PerkinElmer Tricarb 
2800TR liquid scintillation analyzer. Free concentrations of divalent cations were 
calculated with WinMaxC (http://www.stanford.edu/~cpatton/maxc.html). Ki values 
reported in Tab. 1 and Kd values obtained from saturation experiments were 
calculated using the Prism 4.02 software (Graphpad, San Diego, CA, USA). 
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Modeling of the Nucleotide Binding Mode to CyaA. Docking studies were 
performed with the molecular modeling package SYBYL 7.3 (Tripos Inc., St. Louis, 
MO, USA) on a Silicon Graphics Octane workstation. An initial computer model of 
CyaA in complex with PMEApp was generated from the PDB crystal structure 1zot 
(Guo et al., 2005). Hydrogens were added and AMBER_FF99 charges were 
assigned to the protein and the water molecules, followed by a rough pre-
optimization of the model (100 cycles) with the AMBER_FF99 force field (Cornell et 
al., 1995) and fixed PMEApp. The three Mg2+ ions received formal charges of 2. 
Starting conformations of 3´MANT-2´d-ATP (21), 2´MANT-3´d-ATP (22) and TNP-
ATP (26) were derived from complexes of 3´MANT-ATP and TNP-ATP with 
mammalian AC (PDB structures 2gvz and 2gvd, respectively) (Mou et al., 2005, 
2006). PMEApp and the ligands 21, 22 and 26 were provided with Gasteiger-Hueckel 
charges. Initial docking positions resulted from superposition of roughly optimized 
conformations with PMEApp, allowing the modification of rotatable bonds, and from 
consideration of the fluorescence data (interaction of the MANT- and TNP-groups 
with F306). Water molecules in the catalytic site were removed. Each complex was 
refined in a stepwise approach. First, ~50 minimization cycles with fixed ligand 
(AMBER_FF99 force field, steepest descent method) were performed, second, ~100 
minimization cycles of the ligand and the surrounding (distance up to 6 Å) protein 
residues (Tripos force field) (Clark et al., 1989), and third, ~100 minimization cycles 
with fixed ligand (AMBER_FF99 force field, Powell conjugate gradient). The second 
and third steps were repeated with larger number of cycles until a root mean square 
(RMS) force of 0.05 kcal mol-1 Å-1 was approached. In order to avoid overestimation 
of electrostatic interactions, a distance-dependent dielectric constant of 4 was 
applied. Molecular surfaces and lipophilic potentials (protein variant with the new 
Crippen parameter table (Heiden et al., 1993; Ghose et al., 1998)) were calculated 
and visualized by the program MOLCAD (J. Brickmann et al., Technical University of 
Darmstadt, Germany) contained within SYBYL. 
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3.4 Results 
 
3.4.1 Overview on Nucleotide Structures 
We examined the inhibitory effects of 31 nucleotides on the catalytic activity of 
CyaA (Tab. 1). Nucleotides differed from each other in base, phosphate chain length, 
phosphate chain substitution, and MANT-, ANT- or TNP-substituents at the 2´,3´-
ribosyl position. In compounds 8-20, 23-25 and 30, the MANT- or ANT-group 
undergoes spontaneous isomerization between the 2´- and 3´-ribosyl position 
(Jameson and Eccleston, 1997). In 21 and 22, the MANT-group is fixed to the 2´- or 
3´-position because the neighboring ribosyl position is deoxygenated, thus preventing 
isomerization. In 23-25, an ANT-group is attached to the ribosyl residue instead of 
the MANT-group. Compounds 26-29 contain TNP-substituents. In 31, two MANT-
substituents are attached to the 2´- and 3´-ribosyl position. In 9, 11 and 13, the γ-
phosphate group is substituted by a γ-thiophosphate group. The potencies of the 
different nucleotides were determined in the AC activity assay in the presence of 
either Mn2+ or Mg2+. 
 
3.4.2 Structure/Activity Relationships under Mn2+-Conditions 
Under Mn2+-conditions, MANT-ITP (12) displayed the highest potency of all 
MANT-NTPs examined, exhibiting 7-fold higher potency than MANT-ATP (8). The 
rank order of potencies was MANT-ITP > MANT-CTP > MANT-UTP > MANT-ATP > 
MANT-GTP. MANT-GTP (10) exhibited 10-fold lower potency compared to MANT-
ITP. For MANT-NDPs, the order of potency was MANT-IDP ~ MANT-ADP > MANT-
CDP > MANT-UDP; MANT-IDP was 4-fold more potent than MANT-UDP. For ANT-
nucleotides, the adenine base was advantageous compared with guanine; ANT-ATP 
(23) was 22-fold more potent than ANT-GTP (24). Among γS-substituted MANT-
nucleotides, the rank order of potency was MANT-ATPγS > MANT-ITPγS > MANT-
GTPγS; MANT-ATPγS (9) was 4 to 5-fold more potent than MANT-GTPγS (11). 
TNP-ATP (26) was the most potent TNP-nucleotide; the rank order was TNP-
ATP > TNP-CTP > TNP-GTP > TNP-UTP. Among the nucleotides bearing no 
fluorescent substituent at the 2´,3´-ribosyl position, GTP (2) displayed the highest 
affinity, which was 4-fold higher than the affinity of ITP (3) and UTP (6). Interestingly, 
the Ki constants of GTP and CTP were lower than the Km value of the natural 
substrate ATP. Compared to the non-substituted NTPs, the MANT-group increased 
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inhibitor potency 5-fold, 31-fold, 45-fold and 166-fold for MANT-GTP, MANT-CTP, 
MANT-UTP and MANT-ITP, respectively. The TNP-group increased inhibitory 
potency in case of TNP-CTP and TNP-UTP just by factors of 3 and 2, respectively, 
and TNP-GTP (27) was only slightly more potent than GTP (2). MANT-substituted 
nucleotides were 2, 3, 9 and 22 times more potent in inhibiting CyaA compared with 
TNP-nucleotides (8 vs. 26, 10 vs. 27, 14 vs. 28, and 15 vs. 29). While ANT-ATP (23) 
was 3-fold more potent than MANT-ATP (8), the potency of ANT-GTP (24) was 5-fold 
lower compared with MANT-GTP (10). Omission of the γ-phosphate group resulted in 
substantially decreased potencies at all nucleotides. Specifically, MANT-ADP (16) 
was 3-fold less potent than MANT-ATP (8), MANT-GDP (17) 10-fold less than MANT-
GTP (10) (Gille et al., 2004), MANT-CDP (19) 15-fold less than MANT-CTP (14), 
MANT-UDP (20) 17-fold less than MANT-UTP (15) and MANT-IDP (18) 18-fold less 
than MANT-ITP (12). ANT-ADP (25) was 9-fold less potent than ANT-ATP (23). 
Adding the γS-substitution to MANT-NTPs decreased potency of MANT-ITP 3-fold 
(12 vs. 13), increased potency of MANT-ATP 4-fold (8 vs. 9) and left the potency of 
MANT-GTP unchanged (10 vs. 11). Most strikingly, 3´MANT-2´d-ATP (21) and 
2´MANT-3´d-ATP (22) were 22-fold and 14-fold more potent, respectively, than 
MANT-ATP (8). 
 
3.4.3 Structure/Activity Relationships under Mg2+-Conditions 
The exchange of Mn2+ by Mg2+ increased Km and Vmax 14-fold and 5-fold, 
respectively. Inhibitory potencies of all tested nucleotides were differentially lowered 
when Mg2+ was used instead of Mn2+. While the potency of MANT-GTPγS was only 
minimally reduced, 3´MANT-2´d-ATP and 2´MANT-3´d-ATP showed ~160-fold and 
~70-fold lower potency with Mg2+. The rank order of potency for MANT-substituted 
NTPs was MANT-GTP = MANT-ITP > MANT-CTP > MANT-UTP > MANT-ATP. 
While MANT-GTP (10) displayed the lowest potency of all MANT-NTPs under Mn2+-
conditions, it was - together with MANT-ITP (12) - the most potent MANT-NTP when 
Mg2+ was used. ANT-ATP (23) was 3-fold more potent than MANT-ATP (8) and 
exceeded ANT-GTP (24) in potency. MANT-GTPγS (11) was the most potent γS-
substituted nucleotide tested, being 2-fold more potent than MANT-ATPγS (9) and 4-
fold more potent than MANT-ITPγS (13). The introduction of the MANT-group 
increased the potency of CTP, UTP and GTP 7- to 16-fold. Most strikingly, MANT-ITP 
(12) was ~70-fold more potent than ITP (3). Among TNP-nucleotides, potency 
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decreased in the order TNP-ATP, TNP-GTP, TNP-CTP, TNP-UTP. It is noteworthy 
that the TNP-group did not increase potency compared to non-substituted NTPs; 
potency even decreased (2 vs. 27, 5 vs. 28 and 6 vs. 29). 
 
Tab. 1: Potencies of inhibitors at CyaA.  
  Mn2+  Mg2+ 
                                     Km 45 ± 6 609 ± 62 
 
Cpd. 
                                    Vmax 165 ± 21 861 ± 106 
1 PMEApp 0.001 ± 0.0003 0.025 ± 0.002  
2 GTP 27 ± 6 260 ± 32 
3 ITP 100 ± 20 1,100 ± 220 
4 ITPγS 77 ND 
5 CTP 35 ± 1 270 ± 43 
6 UTP 120 ± 14 330 ± 80 
7 UTPγS 36 ND 
8 MANT-ATP 4.3 ± 0.4 51 ± 1 
9 MANT-ATPγS 1.2 ± 0.4 15 ± 2 
10 MANT-GTP 5.9 ± 1.0 16 ± 2 
11 MANT-GTPγS 5.4 ± 0.5 7.4 ± 0.1 
12 MANT-ITP 0.6 ± 0.1 16 ± 4 
13 MANT-ITPγS 1.8 ± 0.3 31 ± 2 
14 MANT-CTP 1.1 ± 0.1 36 ± 4 
15 MANT-UTP 2.6 ± 0.3 42 ± 9 
16 MANT-ADP 12 ± 2 91 ± 16 
17 MANT-GDP 60 ND 
18 MANT-IDP 11 ± 3 > 100 
19 MANT-CDP 18 ± 3 > 100 
20 MANT-UDP 43 ± 1 > 100 
21 3´MANT-2´d-ATP 0.2 ± 0.04 32 ± 7 
22 2´MANT-3´d-ATP 0.3 ± 0.04 22 ± 4 
23 ANT-ATP 1.3 ± 0.1 20 ± 3 
24 ANT-GTP 29 ± 0.3 > 100 
25 ANT-ADP 11 ± 1 > 100 
26 TNP-ATP 6.5 ± 0.2 110 ± 23 
27 TNP-GTP 20 ± 3 320 ± 7 
28 TNP-CTP 10 ± 0.4 410 ± 9 
29 TNP-UTP 58 ± 8 780 ± 38 
30 MANT-IMP > 100 > 100 
31 Di-MANT-IMP 20 ± 3 37 ± 3 
AC toxin activities were determined as described under “Materials and Methods”. Apparent Km and 
Vmax values were obtained by non-linear regression analysis of substrate-saturation experiments and 
are the means ± SEM of 3-5 independent experiments. Km values are given in µM, Vmax values are 
given as molar turnover numbers (s-1). Ki values are given in µM and are the means ± SEM of at least 
3 experiments performed in duplicates. For determination of the inhibitory potencies of various purine 
and pyrimidine nucleotides, reaction mixtures contained 100 mM KCl, 10 µM free Ca2+, 5 mM free 
Mn2+ or Mg2+, 100 µM EGTA, 40 µM ATP, 0.2 µCi/tube [α-32P]ATP, 100 µM cAMP, 100 nM CaM, 10 
pM CyaA in 75 mM Hepes/NaOH, pH 7.4, and nucleotides at concentrations from 100 pM to 2 mM as 
appropriate to construct concentration-response curves. The Ki value for 1 under Mg
2+-conditions was 
taken from (Shen et al., 2004). The Ki values for 4, 7 and 17 under Mn
2+-conditions were taken from 
(Gille et al., 2004). Inhibition curves were analyzed by non-linear regression using the Prism 4.02 
software (Graphpad, San Diego, CA). Cpd., compound. 
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3.4.4 FRET Experiments with MANT-Nucleotides 
In FRET experiments, 2´MANT-3´d-ATP, 3´MANT-2´d-ATP and MANT-ATP 
(final concentrations, 300 nM each) were added first to the buffer, and fluorescence 
of MANT-nucleotides as a result of excitation at 280 nm was detected at 450 nm (Fig. 
1, dotted line). When CyaA was added, tryptophan and tyrosine fluorescence 
occurred at 350 nm (Fig. 1, solid line). Upon addition of CaM, fluorescence intensity 
at 430 nm considerably increased due to FRET using 2´MANT-3´d-ATP and 
3´MANT-2´d-ATP (Fig. 1, A and B, dashed lines), but not using MANT-ATP (Fig. 1C), 
MANT-GTP, MANT-ITP, MANT-CTP and MANT-UTP (data not shown). When FRET 
experiments were performed using the tryptophan-specific excitation wavelength of 
295 nm (Lakowicz, 1999), fluorescence intensity at 350 nm decreased about 3-fold. 
The relative magnitude of FRET with 2´MANT-3´d-ATP and 3´MANT-2´d-ATP 
remained unchanged upon tryptophan-selective excitation (data not shown). Thus, 
FRET resulted from excitation of W69 and W242 and tyrosine residues. Y75, Y122, 
Y263, Y333, Y345 and Y350 are located in a distance of less than 20 Å from the 
catalytic site. Thus, in order to obtain high FRET signals, it is favorable to excite both 
tyrosine and tryptophan residues.  
PMEApp (1) inhibited FRET in a concentration-dependent manner (Fig. 2). 
Half-maximal displacement of 300 nM 3´MANT-2´d-ATP occurred at a PMEApp 
concentration of approximately 50 nM, which is compatible with the notion that 
PMEApp is a much more potent CyaA inhibitor than 3´MANT-2´d-ATP (Tab. 1). 
Kinetics of CyaA FRET stimulation by CaM and inhibition by PMEApp occurred within 
mixing time (few seconds). These data show that FRET was specific and reversible. 
By determining FRET with MANT-nucleotides at increasing concentrations 
after addition of CaM, saturation curves were obtained (Fig. 3). Apparent Kd values 
were 400 nM for 2´MANT-3´d-ATP (A) and 300 nM for 3´MANT-2´d-ATP (B). For 
MANT-ATP, MANT-GTP, MANT-ITP, MANT-CTP, and MANT-UTP, Kd values could 
not be determined because of absent or minimal FRET (data not shown).  
 
 
 
 
 Chapter 3 100 
 
 
 
Fig. 1: Monitoring of MANT-nucleotide binding to the catalytic site of CyaA 
using FRET. The assay buffer consisted of 75 mM Hepes/NaOH, 100 µM CaCl2, 100 
mM KCl and 5 mM MnCl2, pH 7.4. Nucleotides (A: 2´MANT-3´d-ATP; B: 3´MANT-
2´d-ATP; C: MANT-ATP) were added to the buffer to yield a final concentration of 
300 nM, and emission was scanned at an excitation wavelength of 280 nm. CyaA 
protein and CaM were added in sequence to yield a final concentration of 300 nM. 
Shown are superimposed recordings of a representative experiment. Similar data 
were obtained in 3 independent experiments. a.u., arbitrary unit. 
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Fig. 2: Time-resolved activation of CyaA by CaM and stepwise abolishment of 
FRET by PMEApp. Excitation wavelength was 280 nm and emission was detected 
at 430 nm over time. 300 nM 3´MANT-2´d-ATP (1), 300 nM CyaA protein (2), 300 nM 
CaM (3) and PMEApp in the given final concentrations (addition steps 4, 10 nM; 5, 
30 nM; 6, 70 nM; 7, 1.6 µM) were added in sequence. A recording of a representative 
experiment is shown. Similar data were obtained in 4 independent experiments. a.u., 
arbitrary unit. 
 
 
 
  
Fig. 3: Saturation curves of 2´MANT-3´d-ATP and 3´MANT-2´d-ATP binding to 
activated CyaA. Each data point was determined in an independent experiment as 
described under “Materials and Methods”. Final concentrations of CyaA and CaM 
were 300 nM each. The fluorescence increase at 430 nm was calculated by 
subtracting the fluorescence at 430 nm after addition of CyaA from the maximal 
fluorescence at 430 nm after addition of CyaA/CaM. Data were analyzed by non-
linear regression using the Prism 4.02 software. Similar data were obtained in 3 
independent experiments. a.u., arbitrary unit. 
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We used CyaA at a final concentration of just 300 nM in an assay volume of 
70 µL in FRET studies, corresponding to 0.8 µg of CyaA for one measurement. As 
the consumption of protein is low, as the production of CyaA can be accomplished at 
large scale (Shen et al., 2002) and as kinetics occur within seconds (Fig. 2), 
fluorimetric high-throughput screening of potential novel inhibitors is feasible, 
avoiding the use of radioactive AC assays. Since fluorescent nucleotides (e.g. 
3´MANT-2´d-ATP) were competitively displaced from CyaA by PMEApp (Fig. 2), the 
affinity of non-labeled inhibitors may also be estimated using this approach. In 
saturation experiments (Fig. 3), apparent Kd values were estimated to be 400 nM for 
2´MANT-3´d-ATP (A) and 300 nM for 3´MANT-2´d-ATP (B). The results from FRET 
experiments are in good agreement with the corresponding Ki values determined in 
the AC activity assay (Tab. 1). 
 
 
3.4.5 Direct Fluorescence Experiments with MANT-Nucleotides 
Nucleotides were excited at 350 nm and emission was scanned from 380 nm 
to 550 nm. Addition of CyaA to cuvettes containing 2´MANT-3´d-ATP or 3´MANT-2´d-
ATP did not increase their intrinsic fluorescence (Fig. 4, A and B). However, upon 
addition of CaM, fluorescence increased by 120% and 130%, respectively. Moreover, 
the emission maximum of 2´MANT-3´d-ATP and 3´MANT-2´d-ATP showed a shift to 
shorter wavelengths (blue shift). Under these conditions, MANT-ATP fluorescence 
increased by only approximately 40% (data not shown). For comparison, direct 
fluorescence of nucleotides was determined in a polar environment (water) and a 
hydrophobic environment [30% (v/v) dimethyl sulfoxide]. Fluorescence of 100 nM 
3´MANT-2´d-ATP increased by 160% when exposed to dimethyl sulfoxide (Fig. 4C). 
In addition, the emission maximum shifted to shorter wavelengths. Thus, binding of 
MANT-nucleotides to CyaA transferred the MANT-group into a hydrophobic 
environment, probably facilitating interaction with F306 (Guo et al., 2005). 
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Fig. 4: Direct fluorescence of MANT-nucleotides. The excitation wavelength was 
350 nm, and emission was scanned from 380 nm to 550 nm. 100 nM nucleotide, 2.4 
µM CyaA and 2.4 µM CaM were added to cuvettes (A) and (B) in sequence. To 
mimic binding of the MANT-group to a hydrophobic binding pocket, 3´MANT-2´d-ATP 
was directly excited in water plus dimethyl sulfoxide (DMSO) 30% (v/v) (C). Shown 
are superimposed recordings of a representative experiment. Similar data were 
obtained in 5 independent experiments. a.u., arbitrary unit. 
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3.4.6 Fluorescence Experiments with TNP-Nucleotides 
When excited at a wavelength of 405 nm, TNP-ATP, TNP-GTP, TNP-CTP and 
TNP-UTP showed a fluorescence peak at ~550 nm (Fig. 5) The addition of CyaA to 
cuvettes containing TNP-nucleotides increased fluorescence 3- to 5-fold, with TNP-
ATP and TNP-GTP showing the largest increases (Fig. 5, A and B). The 
fluorescence increases with TNP-nucleotides were virtually instantaneous after CyaA 
addition (data not shown), indicative for rapid nucleotide/protein interaction. 
Moreover, we observed a blue-shift of the emission maximum of TNP-nucleotides to 
~540 nm. These data indicate that binding of TNP-nucleotides to CyaA transfers the 
TNP-group into a hydrophobic environment. Furthermore, and in striking contrast to 
the results obtained with MANT-nucleotides (Figs. 2-4), addition of CaM to CyaA 
reduced TNP-nucleotide fluorescence. This reduction in fluorescence was dependent 
on the specific nucleotide studied; TNP-ATP showed the smallest relative reduction 
(Fig. 5A), and TNP-CTP and TNP-UTP showed the largest relative reductions (Fig. 5, 
C and D). 
 
 
Fig. 5: Fluorescence analysis of the interactions of TNP-nucleotides with CyaA. The excitation 
wavelength was 405 nm, and emission was scanned from 480 nm to 620 nm. 5 µM nucleotide, 5 µM 
CyaA and 5 µM CaM were added to the cuvette in sequence. A: TNP-ATP; B: TNP-GTP; C: TNP-
CTP; D: TNP-UTP. Shown are superimposed recordings of a representative experiment. Similar data 
were obtained in 3-5 independent experiments. a.u., arbitrary unit. 
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3.4.7 Modeling of the Binding Modes of MANT- and TNP-Nucleotides to CyaA 
The crystal structure of CyaA in complex with CaM and PMEApp (Guo et al., 
2005) offered us the possibility to predict the binding mode of MANT- and TNP-
nucleotides. The AC domain of CyaA contains the catalytic site at the interface of two 
structural domains, CA (M1-G61, A187-A364) and CB (V62-T186). Compared with 
PMEApp, the substrate ATP and the fluorescent nucleotides are conformationally 
restricted due to the semirigid ribosyl moiety. However, the spacious cavity between 
CA and CB may accomodate the different scaffolds so that an alignment of the 
adenine base and the terminal phosphates is possible (Fig. 6A). It becomes obvious 
that hydrophobic interactions, especially of the lipophilic edge of the deoxyribosyl 
moiety with L60 and of the 3´MANT-group with F306, significantly contribute to the 
binding of 3´MANT-2´d-ATP (21) to CyaA (Tab. 1 and Fig. 3B). In fact, non-
substituted NTPs exhibited 5- to 170-fold lower affinities than their MANT-substituted 
analogs (e.g. ITP vs. MANT-ITP), and CyaA-F306A failed to increase the 
fluorescence signal of 3´ANT-2´d-ATP (Guo et al., 2005).  
However, the question arises why PMEApp (1) is four orders of magnitude 
more potent at inhibiting CyaA than the natural and γS-substituted NTPs (2-7) if the 
alignment indicates similar interactions. First, a reasonable superposition of the 
phosphates and the adenine bases as shown in Fig. 6A is only possible if the 
conformation of the nucleotide moiety retains a certain strain of approximately 3 
kcal/mol. A complete minimization would displace the adenine base and, in 
particular, the phosphate groups from their optimal positions. Therefore, the "true" fit 
must be a balance between conformational strain and binding energy. Second, the 
ethoxy oxygen of PMEApp strongly interacts with E301 and N304 via a water 
molecule, and the ethylene bridge is also in close contact with the edge of F306. 
Fig. 6B represents the docking of 3´MANT-2´d-ATP (21) into CyaA in more 
detail. The deoxyribosyl ring adopts a 3´-exo conformation like the ribosyl moiety of 
MANT-ATP in complex with mammalian AC (Mou et al., 2006). The three Mg2+ ions 
are in positions similar to those in the CyaA-PMEApp complex and form the same 
interactions. Two of them are coordinated with D188 and D190, one additionally with 
H298, and the third with the α- and β-phosphate. The imidazolyl-NH of H298 may be 
H-bonded with an oxygen of the α-phosphate. The γ-phosphate contacts the lysine 
residues K65 and K58 (O-N distances, ~2.8 Å). 
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Fig. 6: Docking of representative MANT- and TNP-nucleotides to CyaA. The 
models are based on the crystal structure of CyaA in complex with PMEApp, PDB 
1zot (Guo et al., 2005; Moreland et al., 2005). Colors of atoms, unless otherwise 
indicated: orange, phosphorous; red, oxygen; blue, nitrogen; white, carbon; green 
spheres, magnesium. A: Overview of the binding site, represented by the lipophilic 
potential mapped onto a MOLCAD Connolly surface (brown, hydrophobic areas; 
green and blue, polar areas). Docked ligands: PMEApp (carbon atoms in magenta); 
3´MANT-2´d-ATP (carbon and hydrogen atoms in yellow). B: Docking of 3´MANT-
2´d-ATP (21). Amino acids within a sphere of ~3 Å around the ligand are labeled. The 
protein backbone is schematically represented by a tube. Carbon atoms of the 
backbone are colored in dark cyan, carbon atoms of the side chains are in light cyan. 
C: Docking of 2´MANT-3´d-ATP (22). Representation of the backbone and the side 
chains as in B. For clarity, some labels are omitted (see B). D: Docking of TNP-ATP 
(26). For comparison, 3´MANT-2´d-ATP is shown in the same position like in B (all 
atoms colored in magenta). Only amino acids with suggested interactions specific for 
TNP-ATP are labeled. Representation of the backbone and the side chains as in B. 
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These interactions account for the higher inhibitory potencies of the 
triphosphates compared with the diphosphate and monophosphate analogs in Tab. 
1. The adenine moiety is sandwiched between the side chains of H298 and N304 
whose amide NH2 group may form an additional H bond with the deoxyribosyl ring 
oxygen. The 6-amino substituent is in proximity to the backbone oxygens of V271, 
G299 and T300. However, the loop between G299 and N304 may align all of the 
nucleobases in similar position. In the case of GTP, ITP, UTP and their MANT- and 
TNP-derivatives, backbone NH functions of, for example, G299 and V271 could 
serve as hydrogen donors for the carbonyl oxygens in 6 and 4 position, respectively. 
This diversity of possible interactions may account for the relatively small and 
inconsistent potency differences when comparing the impact of base substitution in 
different subsets of nucleotides [i.e., natural NTPs, MANT-NTPs, MANT-NDPs and 
TNP-NTPs (see Tab. 1)]. In addition, the affinity of each nucleotide may be affected 
by a specific arrangement of water molecules that cannot be simply transferred from 
the PMEApp-bound CyaA structure. 
Fig. 6B also shows that the high potency of 3´MANT-2´d-ATP (21) is 
particularly due to ideal stacking of the phenyl rings of the inhibitor and F306. This 
stacking also accounts for the efficient FRET and direct fluorescence observed with 
3´MANT-2´d-ATP (Figs. 1-4). The axial position of the hydrogen atom corresponding 
to the 2´-OH group in 3´MANT-ATP suggests that even the 2´,3´di-MANT-ATP 
derivative will be similarly potent since the 2´-MANT-moiety may fit into a 
hydrophobic site consisting of P305 and F261. 
This site would also be occupied by the 2´-MANT-group in 2´MANT-3´d-ATP 
(22) if the deoxyribosyl ring adopts a 3´-exo conformation. However, similar 
potencies of the positional isomers 21 and 22 in the AC assay (Tab. 1) and 
fluorescence assay (Fig. 3) as well as similar magnitudes of FRET and direct 
fluorescence (Figs. 1 and 4) rather indicate analogous interactions between the 
MANT-group and F306 in the complexes of CyaA with 2´MANT-3´d-ATP and 
3´MANT-2´d-ATP, respectively. Fig. 6C illustrates that docking of 2´MANT-3´d-ATP 
may indeed reproduce the interaction pattern of 3´MANT-2´d-ATP with CyaA shown 
in Fig. 6B. The only difference is a 3´-endo conformation of the deoxyribosyl moiety 
as is present, e.g., in A-DNA.  
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Fig. 6D shows the predicted binding mode of TNP-ATP (26) which has a 
potency similar to that of the isomerizing MANT-ATP derivative (8). Despite the 
rigidity of the tricyclic TNP-ATP scaffold containing a spiro junction, a sufficient 
alignment with 3´MANT-2´d-ATP is possible so that the phosphate groups, the 
adenine base, and the phenyl moieties may interact with the same CyaA sites. This 
superposition implies a relatively deep position of TNP-ATP in the cavity. The 
interaction of F306 with the TNP-group is weaker than with MANT (no optimal 
position, lower hydrophobicity). However, hydrogen bonds of two ribosyl oxygens 
with the side chains of H298 and N304, respectively, may counterbalance, in part, 
the reduced hydrophobic interactions and higher conformational strain. In addition, 
the intrinsic fluorescence properties of TNP-nucleotides, i.e. higher fluorescence 
increases upon transfer into a hydrophobic environment than with MANT-nucleotides 
(Jameson and Eccleston, 1997; Hiratsuka, 2003), more than compensate for the 
suboptimal positioning of the TNP-group relative to F306 (Figs. 4 and 5). It is 
noteworthy that the inhibitory potency of TNP-derivatives 26-29 is more dependent 
on the specific nucleobase than in the corresponding subseries of MANT-nucleotides 
8, 10, 14 and 15 and the non-substituted NTPs GTP (2), CTP (5) and UTP (6). The 
rigid scaffold of the TNP-nucleotides probably does not enable an optimal fit of 
guanine and the pyrimidines to the backbone of the loop between G299 and N304. 
The lower substrate Km and Vmax values as well as the generally 5- to 40-fold 
higher potency of the inhibitors under Mn2+-conditions than under Mg2+-conditions 
clearly point to considerably tighter binding with the former cation. This increase in 
the free energy of binding of up to ~2 kcal/mol should be due mainly to stronger 
Mn2+-phosphate binding. No further conclusions can be drawn from the docking 
approaches based on force field methods and without a CyaA crystal structure with 
Mn2+ instead of Mg2+.  
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3.5 Discussion 
 
3.5.1 Spacious Catalytic Site of CyaA 
The catalytic site of CyaA forms a large cavity with substantial conformational 
freedom to accommodate structurally diverse ligands. In particular, not only adenine 
nucleotides, but also other purine and even pyrimidine nucleotides reduce the 
catalytic activity of CyaA (Tab. 1) because of flexible fit to the backbone of the loop 
between G299 and N304 (Fig. 6). Effective interaction of CyaA with purine and 
pyrimidine nucleotides is also clearly documented in the fluorescence experiments 
with TNP-ATP, TNP-GTP, TNP-CTP and TNP-UTP (Fig. 5), monitoring interaction of 
the TNP-group with F306 (Fig. 6D). The distinct fluorescence responses upon 
interaction of CyaA with various TNP-nucleotides in the absence and presence of 
CaM are indicative for slightly different orientations of TNP-nucleotides in the 
catalytic site of CyaA. Moreover, various MANT-nucleotides (12-15) exhibiting higher 
affinity for CyaA than TNP-nucleotides (Tab. 1) did not give rise to FRET with CyaA. 
These findings suggest that differences in affinity do not account for the different 
fluorescence responses with various nucleotides. Rather, the differences in 
fluorescence properties point to differences in orientation of the nucleotides in the 
catalytic site. Taken together, all those findings are in accordance with the modeling 
data and support the notion of a spacious catalytic site of CyaA. 
 
3.5.2 Towards the Development of Selective CyaA Inhibitors 
Because the inhibitory profile of CyaA differs considerably from that of 
mammalian ACs (Gille et al., 2004; Mou et al., 2005, 2006), development of more 
potent and selective CyaA inhibitors is feasible. For all inhibitors studied, the TNP-
substituent was substantially less effective in increasing nucleotide affinity than 
MANT/ANT. Whereas ANT-ATP was more potent than MANT-ATP, the MANT-group 
was superior to ANT in case of MANT-GTP vs. ANT-GTP. The additional methyl 
group in MANT compared with ANT may reduce mobility of the fluorescent group 
and, thereby, facilitate alignment with F306, depending on the specific nucleobase 
present. 
For all MANT-NDP/NTP pairs studied so far, elimination of the γ-phosphate 
group substantially decreased inhibitor affinity. As an example, MANT-IDP (18) was 
almost 20-fold less potent than MANT-ITP (12), and the omission of the β-phosphate 
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in MANT-IMP (30) further reduced affinity compared with MANT-IDP. The importance 
of the polyphosphate chain for effective interaction of nucleotides with the catalytic 
site is also supported by our modeling data (Fig. 6B). For future applications of 
MANT-nucleotides in intact-cell assays, nucleotides with a phosphate tail resistant to 
hydrolysis are needed (Rottländer et al., 2007). As the potency of γS-substituted 
MANT-nucleotides was higher in case of MANT-ATPγS vs. MANT-ATP and MANT-
GTPγS vs. MANT-GTP, the design of potent nucleotides resistant to hydrolysis is 
feasible. 
An unexpected side product in our synthesis scheme of MANT-ITP (12) was 
di-MANT-IMP (31). Even more unexpectedly, addition of a second MANT-group to 
the ribosyl ring in di-MANT-IMP (31) caused an increase in affinity compared with 
MANT-IMP (30) under Mn2+- and Mg2+-conditions (Tab. 1) that may be attributed to 
interactions of the 2´MANT-group with a hydrophobic site consisting of P305 and 
F261 (Fig. 6B). Thus, the introduction of a second MANT-/ANT-group or other bulky 
substituents should be considered in future inhibitor design projects to increase 
inhibitor affinity. In addition, given the surprising differences in fluorescence 
responses between MANT- and TNP-nucleotides, di-MANT-nucleotides may provide 
valuable conformational probes to better understand the mechanisms of CyaA 
activation. 
Considering the bases, hypoxanthine is superior to other purine and 
pyrimidine bases (Tab. 1). Moreover, 2´MANT-3´d-ATP and 3´MANT-2´d-ATP are 
considerably more potent than MANT-ATP. Therefore, 2´MANT-3´d-ITP and 
3´MANT-2´d-ITP are interesting future candidates as potential novel CyaA inhibitors. 
Further increase in potency and selectivity of PMEApp may be achieved by changing 
the adenine base to hypoxanthine and by introducing a MANT-/ANT-substituent. 
Like CyaA, Bacillus anthracis AC toxin edema factor also bears a 
phenylalanine residue close to the catalytic site (Guo et al., 2005). Structural 
comparison of CyaA with edema factor revealed that F306 of CyaA is the analog of 
F586 in edema factor, forming hydrophobic interactions with the MANT-group, thus 
increasing direct fluorescence of MANT-nucleotides. The inhibitory profile of edema 
factor differs considerably from that of CyaA. In particular, MANT-ATP inhibits the 
catalytic activity of CyaA with almost 25-fold lower potency than catalysis by edema 
factor (Gille et al., 2004). In case of 3´MANT-2´d-GTP, 3´MANT-2´d-ATP and MANT-
ADP, the decreases in potency of CyaA inhibition compared to edema factor 
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inhibition were 22-fold, 25-fold and 40-fold, respectively. Based on these differences 
in enzymological properties, it is also reasonable to assume that the fluorescence 
analysis of edema factor with MANT- and TNP-nucleotides will give very different 
results than with CyaA. 
We have solved the crystal structure of mammalian C1:C2 AC in complex with 
MANT-GTP, MANT-ATP and TNP-ATP (Mou et al., 2005, 2006). Based on 
crystallographic studies, we have developed a tripartite model for mammalian AC 
with a binding site for the base, the ribosyl substituent and the phosphate tail (Mou et 
al., 2005, 2006). In this model, the base site possesses the smallest influence, 
whereas the ribosyl substituent has a strong impact. This model can also be applied 
to CyaA (Fig. 6). Specifically, a variety of purine and pyrimidine nucleotides inhibit 
CyaA, suggesting that the base does not greatly determine the potency of 2´,3´-
ribosyl substituted inhibitors. In contrast, introduction of a MANT-/ANT-group 
increased inhibitor potency at CyaA up to 170-fold (e.g. ITP vs. MANT-ITP), pointing 
to the critical importance of the ribosyl substituent. However, TNP-substitution 
showed a much smaller effect on inhibitor affinity for CyaA than for C1:C2 (Mou et 
al., 2006) (Tab. 1), highlighting the substantial structural differences between the 
binding. In particular, mammalian AC possesses a large hydrophobic pocket 
consisting of several amino acids accommodating the 2´,3´-ribosyl substituent (Mou 
et al., 2005, 2006), whereas in case of CyaA, just one amino acid, F306, participates 
in hydrophobic interactions with MANT- and TNP-nucleotides (Fig. 6). 
 
3.5.3 The Role of Divalent Cations 
It is also important to emphasize that in future studies, inhibitors should be 
studied both under Mg2+- and Mn2+-conditions because there are differences in the 
rank order of potency of compounds under those conditions. Moreover, exchange of 
Mn2+ against Mg2+ increases Vmax and Km (Tab. 1). Crystallographic studies are 
required to understand those substantial differences between Mn2+ and Mg2+. It is 
reasonable to assume that under physiological conditions, Mg2+ rather than Mn2+ is 
relevant. It is most likely that Mn2+ is only an (important) experimental tool to facilitate 
molecular analysis of CyaA. In particular, in the presence of Mg2+, detection of 
significant increases in FRET and direct fluorescence with MANT-nucleotides was 
impossible (data not shown). 
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3.5.4 CaM-Independent Interaction of CyaA with Nucleotides 
The fact that fluorescence of TNP-nucleotides increased upon interaction with 
CyaA in the absence of the activator CaM (Fig. 5) indicates that the nucleotide 
binding site of CyaA is already functional in the catalytically inactive toxin. However, 
our data suggest that CyaA does not bind MANT-nucleotides in the absence of CaM, 
because FRET and direct fluorescence with MANT-nucleotides was completely 
dependent on CaM (Figs. 1-4). In contrast to CyaA, mammalian C1:C2 does bind 
MANT-nucleotides, to some extent, in the absence of the activator forskolin (Mou et 
al., 2005, 2006), again supporting the concept of substantial structural differences 
between mammalian and bacterial AC. These data also imply that binding of CaM to 
CyaA induces a conformational change in the toxin that allows MANT-nucleotides to 
bind. The identification of the precise nature of this conformational change requires 
crystallization of CyaA complexes with TNP-nucleotides in the absence and presence 
of CaM as well as of CyaA with MANT-nucleotides in the presence of CaM. The 
opposite fluorescence responses of TNP-nucleotides and MANT-nucleotides to CaM 
are in agreement with the modeling studies showing that the TNP- and MANT-groups 
adopt similar but not identical positions in the catalytic site of CyaA (Fig. 6D). The 
dramatic differences in fluorescence responses of TNP- and MANT-nucleotides in 
the absence and presence of CaM also demonstrate that these nucleotides are 
extremely sensitive probes for detecting small differences in nucleotide/CyaA 
interactions.  
Another implication of the CaM-independent binding of TNP-nucleotides to 
CyaA is that the catalytic site of CyaA possesses different binding properties than the 
site in the presence of CaM, offering additional possibilities for inhibitor design and 
increasing inhibitor selectivity. Comparison of inhibition profiles of non-fluorescent 
nucleotides on TNP-nucleotide fluorescence bound to CyaA in the absence and 
presence of CaM is a feasible approach. With respect to catalysis, such comparison 
is impossible because enzymatic activity obligatorily depends on CaM (Ladant and 
Ullmann, 1999; Shen et al., 2002).  
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3.5.5 Conclusions 
In the present study, we have shown that the catalytic site of CyaA possesses 
unique pharmacological properties compared to other mammalian and bacterial ACs. 
The spacious catalytic site of CyaA accommodates a broad variety of 2´,3´-
substituted nucleotides, even di-MANT-nucleotides. Some inhibitors can bind to 
CyaA even in the absence of CaM, and there is evidence for distinct interaction of 
CyaA with MANT-nucleotides and TNP-nucleotides. Finally, the fluorescence assays 
described in this study can be used for identification of novel CyaA inhibitors, 
ultimately resulting in the development of novel drugs for prophylaxis of whooping 
cough. 
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4.1 Abstract 
 
Cyclic adenosine 3´:5´-monophosphate (cAMP) and cyclic guanosine 3´:5´-
monophosphate (cGMP) are key second messengers for a wide variety of 
mammalian cellular processes. The natural occurrence of a third cyclic nucleotide, 
cyclic cytidine 3´:5´-monophosphate (cCMP) had been discussed very controversially 
30-35 years ago, but later, cCMP was identified unambiguously in various 
mammalian tissues indicating cCMP to be a novel second messenger with potential 
importance in regulation of cell growth, proliferation, tissue development and 
modulation of immune responses. However, the precise identity of the cCMP-forming 
enzyme in mammalian cells is still unclear. Here, for the first time, we provide 
evidence for cytidylyl cyclase (CC) activity of purified bacterial exotoxins. Bacillus 
anthracis and Bordetella pertussis, the causative bacteria of anthrax disease and 
whooping cough, respectively, secrete the adenylyl cyclase (AC) toxins edema factor 
(EF) and CyaA, weakening immune responses through massive cAMP production 
and, thereby, promoting the pathogenesis of the infections. We found that both toxins 
also possess CC activity, resulting in the conversion of CTP to cCMP. In our CC 
activity assay, the radioactively labeled substrate [α-32P]CTP is converted to 
[32P]cCMP which is quantified by liquid scintillation. Upon incubation of the toxins with 
[α-32P]CTP, [32P]cCMP is produced in a linear manner over time. As [32P]cCMP 
production depends on the endogenous toxin activator protein calmodulin, as 
physiological pH promotes the reaction and as potent AC inhibitors show high 
potency on EF and CyaA, catalysis results from specific CC activity. Michaelis-
Menten kinetics of EF CC activity yielded Km = 13 ± 3 µM and Vmax = 9 ± 1 s
-1. When 
CTP consumption and cCMP formation were monitored by HPLC, 100 µM CTP were 
converted to cCMP by 20 nM EF within 1 h. In the presence of heat-inactivated 
enzyme, no cCMP was formed. The identity of cCMP was confirmed by co-eluting 
standard cCMP in HPLC experiments and by mass spectrometry methods. Based on 
these findings and the fact that cCMP inhibits host immune responses, we propose 
that the bacterial exotoxins edema factor (EF) and CyaA generate cCMP, resulting in 
increased infection severity. The molecular targets of cCMP remain to be 
determined. 
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4.2 Introduction 
 
Cyclic adenosine 3´:5´-monophosphate (cAMP) and cyclic guanosine 3´:5´-
monophosphate (cGMP) are key second messengers for a wide variety of 
mammalian cellular processes. The natural occurrence of a third cyclic nucleotide, 
cyclic cytidine 3´:5´-monophosphate (cCMP) had been discussed very controversially 
30-35 years ago. In 1974, Bloch et al. first observed that - in contrast to cAMP and 
cGMP - cCMP initiated the growth of leukemia L-1210 cells in a concentration-
dependent manner suggesting that cCMP exerts a growth-regulatory function (Bloch 
et al., 1974). In 1978, Cech et al. reported the identification of cCMP as product of 
the reaction between mouse liver homogenate, CTP and Mn2+ using chromatography 
on neutral alumina columns for the separation of potential cCMP from other 
nucleotide species (Cech and Ignarro, 1978). This finding was contradicted in 1979 
by Gaion et al. who observed a different behaviour of the reaction product obtained 
according to the method of Cech et al. and authentic cCMP in various 
chromatographic systems, indicating that 5´-CMP and 5´-CDP are the major 
products, with no cCMP being formed (Gaion and Krishna, 1979). 
The natural occurrence of cCMP in various mammalian organs was later 
confirmed unambiguously using mass spectrometry methods (Newton et al., 1984), 
and besides cCMP, four novel cytidine cyclic phosphates were identified as 
biosynthetic products from CTP, providing a feasible explanation of the discrepancies 
in the reports of Cech et al. and Gaion et al. (Newton et al., 1988). Further 
developments in the fields of column chromatography and mass spectrometry 
revealed the kinetic parameters of the CC reaction; similar CC activities were 
observed in nine organs of rat, and the CC activity was found to be inversely 
proportional to the age of the animals (Newton et al., 1990, 1997). cCMP levels in 
urine obtained from leukemic patients were very much elevated in comparison to 
normal human samples as determined by radioimmunoassay methods (Newton et 
al., 1994). The potential importance of cCMP as a regulator of cell function has been 
emphasized by the discovery of phosphodiesterase activity accounting for the 
selective degradation of cCMP (Newton et al., 1986, 1999). Furthermore, protein 
kinase activity responsive to cCMP has been observed (Newton et al., 1992) and ten 
proteins were identified in brain tissue undergoing phosphorylation due to challenge 
with cCMP (Bond et al., 2007; Ding et al., 2008). 
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cCMP may also modulate immune system functions. In macrophages, the cell-
permeant cCMP-analog dibutyryl-cCMP inhibited thromboxane B2 and leukotriene B4 
formation (Elliott et al., 1991). In human neutrophils, dibutyryl-cCMP inhibited 
superoxide radical formation and the rise in cytosolic Ca2+ induced by a chemotactic 
peptide, resulting in neutrophil inactivation (Ervens and Seifert, 1991). Taken 
together, these findings point to cCMP being a potential novel second messenger 
with importance in regulation of cell growth, proliferation, tissue development and 
modulation of immune responses. However, so far the precise identity of the cCMP-
forming cytidylyl cyclase enzyme in mammalian cells is still unclear.  
The causative agents of anthrax disease and whooping cough, Bacillus 
anthracis and Bordetella pertussis, respectively, exert their deleterious effects by the 
release of exotoxins interfering with host signal transduction pathways resulting in 
inhibited immune response (Ahuja et al., 2004; Basler et al., 2006). After interacting 
with surface receptors of eukaryotic host immune cells and translocating into the 
cytosol (Ladant and Ullmann, 1999; Mogridge et al., 2002), the AC toxins edema 
factor (EF) from B. anthracis and CyaA from B. pertussis bind to calmodulin (CaM), 
an endogenous calcium sensor, resulting in activation of the AC activity of the toxins 
(Drum et al., 2000; Gallay et al., 2004; Guo et al., 2005). Both, EF and CyaA catalyze 
massive synthesis of cAMP leading to excessive intracellular cAMP accumulation 
and disruption of intracellular signaling pathways. Consequently, host phagocyte, 
macrophage and dendritic cell function is inhibited rendering the infection more 
severe (Paccani et al., 2005; Tournier et al., 2005; Hewlett et al., 2006). 
Substrate analogs may be used to inhibit the AC activity of EF and CyaA 
(Johnson and Shoshani, 1990; Soelaiman et al., 2003; Gille et al., 2004) in order to 
decrease weakening of the immune response and to mitigate the severity of 
infection. Mammals express nine membranous AC isoforms (mACs 1-9) and a 
soluble AC. We have used the cytosolic catalytic domains C1 of type 5 AC and C2 of 
type 2 AC for molecular AC analysis (Gille et al., 2004; Mou et al., 2005, 2006). 
Serendipitously, we had discovered 2´(3´)-O-(N-methylanthraniloyl)- (MANT)-
substituted NTPs as competitive inhibitors of mammalian ACs and bacterial AC 
toxins (Gille et al., 2003, 2004). Additionally, PMEApp, the active metabolite of 
adefovir, a drug for the treatment of chronic hepatitis B virus infection, was identified 
as a potent inhibitor of EF and CyaA (Shen et al., 2004). 
 Chapter 4 121 
 
Using crystallographic and molecular modeling approaches, we developed a 
three-site pharmacophore model for mAC and bacterial AC toxins, with binding 
domains for the base, the MANT-group and the polyphosphate chain (Mou et al., 
2006; Göttle et al., 2007). We resolved several EF and CyaA crystal structures and 
characterized the amino acids important for nucleotide binding and catalysis (Drum et 
al., 2002; Guo et al., 2005; Shen et al., 2005). Furthermore, we systematically 
examined the interactions of natural purine and pyrimidine nucleotides and MANT-
substituted analogs with EF and CyaA in terms of catalysis, fluorescence changes 
and molecular modeling (Göttle et al., 2007; Taha et al., 2009). MANT-CTP was the 
most potent competitive EF inhibitor among 16 compounds studied, showing unique 
preference of EF for the base cytosine. Taken together, those studies revealed the 
catalytic sites of EF and CyaA to exhibit conformational flexibility and to 
accommodate both purine and pyrimidine nucleotides. Those findings also raised the 
question whether in addition to ATP, other naturally occurring nucleotides, most 
importantly CTP, could be substrates for cyclization. Here, for the first time, we 
unequivocally demonstrate CC activity of the bacterial exotoxins EF and CyaA. 
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4.3 Materials and Methods 
 
Chemicals and Biochemical Reagents. MANT-substituted nucleoside 
triphosphates of cytidine, inosine and uridine were synthesized as described (Taha et 
al., 2009). MANT-ATP, MANT-GTP were from Jena Bioscience, Jena, Germany. [α-
32P]ATP (800 Ci/mmol), [α-32P]CTP (800 Ci/mmol) and [α-32P]UTP (800 Ci/mmol) 
were purchased from PerkinElmer, Wellesley, MA, USA. Aluminum oxide N Super 1 
was purchased from MP Biomedicals, Eschwege, Germany. Acetonitrile (LC grade), 
ammonium acetate (p.A.), CaCl2 dihydrate (p.A.), KCl (p.A.), methanol (LC grade), 
MnCl2 tetrahydrate and MgCl2 hexahydrate (highest quality), ortho-phosphoric acid 
(p.A.), sodium acetate (p.A.) and triethylamine were from Merck, Darmstadt, 
Germany. GTP·2 Na, ATP·2 Na and cAMP were purchased from Roche. cCMP·Na, 
cGMP·Na, cIMP·Na, cUMP·Na, cTMP·Na were from Biolog, Bremen, Germany. 
Bovine serum albumin (fraction V), 2´:3´-cCMP·Na, CMP·2 Na, CDP·3 Na, CTP·2 Na, 
2´d-CTP·2 Na, EGTA, inosine, ITP·3 Na, TTP·Na, UDP·Na, UMP·Na and UTP·3 Na 
dihydrate were purchased from Sigma-Aldrich, Seelze, Germany. Tris (ultrapure) was 
from USB, Cleveland, OH, USA. PMEApp was supplied by Gilead Sciences, Foster 
City, CA, USA. The full-length AC toxin edema factor (EF) from B. anthracis and the 
catalytic domain of B. pertussis AC protein (CyaA, amino acids 1 to 373) were 
purified as described (Drum et al., 2000, 2001). Lyophilized calmodulin from bovine 
brain was purchased from EMD Biosciences, Calbiochem, Darmstadt, Germany. 
 
Isotopic Nucleotidyl Cyclase (NC) Assay. For the determination of the 
potency of AC/CC inhibitors, assay tubes contained 10 µL of inhibitor at final 
concentrations from 1 nM to 100 µM and 20 µL of EF or CyaA dissolved in 75 mM 
Hepes/NaOH, pH 7.4, supplemented with 0.1% (m/v) bovine serum albumin to 
prevent protein adsorption. Final protein concentrations were 10 pM EF or CyaA (AC) 
and 30 pM (CC). Tubes were preincubated for 2 min and reactions were initiated by 
the addition of 20 µL of reaction mixture consisting of the following components to 
yield the given final concentrations: 100 mM KCl, 5 mM free Mn2+, 10 µM free Ca2+, 
100 µM EGTA, 100 µM cAMP and 100 nM CaM. In case of AC activity, ATP was 
added as non-labeled substrate at a final concentration of 40 µM and as radioactive 
tracer [α-32P]ATP (0.2 µCi/tube). In case of CC activity, CTP was added as non-
labeled substrate at a final concentration of 10 µM and as radioactive tracer [α-
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32P]CTP (0.4 µCi/tube). Reactions were carried out for 10 min at 25°C (AC) and 20 
min at 37°C (CC). 
For the determination of Km and Vmax values, assay tubes contained 10 µL of 
NTP/Mn2+ or NTP/Mg2+ and 20 µL of reaction mixture as described above. NTP/Mn2+ 
or NTP/Mg2+ (1 µM to 2 mM) plus 5 mM of free Mn2+ or Mg2+ were added. Reactions 
were initiated by the addition of 20 µL of EF or CyaA to yield the following final 
enzyme concentrations: 10 pM (EF and CyaA AC activities), 40 pM (EF and CyaA 
CC activities with Mn2+), and 400 pM (EF CC activity with Mg2+ and UC activities). 
The amount of radioactive tracers was [α-32P]ATP (0.2 µCi/tube), [α-32P]CTP (0.8 
µCi/tube) and [α-32P]UTP 0.8 µCi/tube. Reactions were carried out for 10 min at 25°C 
(AC), 20 min at 37°C (CC) and 30 min at 37°C (UC). In saturation experiments using 
CTP/Mg2+ or UTP/Mn2+, no extra non-labeled cyclic nucleotide was added to the 
reaction mixture. Saturation experiments using CTP/Mn2+ were performed in the 
presence of extra non-labeled cAMP or cCMP (100 µM each), and in the absence of 
cyclic nucleotide (without yielding significantly different results, data not shown). In 
saturation experiments using ATP/Mg2+ or CTP/Mg2+ on EF, 10 mM Tris/HCl were 
included in addition to the reaction mixture, and 1 mM EGTA and 400 nM free Ca2+ 
were used. In those experiments, the reaction mixture was incubated for 5 min at 
room temperature prior to the addition of CaM and again for 5 min after the addition 
of CaM. 
Reactions were terminated by the addition of 20 µL of 2.2 N HCl, denaturated 
protein was sedimented by a 1-min centrifugation at 12,000 x g. [32P]cNMP was 
separated from [α-32P]NTP by transferring the samples to columns containing 1.4 g 
of neutral alumina. [32P]cNMP was eluted by the addition of 4 mL 0.1 M ammonium 
acetate solution, pH 7.0 (Alvarez and Daniels, 1990). Blank values were about 0.02% 
of the total amount of [α-32P]NTP added; substrate turnover was < 3% of the total 
added [α-32P]NTP. Samples were filled up with 10 mL Millipore water and Čerenkov 
radiation was measured in a PerkinElmer Tricarb 2800TR liquid scintillation analyzer. 
Free concentrations of divalent cations were calculated with WinMaxC 
(http://www.stanford.edu/~cpatton/maxc.html). Ki values, Km values and Vmax values 
reported in Tab. 1 and 2 were calculated using the Prism 4.02 software (Graphpad, 
San Diego, CA, USA). 
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Non-Isotopic Nucleotidyl Cyclase (NC) Assay and HPLC Analysis. 
Reaction mixtures consisted of the following components to yield the given final 
concentrations in a total volume of 3 mL: 5 mM Mn2+, 5 µM Ca2+, 30 mM 
Hepes/NaOH, pH 7.4, 100 µM of the corresponding NTP and CaM at concentrations 
yielding 1:1 stoichiometry of CaM and bacterial cyclase toxin. Prior to the addition of 
enzyme, two sample aliquots (300 µL each) were taken as negative controls: One 
sample aliquot was taken and stored on ice; a second sample aliquot lacking enzyme 
was taken and incubated in parallel with the reaction batch containing enzyme for 60 
min at 37°C. Both, negative controls and reaction samples, later underwent the 
sample preparation process described subsequently. Assay tubes were preincubated 
at 37°C for 4 min and reactions were initiated by the addition of 300 µL of EF or 
CyaA. Final protein concentrations ranged between 20 nM bacterial cyclase toxin 
and 20 nM CaM up to 1,500 nM bacterial cyclase toxin and 1,500 nM CaM as 
described in detail in “Results”. Samples were taken at reaction times between 1 and 
60 min. In order to achieve protein denaturation, sample aliquots (300 µL each) were 
added to 600 µL of acetonitrile and cooled to 4°C. Threehundred µL of 40 µM inosine 
were added as internal standard (IS). Denatured protein was sedimented by a 1-min 
centrifugation at 12,000 x g. In order to achieve separation of the aqueous phase 
from the organic phase, samples were transferred into 5-mL-vials and 2 mL of 
dichloromethane were added. Samples were agitated for 20 min at 4°C and 
centrifuged for 5 min at 1,000 x g. The aqueous phase was transferred into 1.5-mL-
vials and stored at -80°C. 
Nucleotides were quantified using a Shimadzu HPLC system consisting of a 
LC-10AT pump, SIL-10A auto-injector and SPD-10AV UV-VIS detector for monitoring 
nucleotide absorbance at 260 nm. A Phenomenex Synergi® Fusion-RP HPLC column 
(Phenomenex, Aschaffenburg, Germany), 150 x 4.6 mm, 4 µm particle size, Cat. No. 
00F-4424-E0 was eluted with the mobile phase at 1 mL/min. The mobile phase 
consisted of 100 mM triethylamine with pH set to 6.6 using ortho-phosphoric acid. 
The mobile phase contained methanol at a concentration of 6% (v/v) in case of 
cCMP, cUMP and cIMP, 9% (v/v) in case of cGMP and cTMP as well as 12% (v/v) in 
case of cAMP. The mobile phase was run at 1 mL/min, the temperature of the 
column oven was 35°C and the injection volume was 5 µL. Standard substances of 
cCMP, cUMP, cIMP, cGMP, cTMP and cAMP were applied to HPLC analysis, and 
the resulting retention times were compared to those from the cyclic nucleotides 
 Chapter 4 125 
 
resulting from enzymatic reaction. Chromatograms were generated and evaluated 
using the Shimadzu LC solution 1.22 SP1 software. 
 
Mass Spectrometry. LC-MS/MS was performed using an Agilent 1100 HPLC 
system and a TSQ-7000 Thermoquest Finnigan triple quadrupol mass spectrometer. 
A Phenomenex Luna C18 Aqua HPLC column (150 x 2 mm, 3 µm particle size) was 
eluted with the mobile phase at 0.3 mL/min using a gradient of 0.1% formic acid (A) 
and acetonitrile (B) with 0% B (v/v, min 0 to 2), 80% B (v/v, min 2 to 15), 80% B (v/v, 
min 15 to 20), 0% B (v/v, min 20 to 25) and 0% B (v/v, min 25 to 35). The 
autosampler system was cooled to 5°C, the temperature of the column oven was 
40°C and the injection volume was 20 µL. Upon ESI (capillary temperature 250°C, 
ESI spray voltage 4 kV), argon was used for collision-induced dissociation with 
collision energies of 25 V (cCMP), 15 V (cUMP) and 20 V (cIMP). Selective reaction 
monitoring in positive mode was performed monitoring m/z transitions of 306.0 to 
112.2 (cCMP), of 324.2 to 307.0 (cUMP) and of 330.9 to 137.2 (cIMP). Data were 
interpreted using the Xcalibur 3.1 software. 
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4.4 Results 
 
4.4.1 Isotopic Nucleotidyl Cyclase Assay 
Incubation of 20 pM EF with 0.4 µCi/tube [α-32P]CTP and 10 µM unlabeled 
CTP in the presence of 5 mM Mn2+ followed by the alumina solid phase extraction 
procedure described in “Materials and Methods” and by liquid scintillation analysis 
resulted in a pronounced signal increasing linearly over time (Fig. 1A). Blank values 
were generally < 0.02% of the total added amount of [α-32P]CTP indicating full 
retention of [α-32P]CTP on the column matrix during the solid phase extraction. 
By successively increasing the enzyme concentration, the resulting signal 
increased proportionally (Fig. 1B), pointing to dependence of the signal on the 
amount of purified enzyme added. As shown in Fig. 1C, the signal intensity showed 
considerable dependence on pH with the highest intensity obtained at physiological 
pH values and poor intensities at low pH values (pH 6.0) or high pH values (pH 9.0). 
At pH 5.0, liquid scintillation did not show significantly higher signals as compared to 
blank values obtained from negative controls lacking enzyme, indicating that no 
conversion of [α-32P]CTP occurred at this pH. 
In order to investigate if the detected signal resulted from enzymatic 
conversion of [α-32P]CTP by the ACs applied, the EF and CyaA activator CaM was 
added in increasing concentrations yielding concentration-response curves with EC50 
values of 670 ± 50 pM in case of EF (Fig. 1D) and 80 ± 5 pM in case of CyaA (data 
not shown). In the absence of CaM, 40 pM EF increased the detected signal 3-fold 
compared with blank values obtained in the absence of enzyme. With 100 nM CaM 
and 40 pM EF, the detected signal was stimulated up to 200-fold compared with 
blank values obtained in the absence of enzyme. Thus, CaM considerably stimulated 
[α-32P]CTP conversion by EF, but a clear turnover was also observed in the absence 
of CaM. Similar results were obtained with CyaA (data not shown). Our preliminary 
experiments indicated very poor enzymatic activity of EF on 2´d-CTP as compared to 
CTP, pointing to importance of the hydroxyl group at 2´-ribosyl position for catalysis 
(data not shown). Using UTP as substrate and [α-32P]UTP as radioactive tracer, 
signals from liquid scintillation were also detected as shown below. 
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Fig. 1: Signals obtained using the isotopic EF cytidylyl cyclase assay. 
Reactions were carried out for 20 min at 37°C as described in “Materials and 
Methods”. A: Time course experiment using 20 pM EF. Reaction mixtures contained 
the following components to yield the given final concentrations: 100 mM KCl, 5 mM 
Mn2+, 10 µM free Ca2+, 100 µM EGTA, 10 µM CTP, [α-32P]CTP (0.4 µCi/tube), 100 
nM CaM. B: Signal dependence on EF protein concentration. Reaction mixtures 
contained EF at various concentrations, the components listed under A and 
additionally 100 µM cAMP. C: Dependence of CC activity on pH. Reaction mixtures 
contained 80 pM EF and the components listed under B. Buffering systems were 30 
mM sodium acetate·HCl (pH 5.0 and pH 6.0), 30 mM Hepes/NaOH (pH 7.4) and 30 
mM Tris/HCl (pH 8.0 and pH 9.0). D: Activation of CC activity by CaM. Reaction 
mixtures contained 5 mM Mn2+, 10 µM free Ca2+, 100 µM EGTA, 10 µM CTP, [α-
32P]CTP (0.4 µCi/tube), 40 pM EF and CaM at various concentrations. Data shown 
are means ± SD of representative experiments performed in duplicates; similar 
results were obtained in at least 3 independent experiments. 
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4.4.2 Solid Phase Extraction of Cytosine and Uracil Nucleotides and HPLC 
Analysis 
In order to ensure complete retention of the starting material [α-32P]NTP on 
the alumina columns during solid phase extraction, and in order to determine 
recovery values for the product [32P]cNMP, mixtures of non-labeled nucleotides were 
subjected to solid phase extraction (SPE) and HPLC analysis as described in 
“Materials and Methods”. Prior to SPE, HPLC chromatograms from nucleotide 
mixtures show peaks from 15 µM CMP, CDP, CTP and 3´:5´-cCMP (Fig. 2A, dashed 
line) as well as from 15 µM UMP, UDP, UTP and 3´:5´-cUMP (Fig. 2B, dashed line). 
After SPE, 3´:5´-cCMP and 3´:5´-cUMP were eluted while the signals from acyclic 
nucleotides were missing. The recovery values were 70% in case of 3´:5´-cCMP and 
50% in case of 3´:5´-cUMP. Therefore, the SPE procedure used in this work 
completely retained acyclic nucleotides on the alumina columns while cyclic 
pyrimidine nucleotides were eluted. Thus, the signals detected by liquid scintillation in 
the isotopic NC assay can only result from cyclic nucleotides; non-specific signals 
from acyclic nucleotides can be excluded. 
In order to ensure that the cyclic nucleotides formed enzymatically were of 
3´:5´-cNMP structure and not of the also naturally occurring 2´:3´-cNMP structure, we 
applied 15 µM 3´:5´-cCMP and 2´:3´-cCMP to SPE and HPLC analysis. As shown in 
Fig. 2C, a peak from 2´:3´-cCMP at a retention time of 3.3 min was detected while 
the retention time of 3´:5´-cCMP was 8.2 min. Both nucleotides were eluted in SPE 
with recoveries of about 70%. Therefore, 3´:5´-cNMP and 2´:3´-cNMP isomers could 
easily be discriminated based on their retention times, and cyclic nucleotides with 
2´:3´-cNMP structure were never detected in enzymatic reactions within this project. 
The term “cNMP” used in this work thus always refers to 3´:5´-cNMP, if not stated 
otherwise. 
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Fig. 2: HPLC chromatograms of nucleotide mixtures and eluates from solid 
phase extraction (SPE) using alumina. SPE and HPLC analytics were performed 
as described in “Materials and Methods”. A: Chromatogram of a mixture of 15 µM 
CMP, CDP, CTP and 3´:5´-cCMP prior to SPE (dashed line) and chromatogram after 
SPE (solid line). B: Chromatogram of a mixture of 15 µM UMP, UDP, UTP and 3´:5´-
cUMP prior to SPE (dashed line) and chromatogram after SPE (solid line). C: 
Chromatograms of 15 µM 2´:3´-cCMP and 3´:5´-cCMP prior to SPE (dashed line) and 
chromatogram after SPE (solid line). The same results were obtained in at least 3 
independent experiments. 
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4.4.3 Michaelis-Menten Enzyme Kinetics 
Fig. 3 shows the results of substrate saturation experiments using the isotopic 
NC assay with CTP/Mn2+ or UTP/Mn2+ on EF or CyaA; an overview of the kinetic 
properties of the AC activities, CC activities and UC activities of EF and CyaA is 
given in Tab. 1.  
 
 
 
Fig. 3: Michaelis-Menten kinetics of CC and UC activities of EF and CyaA using 
the isotopic NC assay. Reactions were carried out as described in “Materials and 
Methods”. Reaction mixtures contained the following components to yield the given 
final concentrations: 100 mM KCl, 10 µM free Ca2+, 100 µM EGTA, [α-32P]CTP (0.8 
µCi/tube) or [α-32P]UTP (0.8 µCi/tube), 100 nM CaM and non-labeled cyclic 
nucleotides as described in “Materials and Methods”. CTP/Mn2+ or UTP/Mn2+ (1 µM 
to 1 mM) plus 5 mM of free Mn2+ were added. The final protein concentration was 40 
pM EF or CyaA in case of CC activity (A and B) and 400 pM EF or CyaA in case of 
UC activity (C and D). Reactions were carried out at 37°C for 20 min in case of CC 
activity and for 30 min in case of UC activity. Data shown are means ± SD of 
representative experiments performed in duplicates; similar results were obtained in 
at least 5 independent experiments. 
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Tab. 1: Kinetic properties of AC activities, CC activities and UC activities from 
EF and CyaA. 
Enzyme NC activity Divalent Cation Km [µM] Vmax [s
-1] 
Mn2+ 35.3 ± 3.7 501.5 ± 55.9 AC 
Mg2+ 175.8 ± 29.2 684.2 ± 272.5 
Mn2+ 12.5 ± 3.4 8.8 ± 1.4 CC 
Mg2+ 419.7 ± 115.1 7.2 ± 3.1 
EF 
UC Mn2+ 134.5 ± 23.5 2.3 ± 0.2 
AC Mn2+ 57.7 ± 4.6 332.0 ± 42.4 
CC Mn2+ 46.6 ± 9.7 8.9 ± 2.0 
CyaA 
UC Mn2+ 68.6 ± 9.8 0.3 ± 0.05 
AC activities, CC activities and UC activities were determined as described under 
“Materials and Methods”. 1 µM to 2 mM NTP/Mn2+ or NTP/Mg2+ were added, plus 5 
mM of free Mn2+ or Mg2+. As radioactive tracer, [α-32P]ATP (0.2 µCi/tube), [α-
32P]CTP (0.8 µCi/tube) or [α-32P]UTP (0.8 µCi/tube) were added. The final enzyme 
concentrations were: 10 pM (EF and CyaA AC activities), 40 pM (EF and CyaA CC 
activities with Mn2+), and 400 pM (EF CC activity with Mg2+ and UC activities). 
Reactions were carried out for 10 min at 25°C (AC), 20 min at 37°C (CC) and 30 min 
at 37°C (UC). Apparent Km and Vmax values were obtained by non-linear regression 
analysis of substrate-saturation experiments and are the means ± SD of 3-4 
independent experiments performed in duplicates. Saturation curves were analyzed 
by non-linear regression using the Prism 4.02 software (Graphpad, San Diego, CA). 
 
 
Using Mn2+, the Km value of EF CC activity was 3-fold lower than the Km value 
of EF AC activity. The Km value of EF UC activity was 4-fold higher than the value of 
AC activity. Using Mg2+, the Km value of EF CC activity was 2-fold higher than the 
value of AC activity. Using CyaA and Mn2+ yielded similar Km values in case of AC, 
CC and UC activity. Interestingly, enzyme activities decreased in the order AC > CC 
> UC as shown by the Vmax values. Using Mn
2+, the Vmax value of EF CC activity was 
57-fold lower than the value of AC activity, and UC activity was even 4-fold lower 
than CC activity. Using CyaA and Mn2+, the Vmax value of CC activity was 37-fold 
lower than compared to the value of AC activity, and UC activity was even 30-fold 
lower than CC activity. However, the isotopic assay was sensitive enough to detect 
even those low enzyme activities. 
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4.4.4 Inhibition Data from the Isotopic Nucleotidyl Cyclase Assay 
EF and CyaA CC activity was inhibited using standard AC inhibitors. Using 
Mn2+, PMEApp (Shen et al., 2004) inhibited EF AC activity with a Ki value of 2.0 ± 0.5 
nM, while PMEApp inhibited CC activity with a Ki value of 4.5 ± 0.4 nM. The Ki values 
of PMEApp on CyaA were 1.0 ± 0.3 nM (AC activity) and 1.1 ± 0.02 nM (CC activity). 
The Ki values of five MANT-substituted nucleotides on EF and CyaA AC and CC 
activities are given in Tab. 2. MANT-CTP was found to be the most potent MANT-
nucleotide on EF AC and CC activity, yielding similar Ki values. MANT-ATP inhibited 
EF CC activity with about 7-fold lower potency than MANT-CTP, followed by MANT-
GTP, MANT-UTP and MANT-ITP. The order of potency of MANT-nucleotides on 
CyaA CC activity was MANT-ITP > MANT-CTP > MANT-UTP > MANT-ATP > MANT-
GTP.  
 
 
Tab. 2: Inhibitor potencies at EF and CyaA AC and CC activities. 
Ki (µM) 
Nucleotide EF 
AC activity 
EF 
CC activity 
CyaA 
AC activity 
CyaA 
CC activity 
MANT-ATP 0.43 ± 0.02 0.58 ± 0.03 4.3 ± 0.4*** 4.4 ± 0.1 
MANT-CTP 0.06 ± 0.01* 0.08 ± 0.01 1.1 ± 0.1*** 1.3 ± 0.1 
MANT-GTP 2.5 ± 0.1* 2.8 ± 0.4 5.9 ± 1.0*** 6.1 ± 2.0 
MANT-ITP 4.1 ± 0.1* 5.7 ± 0.03 0.6 ± 0.1*** 1.0 ± 0.04 
MANT-UTP 3.7 ± 0.1* 3.8 ± 0.6 2.6 ± 0.3*** 1.8 ± 0.3 
CC activities were determined as described under “Materials and Methods”. Reaction 
mixtures contained the following components to yield the given final concentrations: 
100 mM KCl, 5 mM free Mn2+, 10 µM free Ca2+, 100 µM EGTA, 10 µM CTP, [α-
32P]CTP (0.4 µCi/tube), 100 µM cAMP, 100 nM CaM. The final protein concentration 
was 30 pM EF or CyaA, reactions were carried out for 20 min at 37°C. Values 
labeled with (*) and (***) were taken from (Taha et al., 2009) and (Göttle et al., 2007), 
respectively. Ki values are given in µM and represent the means ± SD of at least 
three independent experiments performed in duplicates. Inhibition curves were 
analyzed by non-linear regression using the Prism 4.02 software (Graphpad, San 
Diego, CA). 
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As shown in Tab. 2, similar Ki values were obtained inhibiting AC activity and 
CC activity by MANT-nucleotides. This result was found for both EF and CyaA 
activities. Linear regression analysis was performed for the quantification of the 
correlations (Fig. 4). On EF and CyaA, the Ki values of AC and CC inhibition showed 
significant correlation. 
 
 
Fig. 4: Linear correlation of the Ki values of AC and CC inhibition by MANT-
nucleotides. Data shown in Tab. 2 provide the basis for the correlations. Dashed 
lines represent 95% confidence intervals of the linear regression lines. A: Inhibition of 
EF; slope, 1.224 ± 0.1604; r2, 0.9510; p, 0.0047; significant. B: Inhibition of CyaA; 
slope, 0.9847 ± 0.1226; r2, 0.9555; p, 0.0040; significant. Linear regression analysis 
was performed using the Prism 4.02 software (Graphpad, San Diego, CA). 
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4.4.5 Non-Isotopic Nucleotidyl Cyclase Assay and HPLC Analysis 
Within a screening for potential AC toxin substrates, EF and CyaA were 
incubated with several nucleoside 5´-triphosphates, and the formation of the 
corresponding cyclic nucleotides was analyzed. Fig. 5 shows HPLC chromatograms 
of reaction samples taken after reaction times between 0 min and 60 min. The 
chromatogram of the incubation of 20 nM EF with 100 µM CTP at a reaction time of 0 
min (Fig. 5A, purple line) showed a peak resulting from the starting material CTP at a 
retention time of 3.8 min while the internal standard (IS) inosine (40 µM) gave a peak 
at 5.7 min; no additional peaks were detected for 0 min reaction time at retention 
times of 6 min to 10 min. 
 
 
Fig. 5: HPLC chromatograms of reaction mixtures from the non-isotopic NC 
assay. The non-isotopic NC assay, sample preparation and HPLC analytics were 
carried out as described in “Materials and Methods”. Reaction mixtures contained 5 
mM Mn2+, 10 µM Ca2+ and 100 µM CTP (A), UTP (B) or ITP (C). Protein 
concentrations were 20 nM EF and 20 nM CaM (A), 120 nM EF and 120 nM CaM (B) 
and 300 nM EF and 300 nM CaM (C). Samples were withdrawn at the indicated 
reaction times (colored solid lines). 20 µM inosine were added as internal standard 
(IS); cCMP, cUMP and cIMP were also added as standard substances (black, dotted 
lines). In order to prevent overlapping of the lines, the chromatograms of the 
standard substances were moved vertically. D: Chromatograms of reaction samples 
containing 20 nM EF, 20 nM CaM and 100 µM CTP after 60 min reaction time. 
Results for active enzyme (solid line) and heat-inactivated enzyme (dotted line). 
Similar results were obtained in at least 3 independent experiments. 
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With increasing reaction time, the CTP peak at a retention time of 3.8 min 
decreased, while at a retention time of 8.3 min, a new peak was detected. This peak 
increased proportionally to the decrease of the CTP peak. This newly detected signal 
at a retention time of 8.3 min exhibited an identical retention time as 20 µM 3´:5´-
cCMP applied as external standard (Fig. 5A, dashed line). At different reaction times, 
the internal standard (inosine, 40 µM) yielded constant signals at a retention time of 
5.7 min ensuring reproducible nucleotide recoveries. 
In order to answer the question which NTP is converted preferentially by EF, 
ATP or CTP, both NTPs (100 µM each) were incubated simultaneously with 1 nM EF 
and 1 nM CaM in one reaction vial, allowing competition of ATP and CTP for the 
catalytic site. ATP turned out to be converted preferentially, e.g. after 2 h of 
incubation at 37°C, the turnover was about 90% for ATP and about 10% for CTP 
(data not shown). 
When 120 nM EF were incubated with 100 µM UTP, chromatograms showed 
the UTP signal at a retention time of 4.9 min (Fig. 5B, purple line). With increasing 
reaction time, a decrease of the UTP signal was observed, and at a retention time of 
10.8 min, a new signal was detected exhibiting the identical retention time as 20 µM 
3´:5´-cUMP applied as external standard (Fig. 5B, dashed line). 
Similarly, upon incubation of 100 µM ITP with 500 nM EF (Fig. 5C), a 
decrease of the ITP peak at a retention time of 6.2 min was observed while a new 
peak increased at a retention time of 14.2 min, exhibiting the identical retention time 
as 20 µM 3´:5´-cIMP applied as external standard (Fig. 5C, dashed line). 
In order to ensure that the observed NTP conversions resulted from specific 
enzymatic activity, 20 nM EF and 100 µM CTP were incubated similarly to the 
experiment shown in Fig. 5A, and for comparison, 20 nM of heat-inactivated EF were 
incubated with 100 µM CTP. After 60 min of incubation using EF, the CTP peak at a 
retention time of 3.8 min had been converted to a signal at 8.3 min exhibiting the 
retention time of cCMP external standard (Fig. 5D, solid line). The chromatogram 
resulting from an incubation of 60 min using heat-inactivated EF showed no new 
peak from cCMP at a retention time of 8.3 min, but the peak from the starting 
material CTP persisted at a retention time of 3.8 min (Fig. 5D, dashed line). Thus, no 
conversion of CTP was detected using heat-inactivated enzyme. 
HPLC chromatograms shown in Fig. 5 were used to calculate nucleotide 
concentrations and to depict NTP conversion to cNMP by EF with increasing reaction 
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time (Fig. 6). EF concentrations were adjusted according to the efficiency of 
conversion of the individual NTPs. With 20 nM EF, 120 nM EF and 500 nM EF, 
respectively, complete conversion of 100 µM CTP, UTP and ITP occurred within 60 
min. When 500 nM EF were incubated with 100 µM GTP, chromatograms showed a 
decrease of the signal from GTP and a new signal exhibiting the retention time of 
standard cGMP (data not shown). However, although the EF concentration was high 
(500 nM), the turnover of GTP within a reaction time of 60 min was 13% only, 
showing inferior enzymatic activity of EF on GTP as compared to CTP, UTP and ITP. 
When 500 nM EF were incubated with 100 µM TTP, chromatograms showed a 
decrease of the signal from TTP and the appearance of a new signal displaying the 
retention time of standard cTMP. The turnover of TTP after 60 min was only 5%, 
pointing to minimal enzymatic activity of EF on TTP.  
When CyaA was used instead of EF, similar chromatographic results were 
obtained (data not shown). Chromatograms also showed complete conversion of 
CTP, UTP and ITP within 60 min yielding peaks at retention times of the 
corresponding cyclic nucleotide standards. CyaA concentrations needed for complete 
turnover of 100 µM NTP within 60 min were 30 nM (CTP), 600 nM (UTP) and 1,500 
nM (ITP). When 1,500 nM CyaA were applied to 100 µM GTP or 100 µM TTP, the 
turnover within 60 min was 90% or 30%, respectively. 
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Fig. 6: Turnover of NTPs to cNMPs by EF using the non-isotopic NC assay. 
Nucleotide concentrations were calculated by evaluating the chromatograms shown 
in Fig. 5. CTP (A), UTP (B) or ITP (C), 100 µM each, were converted to the 
corresponding cyclic nucleotides by the indicated concentrations of EF and 
equivalent concentrations of CaM ensuring 1:1 stoichiometry of EF and CaM. 
Experiments were performed as described in “Materials and Methods”. Similar results 
were obtained in at least 3 independent experiments. 
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4.4.6 Mass Spectrometry 
In order to ensure the exact identities of the cyclic nucleotide products from 
enzymatic reactions, samples were applied to LC-MS/MS and the resulting data were 
compared to results from cNMP standards. Fig. 7 shows mass spectra and 
chromatograms from selective reaction monitoring (SRM) in case of cCMP (A-C), 
cUMP (D-F) and cIMP (G-I). 
 
 
 
Fig. 7: Verification of the identities of the cyclic nucleotides formed in the non-
isotopic NC assay by mass spectrometry. HPLC-MS analytics were performed as 
described in “Materials and Methods”. Shown are fragmentation patterns of the 
standard cyclic nucleotides, chromatograms from standard cyclic nucleotides and 
chromatograms from reaction samples for cCMP (A-C), cUMP (D-F) and cIMP (G-I). 
Similar results were obtained in at least 3 independent experiments. 
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The mass spectrum of cCMP (Fig. 7A) shows signals from protonated cCMP 
(m/z = 306.0) and from the protonated cytosine base (m/z = 112.2). Selective 
reaction monitoring of the m/z transition of 306.0 to 112.2 proofed the existence of 
cCMP in the nucleotide standard (Fig. 7B) as well as in samples from the enzymatic 
reaction of EF with CTP (Fig. 7C). In case of cUMP, mass signals resulted from the 
protonated cUMP molecule (m/z = 307.0), the cUMP-ammonia adduct (m/z = 324.2) 
and the protonated uracil base (m/z = 113.3) (Fig. 7D). SRM of the m/z transition of 
324.2 to 307.0 proofed the existence of cUMP in the nucleotide standard (Fig. 7E) 
and in reaction samples (Fig. 7F). The mass spectrum of cIMP (Fig. 7G) shows 
signals from protonated cIMP (m/z = 330.9) and from the protonated hypoxanthine 
base (m/z = 137.2). As determined by SRM of the m/z transition of 330.9 to 137.2, 
cIMP was found in nucleotide standard and reaction sample (Fig. 7H-I). 
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4.5 Discussion 
 
4.5.1 Multiple cNMPs Formed by EF and CyaA 
The signals obtained in the isotopic NC assay using [α-32P]NTP as substrate 
were dependent on the amount of “AC” toxin (Fig. 1B), on pH (Fig. 1C) and on the 
cyclase toxin activator CaM (Fig. 1D). HPLC analytics confirmed that only cyclic 
nucleotides were eluted in the SPE procedure applied in this work (Fig. 2A and B), 
and no cyclic nucleotide was formed when heat-inactivated enzyme was used (Fig. 
2C). The turnover of [α-32P]NTP was inhibited by PMEApp, a standard AC toxin 
inhibitor and by five MANT-nucleotides. Thereby, similar Ki values were obtained in 
both cases, i.e. when AC was inhibited (use of [α-32P]ATP as substrate) and when 
CC was inhibited (use of [α-32P]CTP as substrate, Tab. 2). Linear correlation analysis 
showed significant correlation between the Ki values obtained from AC and CC 
inhibition (Fig. 4). Mass spectrometry confirmed the existence of the corresponding 
cyclic nucleotides in the reaction samples. Taken together, these data corroborate 
that the signals detected in the isotopic NC assay and in the non-isotopic assay only 
originated from specific enzymatic catalysis by EF or CyaA. 3´:5´-cNMP and 2´:3´-
cNMP isomers could easily be discriminated based on their different retention times, 
allowing us to exclude the formation of cyclic nucleotides possessing 2´:3´-cNMP 
structure. The EC50 values for CaM obtained from the isotopic CC assay are in good 
agreement with values from literature. While CaM stimulated CC activity with EC50 
values of 670 ± 50 pM (EF) and 80 ± 5 pM (CyaA), AC activity was stimulated with 
EC50 values of 1,600 pM in case of EF (Gupta et al., 2006) and 200 pM in case of 
CyaA (Glaser et al., 1991; Bouhss et al., 1996). On the basis of the Vmax values given 
in Tab. 1 and as a result from the non-isotopic NC assay, the rank order of substrate 
preference was ATP > CTP > UTP > ITP > GTP > TTP, for both EF and CyaA. The 
decreasing efficiencies of substrate cyclization to yield rare cyclic nucleotides 
required the use of higher enzyme concentrations, higher temperature and lower 
concentrations of non-labeled NTP (in the isotopic NC assay) as compared to the 
more efficient conversion of ATP. When substrate saturation experiments using the 
isotopic NC assay were performed with CTP/Mg2+ instead of CTP/Mn2+, similar Vmax 
values were obtained under both conditions (Tab. 1), showing that CC activity is not 
restricted to the use of Mn2+; the physiological divalent cation Mg2+ enables EF to 
convert CTP, too. 
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4.5.2 Accommodation of Various Purine and Pyrimidine Nucleotides at the 
Catalytic Sites of EF and CyaA 
In our previous work, we characterized the interactions of the catalytic sites of 
EF and CyaA with non-substituted NTPs and various MANT-nucleotides possessing 
various purine and pyrimidine bases (Göttle et al., 2007; Taha et al., 2009). We 
developed a three-site pharmacophore model for mAC, EF and CyaA attributing 
major importance to the ribose substituent for nucleotide affinity, followed by the 
phosphate tail (Gille et al., 2005; Mou et al., 2006). The higher affinity of MANT-
substituted nucleotides is a result from additional hydrophobic interactions of the 
MANT-group with F586 in EF and F306 in CyaA (Göttle et al., 2007; Taha et al., 
2009). The base turned out to play a minor role as the catalytic site of AC is spacious 
and conformationally flexible and accommodates various purine and pyrimidine 
nucleotides (Göttle et al., 2007; Taha et al., 2009). Using kinetic FRET competition 
experiments, we have shown that both MANT-ATP and MANT-CTP reversibly bind to 
the catalytic site of EF, further corroborating a single nucleotide binding site in EF 
(Taha et al., 2009). Modeling the binding modes of MANT-ATP and MANT-CTP to 
the catalytic site of EF, we found that in 3´-MANT-CTP, the oxygen in the 2´-position 
of the base may align with the positive pole of the amide dipole of N583. The 
cytosine oxygen may be close to the guanidine group of R329. Additionally, a water 
molecule may mediate H-bonding between the cytosine oxygen with the side chains 
of R329 and E580. Taken together, these results confirm that various bases, in 
particular cytosine, can be accommodated by the EF catalytic site. Modeling of the 
binding modes of MANT-nucleotides to the catalytic site of CyaA suggested that all of 
the nucleobases may be aligned in similar position (Göttle et al., 2007). In case of 
GTP, ITP and UTP, backbone NH functions of G299 and V271 could serve as 
hydrogen donors for the carbonyl oxygens in the 6 and 4 positions, respectively. 
Therefore, the catalytic site of CyaA forms a large cavity with considerable 
conformational freedom to accommodate various nucleotides. Collectively, our 
previous studies show that other NTPs than ATP can bind to both EF and CyaA 
opening up the formation of rare cyclic nucleotides. 
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4.5.3 Multiple cNMPs: A Strategy to Blunt Host Immune Responses? 
The natural occurrence of cCMP resulting from specific CC activity was 
confirmed unambiguously in various mammalian organs (Newton et al., 1984, 1990, 
1997). Additionally, phosphodiesterase activity mediating degradation of cCMP was 
found (Newton et al., 1986, 1999). Moreover, protein kinase activity responsive to 
cCMP has been observed (Newton et al., 1992; Bond et al., 2007; Ding et al., 2008). 
Accordingly, cCMP may be a novel cyclic nucleotide with second messenger 
function, regulating cell functions such as cell growth and differentiation. To the best 
of our knowledge, we have shown for the first time that an enzyme purified to 
apparent homogeneity possesses cytidylyl cyclase activity. Additionally, we observed 
broad NTP specificity of both adenylyl cyclase toxins, EF and CyaA, forming cCMP, 
cUMP, cIMP, cGMP and cTMP. As the cell-permeant cCMP-analog dibutyryl-cCMP 
blunts host immune responses, e.g. formation of cytokines in macrophages (Elliott et 
al., 1991) and oxygen radical formation in neutrophils (Ervens and Seifert, 1991), we 
hypothesize that the formation of multiple cyclic nucleotide species by EF and CyaA 
synergizes with adenylyl cyclase activity to accomplish effective disruption of immune 
responses during infection. The discovery of these multiple nucleotidyl cyclase 
activities contributes to our understanding of the mechanisms of action of bacterial 
exotoxins, providing the basis for the rational development of potent and selective EF 
and CyaA inhibitors for the treatment of toxinemia and antibiotic-resistant bacteria 
strains. 
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The specific aims of this thesis were to provide the basis for exploring AC as 
target for the treatment of heart failure and several bacterial infections and to explore 
the enzymatic activities of AC toxins. 
 
1. As one major achievement of this thesis, a biochemical method was 
developed to prepare membranous AC from cardiac tissue, yielding the components 
of the cAMP signaling cascade, i.e. GPCRs, G proteins and AC in intact form. A 
radiochemical approach was used to determine the parameters required for AC 
activity, producing robust signals from cardiac AC activity by both direct stimulation of 
AC and by stimulation via GPCRs. With these prerequisites fulfilled, we applied 
pharmacological approaches to characterize AC enzyme activity in mouse heart 
membranes. Using forskolin analogs for stimulating AC activity and MANT-
substituted nucleotides as inhibitors, and by investigating Michaelis-Menten enzyme 
kinetics, we found AC from heart tissue to correlate to some extent with recombinant 
AC5, compatible with the notion that AC5 is the major AC isoform in the heart. 
However, AC isoforms other than AC5 appear to contribute to total AC activity in 
mouse heart membranes, too. These findings were corroborated by results obtained 
by applying further techniques, i.e. real-time PCR and immunoblot analysis. In the 
course of this work, MANT-substituted hypoxanthine nucleotides were found to inhibit 
cardiac AC with very high potencies. In summary, by the use of several techniques, 
we provide a pharmacological profile of cardiac AC and an excellent starting point for 
the design of potent and selective inhibitors. When conventional treatment of heart 
failure is limited, e.g. due to ineffective β-adrenoceptor antagonist therapy, as a 
promising novel therapeutic strategy, future clinical treatment strategies may be 
complemented by nucleotide prodrugs accomplishing beneficial effects on the heart 
and increased survival of the patient. 
 
2. The bacterial AC toxins CyaA and EF are key virulence factors impairing 
host immune responses and worsening the infections by Bordetella pertussis, the 
causative agent of whooping cough, and Bacillus anthracis, causing anthrax disease. 
The second aim of this doctoral thesis was to investigate the detailed modes of 
action of EF and CyaA and to provide the basis for the development of AC toxin 
inhibitors. 
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Using radiochemical methods, we investigated the structure/activity 
relationships of substituted NTPs as CyaA inhibitors, revealing hypoxanthine 
nucleotides to be superior to other purine and pyrimidine nucleotides. Molecular 
modeling revealed hydrophobic interactions of the ribosyl substituent and lipophilic 
amino acid residues in CyaA to account for the increased potency of MANT-
substituted nucleotides compared with non-substituted NTPs. One major 
achievement of this thesis is the development of fluorescence-based approaches 
allowing monitoring the binding of potential inhibitor molecules to CyaA. Actually, two 
approaches were considered: First, a method basing upon fluorescence resonance 
energy transfer (FRET) from enzyme tryptophan residues to fluorescent inhibitor 
molecules, and second, a technique basing upon direct inhibitor fluorescence. These 
powerful techniques were applied to investigate the interactions of fluorescent 
MANT-, ANT- and TNP-substituted nucleotides with CyaA and to determine inhibitor 
potencies. Even the binding of non-labeled inhibitors to CyaA was monitored with this 
approach. Selective CyaA inhibitors may be used to prevent dampening of the 
immune response upon Bordetella pertussis infection and to reduce mortality in 
severe courses of disease. The fluorescence-based approaches developed in this 
thesis are available for future high-throughput screening to support the development 
of highly potent and selective CyaA inhibitors. 
 
3. Cyclic cytidine 3´:5´-monophosphate (cCMP) was identified unambiguously 
in various mammalian tissues, protein kinase activity responsive to cCMP was 
observed and phosphodiesterase activity accounting for the selective degradation of 
cCMP was discovered. Therefore, cCMP may be a novel second messenger with 
potential importance in many physiological processes, including regulation of immune 
responses. However, so far, the precise identity of the cCMP-forming enzyme is 
unknown. As the aim of this doctoral thesis was to investigate the detailed modes of 
action of bacterial AC toxins, we investigated the interactions of various NTPs with 
EF and CyaA. Thereby, we found hitherto unknown enzymatic activities: For the first 
time, we provide evidence for cytidylyl cyclase (CC) activity of purified bacterial 
exotoxins, resulting in the conversion of CTP to cCMP. 
As a major achievement of this thesis, various nucleotidyl cyclase activities of 
bacterial AC toxins were investigated and monitored by the use of several 
techniques. First, the isotopic nucleotidyl cyclase assay based upon detection of 
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radioactively labeled cNMPs showed that EF and CyaA possess CC activity, and 
additionally, we also observed the conversion of UTP to cUMP. We performed 
substrate saturation experiments to determine the kinetic properties of CC and UC 
activities. Moreover, we determined the potencies of AC inhibitors at CC activity and 
obtained similar Ki values when inhibiting AC activity and CC activity. 
Second, the non-isotopic nucleotidyl cyclase assay basing upon an advanced 
sample preparation process and detection of cNMPs by HPLC was developed and 
used to monitor NTP consumption and cNMP formation by both AC toxins. Using this 
approach, in addition to the formation of cAMP, cCMP and cUMP, we also observed 
the formation of cIMP, cGMP and cTMP. The rank order of substrate preference was 
ATP > CTP > UTP > ITP > GTP > TTP, for both EF and CyaA. Third, mass 
spectrometry was used to unambiguously identify the corresponding cNMPs obtained 
from enzymatic reactions. 
Based on the fact that cCMP-analogs inhibit immune responses, we 
hypothesize that cCMP may be a novel endogenous second messenger and that the 
multiple nucleotidyl cyclase activities of bacterial AC toxins described in this thesis for 
the first time contribute to weakening of the immune defense by bacterial exotoxins, 
resulting in increased infection severity. Regarding future research, the endogenous 
CC enzyme remains to be discovered. The physiological role and the molecular 
targets of cCMP remain to be determined. What is the impact of multiple nucleotidyl 
cyclase activities of bacterial AC toxins on cyclic nucleotide metabolism in host cells? 
And finally, - regarding the occurrence of bacterial strains resistant to antibiotic 
treatment - can our findings lead to advancements in the prevention and therapy of 
bacterial infections? 
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